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The threat of a pandemic spread of highly virulent influenza A viruses currently represents a 
top global public health problem. Mass vaccination remains the cornerstone of influenza 
prevention. Current vaccination strategies face the challenge to meet the demands in a 
pandemic situation. The potential emergence of an influenza pandemic at any time combined 
with limited vaccine supplies, have rendered the development of novel universal influenza 
vaccines that would provide cross-clade protective immunity a public health priority.  
As a strict human pathogen that naturally infects the respiratory tract, Bordetella pertussis is 
particularly well-adapted for the nasal delivery of heterologous vaccine candidates and 
represents a promising mucosal vaccine delivery system when suitably attenuated. In addition, 
ideally immunization with recombinant B. pertussis bacteria should provide a concomitant 
protection against both pertussis and the target disease. A highly attenuated B. pertussis strain, 
named BPZE1, has been described in which three toxins have been genetically inactivated. 
Despite a markedly reduced lung inflammation, BPZE1 is able to colonize the murine lungs 
efficiently and induce a strong protective immune response. BPZE1 has recently completed a 
phase I clinical trial in adult human volunteers as a nasal live pertussis vaccine candidate.  
In our study, we investigated the feasibility of using BPZE1 as a vaccine delivery vehicle for 
the conserved ectodomain of M2 protein from influenza virus (M2e) using the BrkA 
autotransporter protein for cell surface expression. Three copies of M2e were fused within the 
passenger domain of BrkA and expressed in BPZE1. BrkA-(M2e)3 chimeras were efficiently 
produced and presented at the bacterial surface. Nasal administration of the live recombinant 
bacteria expressing the BrkA-(M2e)3 chimeras induced suboptimal levels of M2e-specific 
 XXX 
 
antibodies in the respiratory tract that reduced the viral load in murine lungs. However, it did 
not further improve the protection offered by BPZE1 alone which has been previously 
demonstrated to induce non-specific cross-protection against influenza infections.  
Furthermore, an earlier study conducted in the lab has reported that cloning the cysteine-
containing M2e protein into B. pertussis filamentous hemagglutinin (FHA) impaired the 
secretion efficiency of FHA-(M2e)3 chimeras and resulted in induction of suboptimal levels 
of M2e-specific antibodies in mice. Therefore, we constructed a recombinant B. pertussis 
strain expressing FHA-(M2e)3 in which cysteine residues were replaced with serine residues 
to improve secretion efficiency of the FHA-(M2e)3 chimeras. Although there was a 
significant improvement in the secretion efficiency upon amino acid substitution, severe 
attenuation in the recombinant bacteria’s ability to colonize murine lungs with rapid bacterial 
clearance was observed. This correlated with the inability of the recombinant bacteria to 
prime in an efficient and sustained manner the host immune system.  
Our studies thus suggested that BPZE1 may not represent an appropriate vaccine delivery 
system for M2e which is poorly immunogenic.  
We also evaluated the potential of BPZE1 as a vaccine delivery vehicle for T cell epitopes 
against influenza viruses. Similar to BPAL3, four copies of NP366-374, an immunodominant 
CD8 T cell epitope in murine models of influenza, were fused to the passenger domain of 
BrkA and expressed in BPZE1. Although BrkA-(NP366-374)4 chimeras were successfully 
presented on the bacterial surface of B. pertussis, no significant NP366-374 CD8 T cell 
responses were detected upon nasal administration in mice. The absence of expansion in 
 XXXI 
 
NP366-374-specific CTL population may be due to the inability of the B. pertussis to induce a 
CD8 response. Therefore, this suggests that B. pertussis may not represent a suitable delivery 
system for CD8 T cell epitopes.     
Finally, BPZE1 still produces parental levels of adenylate cyclase (AC), one of the remaining 
major toxins and a potential antigen that may participate to the cell-mediated BPZE1 
protective efficacy. In order to evaluate the role of AC in BPZE1-induced protection, we thus 
generated an AC-deficient BPZE1 strain and compared its protective efficacy in an infant 
mouse model with that of its parental counterpart BPZE1. Our findings indicate that the 
protective efficacy of the AC-deleted BPZE1 strain was comparable to that of BPZE1 at high 
vaccine dose but was significantly impaired at low vaccine dose. Such impairment was 
correlated to reduced levels of IFN-producing T cells in the immunized animals. Therefore, 
while the optimal vaccination dose has yet to be worked out for humans, BPZE1 appears to 
be a more attractive vaccine candidate with the right balance between attenuation and 
protective efficacy. 
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1. INTRODUCTION 
Influenza A infections remains a pervasive public health problem worldwide. Annual 
epidemics caused by seasonal influenza infections result in millions of human infections 
worldwide and have significant health and economic burden (Molinari et al. 2007). Influenza 
pandemics, on the other hand are unpredictable but recurring events that can have severe 
consequences globally, resulting in millions of death. In 1997, the first human case of highly 
pathogenic avian influenza (HPAI) H5N1 infection was reported (Claas et al. 1998) and with 
that, the spread of HPAI H5N1 virus across different parts of the world, as well as sporadic 
infections of humans with an overall fatality rate of over 60%, have caused worldwide 
concern about a potential new influenza pandemic (Chow, Tambyah and Goh 2008). 
Recently, a novel H1N1 swine origin influenza virus (SOIV) emerged to produce the first 
human influenza pandemic of the twenty-first century, spreading globally at an 
unprecedented speed. Within a year, the virus spread to 214 countries and caused an 
estimated 18,000 deaths worldwide (WHO 2009). 
Vaccination remains as the most cost-effective primary prevention against influenza infection. 
Current vaccines rely on raising antibodies against the major surface glycoproteins, 
hemagglutinin (HA) and neuramidase (NA). Because of the high mutation rates in the viral 
genome segment encoding HA and NA due to antigenic “drift” and “shift”, influenza 
vaccines have to be updated annually in order to match the circulating viral strains. 
Furthermore, a rapidly developing pandemic may not provide sufficient time for the 
identification and mass production of the antigenically matched vaccine strains.  Therefore, a 
vaccine containing conserved epitopes from influenza A virus that can provide cross-
protection against different influenza variants or strains and which does not require frequent 
updates is highly desirable.  
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Furthermore, given that influenza virus is a respiratory pathogen and influenza infections are 
initiated at mucosal surfaces, it is expected that mucosal vaccines that are able to elicit both 
local and systemic immune responses would provide a more effective protection to arrest 
infection in its initial stages. Therefore, live recombinant bacteria adapted to the respiratory 
tract appear to be attractive and promising vehicles for the presentation of vaccine antigens to 
the respiratory mucosa due to their ability to stimulate mucosal, humoral and cellular 
immunity (Thole et al. 2000). In addition, the ability of the live bacterial vectors to replicate 
within their host may provide a sustained exposure of the vaccine candidate to the host 
immune system, thereby inducing a strong specific immune response ideally upon a single 
administration.   
Bordetella pertussis, a strict human respiratory pathogen, is the causative agent of whooping 
cough. Despite high vaccination coverage, pertussis or whooping cough remains endemic and 
reports of increasing incidence worldwide have been accumulating for the past twenty years. 
The waning and/or sub-optimal efficacy of the current pertussis vaccines in adults have been 
proposed to account for resurgence. Antigenic shift and adaptation of the circulating strains to 
the vaccines may also be involved, thus calling for the development of a new generation of 
pertussis vaccines. Natural infection with B. pertussis has been shown to induce strong and 
long-lasting immunity (Siegrist 2001); therefore vaccination with a live attenuated B. 
pertussis strain represents an interesting approach to confer strong protection against 
pertussis. However, the right balance between attenuation and immunogenicity must be 
achieved. A highly attenuated B. pertussis strain, BPZE1, has been engineered (Mielcarek et 
al. 2006) in which three toxins have been genetically inactivated. BPZE1 has recently entered 
a phase I clinical trial in human as a live nasal pertussis vaccine (http://www.child-
innovac.org). Although highly attenuated as evidenced by a markedly reduced lung 
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inflammation in the infected mice, BPZE1 bacteria still retain the ability to colonize the 
respiratory tract efficiently and induce effective protective immunity against pertussis 
infection (Mielcarek et al. 2006). Furthermore, high stability in vitro and in vivo (Stevenson 
and Roberts 2003), and good safety profile in immunocompromised animals (Mielcarek et al. 
1998) have been demonstrated for this vaccine strain. In all, these features not only make the 
B. pertussis BPZE1 strain an attractive live pertussis vaccine candidate, but also a promising 
vehicle for vaccine delivery via the nasal route. Several heterologous antigens have been 
successfully expressed in recombinant B. pertussis and in particular, a neutralizing epitope, 
SP70 from Enterovirus71 has been successfully produced in the live attenuated BPZE1 and 
the resulting strain was able to induce systemic SP70-specific neutralizing antibodies in mice 
upon immunization (Ho et al. 2008).  
In this project, we aimed to develop a universal vaccine against influenza A viruses using the 
attenuated Bordetella pertussis strain BPZE1 as live vector for nasal delivery of influenza 
vaccine candidates. We have selected two relatively conserved antigens from influenza A 
virus, namely the ectodomain of M2 protein (M2e) and the immunodominant CTL epitope of 
nucleocapsid protein (NP366-374) that induce humoral and cell-mediated immunity respectively. 
M2e was expressed as a chimeric protein with either the filamentous hemagglutinin (FHA) or 
the Bordetella resistance killing antigen (BrkA) for secretion and/or exposure at the bacterial 
surface of BPZE1. Upon nasal administration of the live recombinant bacteria, the specific 
anti-M2e antibody responses were studied in mice and influenza challenge experiments were 
performed to assess the protective efficacy of the vaccine candidates.  
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Several copies of the NP366-374 epitope were cloned into the passenger domain of BrkA for 
exposure at the bacterial surface of BPZE1. The NP366-374-specific CD8 cytotoxic T 
lymphocyte (CTL) activity elicited by the recombinant B. pertussis strains upon nasal 
administration in mice was investigated. 
Furthermore, the successful attenuation of a bacterial pathogen relies on the 
deletion/inactivation of major virulence factors while maintaining a good colonization ability 
and strong immunogenicity. BPZE1 bacteria still produce parental levels of adenylate cyclase 
(AC), another major toxin produced by B. pertussis . Due to its ability to interact with the 
host major histocompatibility (MHC) molecules, AC may also represent an important 
protective antigen involved in the cell-mediated protective efficacy. Therefore, in order to 
address the role of AC in BPZE1-mediated protection, we generated an AC-deficient BPZE1 
strain and evaluated in an infant mouse model its colonization ability, immunogenicity and 
protective efficacy compared to its parental counterpart BPZE1.  
Chapter 2 Survey of Literature 
5 | P a g e  
2. SURVEY OF LITERATURE 
2.1. Influenza Viruses 
2.1.1. History of Influenza Pandemics 
For years, influenza A viruses have been in constant circulation in several animal hosts, 
including humans, birds, horses, dogs and pigs. Seasonal influenza infections cause 
annual epidemics that result in millions of human infections worldwide and have 
significant health and economic burden (Molinari et al. 2007). Influenza pandemics, on 
the other hand are unpredictable but recurring events that can have severe consequences 
globally, resulting in millions of death. The onset of pandemics is triggered by antigenic 
shift, the successful introduction and adaptation of a novel hemagglutinin subtype to 
human from an animal source. In the twentieth century, three novel influenza strains 
emerged, causing the 1918 Spanish flu (H1N1), 1957 Asian flu (H2N2), and 1968 
Hong Kong flu (H3N3) pandemics, with the 1918 Spanish influenza virus bringing 
about the most devastating impact with an estimated 20 to 50 million deaths (Johnson 
and Mueller 2002). In 1997, the first human case of highly pathogenic avian influenza 
(HPAI) H5N1 infection was reported (Claas et al. 1998). The spread of HPAI H5N1 
virus across parts of East and Southeast Asia, Africa, Europe and the Middle East, as 
well as sporadic infections of humans with an overall fatality rate of over 60%, have 
caused worldwide concern about a potential new influenza pandemic (Chow et al. 
2008). Fortunately, the virus has yet to sustain human-human transmission and most 
cases have been associated with direct human contact with infected avian species. In 
2009, a novel H1N1 swine origin influenza virus (SOIV) emerged to produce the first 
human influenza pandemic of the twenty-first century, spreading globally at an 
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unprecedented speed. Within a year, the virus spread to 214 countries and caused an 
estimated 18,000 deaths worldwide (WHO 2009).  
2.1.2. Clinical Manifestations and Complications of Influenza Infections 
To date, diagnosis of influenza infections still remains as a major challenge in the 
clinical setting, because many respiratory viruses such as parainfluenza, respiratory 
syncytial virus, adenovirus and coxsackievirus display similar symptoms and signs. 
One of the ways to distinguish influenza from other respiratory viruses causing 
influenza-like illness is the early onset of fever (oral temperature ≥ 37.8° C) (Monto et 
al. 1999). The other common symptoms observed in influenza infections include 
headache, myalgia, malaise, rhinitis, sore throat and cough, occasionally accompanied 
by manifestations of lower respiratory tract infections such as croup, bronchitis and 
bronchiolitis. Also, the central nervous system may be affected during influenza 
infection which may lead to encephalopathy, post-influenza encephalitis, transverse 
myelitis, Guillain-Barré syndrome and acute necrotizing encephalitis (Cox and 
Subbarao 1999, Huang et al. 2004).  
Complications of influenza virus infection generally occur in the very young or elderly 
(> 65 years old) and have the potential to aggravate underlying health conditions such 
as chronic pulmonary and cardiopulmonary diseases. Pneumonia remains one of the 
most common causes of complication in major pandemics in the 20th century, regardless 
of the involvement of secondary bacterial pneumonia.  Secondary bacterial pneumonia 
usually occurs late in the course of disease, after a period of improvement has been 
observed for the acute disease. Staphylococcus aureus is often documented in 
secondary pneumonia of influenza infections due to the production of proteases by 
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strain-specific S. aureus that cleaves the virus haemagglutinin to facilitate viral 
establishment in host (Finelli et al. 2008, Hageman et al. 2006, Frazee 2007, Reed et al. 
2009, Cheng et al. 2009).  
A unique feature of the 1918 Spanish flu and 1997 HPAI H5N1 outbreak was the 
multisystem dysfunction and immune dysregulation observed in infected individuals 
(Hsieh et al. 2006). Interestingly, the unusual W-shaped mortality pattern, with a peak 
in deaths among young adults aged 20 to 40 years during the 1918 Spanish flu 
pandemic further suggests immune-mediated pathology (Luk, Gross and Thompson 
2001). Hemophagocytic syndrome, a disorder characterized by excessive activation of 
mononuclear phagocytosis of erythrocytes, platelets, and leukocytes, was a significant 
pathologic characteristic in these patients (Risdall et al. 1979, Larroche and Mouthon 
2004, Peiris et al. 2004, To et al. 2001). The increase in proliferation and overactivation 
of macrophages throughout the reticuloendothelial system resulted in abnormal 
phagocytic activity and massive secretion of cytokines such as interferon-γ (IFNγ), 
tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), soluble interleukin-2 (IL-2) 
receptor and interferon-induced protein-10 (IP-10) (Peiris et al. 2004, Akashi et al. 1994, 
Imashuku et al. 1996, To et al. 2001). Consequently, apparent dysregulation of cytokine 
responses contributes to the pathology of the deadly complications in the affected 
patients.  
Histopathological examinations of autopsy samples from patients infected with the 
2009 SOIV revealed similar observations seen with the HPAI H5N1; diffuse alveolar 
damage (DAD), reactive hemophagocytosis and lymphoid atrophy. Elevated levels of 
proinflammatory cytokines such as IL-6, IL-10, IL-15 and TNFα were also detected, 
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suggesting the possible role of a cytokine storm in the observed immunopathological 
effects (To et al. 2010).  An interesting feature unique to the SOIV is its ability to 
replicate at high levels in both the upper and lower respiratory tracts hence its great 
transmissibility (Childs et al. 2009, Maines et al. 2009).   
2.1.3. Classification and Structure  
Influenza viruses are enveloped viruses that belong to the Orthomyxoviridae family. 
They can be further classified into three genera, Influenza “A”, “B” and “C”.  Among 
the three genera, Influenza A viruses exhibit the broadest range of host specificity and 
is the main human pathogen associated with epidemics and pandemics. Although 
waterfowl is the natural host for all influenza A viruses, these viruses are able to infect 
and establish disease of varying severity in domesticated poultry and several mammal 
species, including humans (Crawford et al. 2005, Palese and Shaw 2007).  
Influenza A viruses contain a single stranded, negative sense RNA genome made of 
eight segments that encode 11 or 12 proteins (Palese and Shaw 2007), including N40, a 
newly characterized protein that is expressed from the PB1 segment (Wise et al. 2009) 
(Figure 2-1). They can be further subtyped according to the antigenic properties of the 
two major surface glycoproteins, hemagglutinin (HA) and neuramidase (NA). Currently, 
there are 16 HA subtypes and 9 NA subtypes that have been described. HA is a major 
factor that determines host tropism through its interaction with host cell receptors that 
contain terminal α-2,6-linked or α-2,3-linked sialic acid (α-2,6-SA or α-2,3-SA) 
moieties. Furthermore, it contains a cleavage site for host cell proteases, whose amino 
acid sequence modulates tissue tropism and systemic spread, affecting tissue severity 
(Medina and García-Sastre 2011).  NA plays an important role in the proper budding 
Chapter 2 Survey of Literature 
9 | P a g e  
and release of progeny virions from the host cell surface through digestion of the SA-
containing hemagglutinin receptors holding the viruses to the cell.  
 
Figure 2-1 Structural features of Influenza A virus.  
The influenza A virus particle has a lipid envelope that is derived from the host cell 
membrane. There are three surface glycoproteins embedded in the lipid bilayer of the 
viral envelope, haemagglutinin (HA), neuraminidase (NA) and an ion channel protein 
(matrix protein 2, M2). HA and NA are the main surface glycoproteins of influenza A 
viruses.  Adapted from Medina and Garcia-Sastre, 2011. (Medina and García-Sastre 
2011) 
 
2.1.4. Antigenic “Drift” and “Shift” 
Although influenza viruses have been circulating for generations, they retain the 
potential of being highly infectious through their ability to evade the host immune 
system. HA and NA surface glycoproteins, which are the major targets of the protective 
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immune response, are prone to antigenic evolution through repeated processes of 
antigenic drift and antigenic shift.   
Antigenic drift refers to subtle modifications in the antigenicity of HA and NA by point 
mutations within their antibody-binding sites. On average, it occurs every 2 to 8 years 
in response to selection pressure to evade host immunity (Smith et al. 2004, Plotkin, 
Dushoff and Levin 2002, Koelle et al. 2006).  Most of the mutations are ‘silent’, 
whereby they do not change the conformation of the viral proteins; however, some 
mutations may result in altered conformation such that the binding efficacy of the host 
antibody is impaired. Subsequently, the infecting viruses can no longer be inhibited 
effectively by host antibodies raised to previously circulating strains, allowing rapid 
transmission of the virus among the population (Webby and Webster 2001). Antigenic 
drift has been reported to occur in all strains of influenza A and B viruses. In contrast, 
antigenic shift, which involves the genetic reassortment of the eight gene segments, has 
been observed only in influenza A viruses.  Genetic reassortment (mixing of genetic 
material between different viral strains) can occur as a result of co-circulation of 
different influenza A subtypes or co-infection of influenza A subtypes from different 
species, a process with the potential to produce novel subtypes with substantial 
antigenic changes in HA (less frequently, NA) (Carrat and Flahault 2007). Emergence 
of these novel subtypes may lead to an influenza pandemic in a population with little or 
no immunity. The novel H1N1 swine origin influenza virus is a recent example 
whereby reassortment of two swine viruses, each of which ultimately arose from 
interspecies transmission resulted in a novel influenza subtype that has efficient human-
to-human transmission (Christman et al. 2011). Furthermore, these novel subtypes 
remain susceptible to antigenic drift. Currently, there remains the concern that the 
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HPAI H5N1 and SOIV may undergo antigenic drift and result in new strains that allow 
human-to-human transmission or increased virulence respectively (Smith et al. 2006).    
2.1.5. Antivirals Treatment 
There are two classes of antiviral agents available for influenza treatment and 
chemoprophylaxis, the adamantanes (amantadine and rimantadine) and neuramidase 
inhibitors (oseltamivir and zanamivir). The adamantanes are active against influenza A 
viruses, while neuramidase inhibitors are active against both influenza A and B viruses. 
The WHO recommends the administration of antiviral agents to the contacts and 
residents within the containment zone in the face of influenza pandemic (WHO 2007). 
Prophylactic treatment should be initiated within the first 24-48 h following exposure, 
preferably within the first 12 h.  
The adamantanes are the first drugs used against influenza and they act by inhibiting 
the action of the M2 ion channel protein, thus preventing the influx of hydrogen ions 
into the virus to create an acidic environment required for virus uncoating. There are 
advantages to stockpiling of adamantane for treatment of influenza; long shelf life of 
more than 25 years and low cost. However, adamantanes are no longer the drug of 
choice for treatment against influenza as they possess several limitations. Firstly, they 
are neurotoxic and adverse side effects involving the central nervous system may 
surface upon administration. Secondly, adamantane resistance emerges rapidly during 
treatment and resistant viruses are fully pathogenic and transmissible. Lastly, M2 gene 
mutations were reported in recent isolates of A/H5N1 from the Indochina clade in 
Cambodia-Thailand-Vietnam, thus rendering the adamantanes ineffective in the 
treatment and prevention of this emerging epidemic (Li et al. 2004).  
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Neuramidase inhibitors act by binding to the active site of NA and thus prevent viral 
release. Currently, they are replacing adamantanes as the preferred antiviral agent for 
treatment against influenza as there is little evidence of naturally occurring resistance to 
neuramidase inhibitors until recently. Oseltamivir-resistant viruses with neuramidase 
mutations (H274Y and N294S) isolated from patients have been reported to be highly 
pathogenic in mammalian species (Le et al. 2005, Yen et al. 2007). Despite variable 
efficacies of the neuramidase inhibitors in the treatment of influenza infections, 
neuramidase inhibitors are the most commonly prescribed for seasonal influenza and 
are being stockpiled in the global plan against pandemic influenza. Oseltamivir 
treatment is advised for all suspected cases of human influenza infection up to 3 days 
following symptom onset. Aside from the relatively lower levels of serum zanamivir 
and lack of its treatment data for H5N1 infections in humans, oseltamivir is generally 
preferred for its ease of administration through the oral route and theoretically more 
effective when there is systemic infection of severe pneumonia which could potentially 
impair penetration of the inhaled zanamivir (SS and KY 2006). Initial observations 
have suggested the time to initiate drug treatment and drug dose to be critical in the 
amelioration of the disease (Andrade et al. 2009). However, it is important to note that 
patients with influenza-like illness early in the course of the disease often do not seek 
immediate medical attention and patients in remote or rural areas of developing 
countries often have delayed access to medical services, which may in turn lead to the 
delay in the commencement of treatment. 
Therefore, current antiviral drug regimes against influenza still pose several challenges 
and these may not be easily overcome with the constant antigenic evolution of influenza 
viruses.  
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2.1.6. Clinically Approved and Experimental Influenza Vaccines 
Vaccination still remains as the most cost-effective primary prevention against 
influenza infection. Currently, there are two forms of clinically approved influenza 
vaccines available in the market, conventional inactivated virus vaccine and live 
attenuated vaccine. However, the rapid evolution of influenza A viruses have proved to 
be a major challenge to the protective efficacies of these vaccines in humans. Influenza 
vaccines are designed and formulated annually by the World Health Organization 
surveillance network in order to match the circulating strain. However, the time lag 
between vaccine production in eggs and seasonal flu outbreaks (often 6 months or more) 
may result in a mismatch between the vaccine strains and circulating virus. There are 
several limitations to vaccine production in eggs. Firstly, the process is slow as the eggs 
generally need an incubation of about half a year. Secondly, there is an inefficient 
vaccine yield with an average of one to two eggs for a single dose of vaccine. Thirdly, 
inconsistency in production is observed whereby inoculated eggs may not survive or 
they may also produce the virus at varying rates (Bond 2009). Furthermore, allergies to 
egg albumins may develop in immunized individuals. Therefore, other technologies of 
vaccine production are being researched including the mammalian cell-based vaccine 
production and recombinant vaccines by genetic engineering,  
2.1.6.1. Conventional Inactivated Vaccines 
The conventional inactivated vaccine (CIV) is a trivalent vaccine derived from 
formalin-inactivated, high yield reassortant viruses whose internal genes are from a 
A/PR/8/34 high yield donor parent and HA and NA originating from recently prevalent 
influenza A and B viruses predicted to cause widespread infection. The vaccine is 
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available in whole, split (chemically disrupted) and subunit (purified surface 
glycoproteins) formulations and administered intradermally or intramuscularly. 
Vaccination with CIV induces robust serum antibody responses but poor mucosal IgA 
antibody and weak cell-mediated immunity.  
There are several factors that affect the serologic response to the vaccine; the age of the 
recipient and previous exposure to influenza virus. Protective efficacy of CIV against 
influenza infection has been 70-90% in studies of vaccinated military personnel but 
highly variable (0-80%) in high-risk categories (very young and elderly) (Gross et al. 
1977). This could be due to the immune status of the recipient during vaccination. 
Studies have observed that prior exposure to influenza virus before vaccination will 
prime the vaccine recipient in inducing protective levels of serum anti-HA antibodies 
that prevent infection (Wise et al. 1977). Generally, serum anti-HA antibodies are low 
after a single dose of vaccine but increase significantly in response to a second dose. 
The boost effect may be attributed to the induction of greater B-cell memory as a result 
of cross-reactive helper T-cell population induced during prior infection and 
vaccination (Johansson, Moran and Kilbourne 1987, Rasmussen et al. 2001, 
Lanzavecchia 1985). 
Furthermore, one of the major limitations of the CIV vaccine is its inability to protect 
against infection with a heterovariant virus. Effective protection will occur only if HA 
of the vaccine strain closely matches the antigenic structure of HA expressed by the 
circulating strain. During the 2003-2004 influenza season, a mismatch in the antigenic 
structure of HA in the seasonal flu vaccine led to an increase in incidence of influenza 
(Besselaar et al. 2004). 
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2.1.6.2. Live Attenuated Vaccines 
Live attenuated virus vaccine (LAIV) is derived from the master donor virus (MDV) 
strain, ca A/Ann Arbor/6/60 or ca B/Ann Arbor/1/66 containing temperature sensitive, 
cold-adapted and attenuation mutations in several genes coding for internal proteins and 
contains the HA and NA from a vaccine candidate strain. Cold-adaptation of the master 
donor virus was predicted to result in changes to its genetic makeup making it less fit to 
replicate at normal and elevated body temperatures, thereby attenuating the strain. 
Furthermore, reversion to virulence is highly unlikely as the attenuation of LAIV is 
polygenic. Alike the conventional inactivated virus vaccine, LAIV is a trivalent vaccine 
of A/H1N1, A/H3N2, and B, each recommended annually by the U.S. Public Health 
Service to antigenically match the strains expected to circulate in the upcoming 
influenza season.  
Administration of LAIV is via the nasal route and mimics natural infection by influenza 
virus. Natural infection with wild-type influenza virus is known to elicit a strong 
immunological memory that protects the individual from subsequent re-infections with 
the same or similar, strain of influenza for decades. Unlike CIV, LAIV is capable of 
inducing a broader and more robust immune response and this effect is more 
pronounced in young children with no previous exposure to influenza virus. In 
particular, studies have reported high seroconversion rates of 80-90% in LAIV-
vaccinated young children who are seronegative for influenza at the time of vaccination 
(Belshe et al. 2000b, Lee et al. 2004, Mendelman et al. 2004). Furthermore, a variety of 
immune response effector types to LAIV have also been documented in young children 
which includes secretory IgA in nasal secretions, IgG and IgA antibody secreting cells 
(ACS) in the circulation (Sasaki et al. 2007, Sasaki et al. 2008), IFN-γ-secreting cells in 
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PBMCs (Forrest et al. 2008) and increased CD4+ and CD8+ influenza-specific T cells 
(He et al. 2008b, He et al. 2006, He et al. 2008a). Also, immunity elicited by LAIV may 
provide a larger margin error for antigenic mis-matching as LAIV has been shown to 
protect against significantly antigenically drifted variants in several clinical settings 
(Belshe et al. 2000a, Belshe et al. 2007, Nichol et al. 1999). Besides its ability to elicit a 
more robust immune response, one dose of LAIV represents less than approximately 1% 
of an inactivated (15µg) vaccine dose of antigen which translates into the potential to 
produce large amounts of bulk LAIV as compared to CIV.  
However, there remains a critical limitation in the use of LAIV. LAIV is labelled for 
use only in healthy non-pregnant individuals 2 to 49 years of age; consequently, it 
cannot be used in patients at high risk for influenza morbidity and mortality. Also, there 
are a number of potential safety concerns raised on the use of LAIV; the close 
proximity of the site of administration to the central nervous system (CNS) that may 
lead to vaccine-induced CNS complications (Fenichel 1982), spontaneous mutations in 
the vaccine strain and reassortment between the vaccine strain and another influenza 
virus which has infected the recipient at the time of vaccination to produce a new 
potential pandemic strain. 
2.1.6.3.  Alternative Vaccine Delivery Systems 
As mentioned in Section 2.1.6, the outdated technology of vaccine production in eggs 
urgently requires innovation and improvement. In recent years, there has been ongoing 
research on alternative vaccine delivery systems that will allow vaccine production to 
be both time- and cost-effective and eliminates the need to handle pathogenic viruses or 
to adapt the viruses to grow in eggs or cells (Figure 2-2).  
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Figure 2-2 New Approaches to Influenza Vaccine Production. 
Adapted from Lambert LC and Fauci AS, 2010. (Lambert and Fauci 2010) 
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2.1.6.4. Recombinant Proteins 
There are several potential systems that can be exploited for the production of 
recombinant HA proteins which include insect cells, plants, yeast, bacteria and 
chemically synthesized peptides (Figure 2-2A). Of all, the insect cell culture system is 
the most advanced in its development in influenza vaccine production.  
In the insect cell culture system, upon selection of the influenza vaccine strains, the 
genes encoding the HA proteins are cloned into the baculovirus (BV) vectors. The gene 
of interest is inserted in-frame into the polyhedrin gene, an abundant protein of the 
natural BV virus. Expression of the polyhedrin gene is controlled by a strong promoter, 
which drives the synthesis of the recombinant HA proteins. The recombinant BV 
vectors are then introduced into insect cells. Infected insect cells express HA proteins, 
which are then purified and formulated into trivalent vaccines (Treanor et al. 2006). 
Currently, there are several companies that are working on insect cells as vectors for 
making recombinant HA protein, of which Protein Sciences and Novavax are major 
players in the market. The potential in this system is seen in a recombinant trivalent HA 
protein–based influenza vaccine which is in the late stages of clinical development in 
the United States. Safety, immunogenicity, and efficacy profile of this vaccine have 
been reported, and an application has been submitted to the Food and Drug 
Administration for its approval for use in healthy individuals aged 18 years and older 
(Treanor et al. 2007). 
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2.1.6.5. Virus-like Particles (VLPs) 
Insect cell-culture based systems can be further exploited in the production of non-
infectious virus-like particles (VLP). This system approach is employed by Novavax in 
its co-expression of influenza virus’s surface glycoproteins, HA, NA and M1 protein 
(structural protein involved in viral assembly and budding). The resultant proteins will 
then spontaneously self-assemble at the plasma membrane and bud from infected cells, 
forming empty particles that resemble wild-type influenza virus (Figure 2-2B). This is a 
promising approach whereby a lower dose is shown to protect against infection in a 
mouse model as compared to the recombinant HA protein (Bugliarello 2006). Several 
VLPs have shown potential in animal studies and a few have entered the early stages of 
clinical trials (Kang et al. 2009).    
2.1.6.6. Viral Vectors 
Viruses that are incapable of replication or that replicate but cannot cause disease have 
been explored as potential vectors to deliver influenza antigens to the host immune 
system (Figure 2-2C). To date, several carrier viruses have been used for expression of 
influenza HA genes, including adenoviruses, alphaviruses, vaccinia virus, Newcastle 
disease virus, baculovirus and vesicular stomatitis virus. 
Adenovirus was first isolated from the human adenoids (tonsils) and most people within 
the population have antibodies against the virus. Attenuation of adenoviruses for use as 
vectors can be achieved through removal of part of their genomes such that the virus is 
unable to replicate unless the host cell provides the missing portion of the genome 
(usually the E1 genes) (Figure 2-3a). Adenoviruses are attractive carrier viruses as they 
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have a high affinity for infecting dendritic cells, which are the antigen presenting cells 
that carry antigens to the lymph nodes for presentation to naïve CD4+ T cells (Rea et al. 
1999). Therefore, proteins expressed by an adenovirus may be rendered more 
immunogenic. Furthermore, pre-existing immunity to adenovirus do not seem to have a 
significant impact on the resultant HA—specific immune response (Vemula and Mittal 
2010). Recently, a non-replicating adenovirus-vectored nasal influenza vaccine 
produced by Vaxin has completed the initial phase I clinical trials with demonstrated 
safety and serological response.  
Another well-studied virus-vector system is that of the alphavirus. Generally pathogenic 
for horses, alphavirus overcomes the limitation encountered with adenovirus whereby 
humans are not the natural host for alphavirus; therefore, humans do not have pre-
existing immunity against this virus. Alphaviruses have a unique two-component 
expression system whereby the early and late genes are expressed separately and 
influenza antigen can be inserted into the RNA of the late genes for expression. The 
early genes encode the nonstructural proteins that are translated upon viral entry into 
the cytoplasm and are involved in the transcription and replication of viral RNA 
whereas the late genes encode the structural proteins responsible for viral RNA 
encapsidation and final assembly into enveloped particles (Figure 2-3b) (Rayner, Dryga 
and Kamrud 2002). Systemic delivery of alphavirus-vectored viral antigens has been 
shown to elicit strong antibody responses in immunized mice, swine and primates 
(Lundstrom 2003, Erdman et al. 2010). In 2007, Alphavax, the leading company in 
alphavirus-vectored technology reported safety and serological response of the 
alphavirus-vectored influenza vaccine in Phase I clinical trials (Smith 2007).  
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Figure 2-3 Schematic diagram of viral-vectored gene delivery.  
(a) Adenovirus vector. (b) Alphavirus Adapted from Dubensky, Polo and Liu, 1998.  
(Dubensky, Polo and Liu 1998)  
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2.1.6.7. DNA-based Vaccines 
Research on DNA vaccination has been in progress for more than 20 years but data 
generated from human clinical trials have been disappointing (Drape et al. 2006, Jones 
et al. 2009, Smith et al. 2010) despite encouraging results from animal experiments 
(Kim and Jacob 2009, Laddy et al. 2008). The principle of DNA-based vaccines is the 
expression of the antigen of interest into a plasmid vector followed by propagation in 
E.coli (Figure 2-2D). The resultant recombinant plasmid is purified and injected 
intramuscularly as naked DNA or subcutaneously as DNA-coated gold beads. Upon 
injection, DNA is taken up by the host cells and transported to the nucleus for 
expression of the antigen. However, inefficiency of DNA transfer may occur as a result 
of the nucleases and enzymes that break down “free” DNA present in the human body. 
Recently, Ledgerwood and lab has reported the priming potential of DNA vaccines 
whereby a majority of study volunteers who received the DNA vaccine 24 weeks before 
receiving a booster vaccine made from whole, inactivated H5N1 virus produced high 
levels of broadly neutralizing antibodies against the highly variable globular head 
region of HA (Ledgerwood et al. 2011). 
2.1.7. Universal Influenza Vaccine Candidates 
The ideal influenza vaccine would be one that is safe, elicits humoral and cell-mediated 
immunity identical to those triggered during natural infection, provides long-lasting 
protection against homologous and heterologous viruses and can be manufactured 
rapidly on a large scale with consistency during pandemics (Lambert and Fauci 2010). 
Current vaccines rely on raising antibodies against the two major surface glycoproteins, 
HA and NA but as mentioned in Section 2.1.4, they are prone to antigenic drift and shift 
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and thus require annual re-formulation to match the circulating strain of the next flu 
season. 
Studies have been conducted to explore potential “universal” influenza vaccine 
candidates which include the highly conserved external domain of the influenza matrix 
2  protein (M2e), non-structural protein (NS1) and conserved epitopes from the 
influenza nucleocapsid (NP), Matrix 1 (M1), and HA (Du, Zhou and Jiang 2010, Sui et 
al. 2009, Steel et al. 2010). In this section, two “universal” influenza vaccine candidates, 
M2e and NP366-374 epitope will be developed further; detailed discussion of other 
vaccine candidates is beyond the scope of this thesis. 
2.1.7.1. Ectodomain of M2 Protein (M2e) 
The M2 protein was first described by Lamb et al. (Lamb, Lai and Choppin 1981); it is 
produced by translation from a spliced mRNA derived from influenza gene segment 7, 
which also codes for the matrix protein M1.  The M2 protein, a type III integral 
transmembrane protein, functions as a proton-selective ion channel essential in viral 
replication and protection of HA maturation and structural integrity. Upon viral entry, 
via receptor-mediated endocytosis, M2 transport protons across the virus membrane, 
thus reducing the pH of the virion interior. The low pH provides the acidic environment 
required for the dissociation of the matrix protein and the viral ribonucleoprotein (RNP) 
complexes for release of RNPs into the cytosol. During infection by HPAI subtypes H5 
and H7, M2 ion channel increases the pH of the trans-Golgi network to prevent 
premature release of newly synthesized HA that may lead to consequent inactivation of 
the progeny virus (Ciampor et al. 1992, Grambas and Hay 1992, Sugrue, Belshe and 
Hay 1990, Iwatsuki-Horimoto et al. 2006). Although scarcely present on viral particles, 
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M2 protein is highly abundant on the surface of viral-infected cells. The M2 protein 
exists as homo-tetramers formed by two disulfide-linked dimers in its native form and 
each monomer is composed of 97 amino acids (Sugrue and Hay 1991, Holsinger and 
Lamb 1991).  There are three structural domains to the M2 protein; the N-terminal 
extracellular domain (M2e), transmembrane domain (TM) and a cytoplasmic domain 
(Figure 2-4). 
M2e, which consists of the N-terminal 24 residues, is remarkably conserved, and the N-
terminal epitope SLLTEVET (residues 2 to 9) is conserved among all subtypes of 
influenza A viruses. Nevertheless, 5 amino acid positions within the region of amino 
acids 10-20 were shown to be host restricted (Table 2.1). The sequence conservation of 
M2e may be attributed to the following reasons; no significant immune selection 
pressure as M2e induces no or weak and transient immune response upon infection 
(Black et al. 1993, Liu, Li and Chen 2003, Feng et al. 2006) or its close genetic relation 
with M1 which is the most conserved protein of the influenza virus (Ito et al. 1991). 
The first 8 amino acid of M2e are identical to the N-terminus of M1 and therefore come 
under the same sequence constraint as the latter. 
The primary attribute of M2e as an influenza vaccine antigen candidate lies in its highly 
conserved amino acid sequence. M2e-specific antibodies have a high affinity for virus 
infected cells and act via antibody dependent cell cytotoxicity (ADCC), and mediate the 
killing of infected cells by the complement or cells of the innate immune system, 
natural killer (NK) cells (Mozdzanowska et al. 1999). Also, M2e-specific antibodies 
have been shown to bind virus to the cell and prevent release of viral contents into the 
extracellular fluid and enhance the uptake by phagocytic cells via the Fc receptor 
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(Subbarao and Joseph 2007).  However, M2e is poorly immunogenic in its native form 
and has to be coupled to an appropriate carrier to be rendered immunogenic. Neirynck 
and group first demonstrated the potential of M2e as an influenza vaccine candidate 
through coupling of M2e to the N-terminus of HBc particle, a VLP formed by the 
hepatitis B virus (Neirynck et al. 1999). The vaccine was shown to induce a potent 
immune response, as measured by the level of serum antibodies reacting with the M2e 
peptide. Furthermore, vaccination of mice, followed by a lethal challenge with a mouse-
adapted virus strain provided complete protection. Also, morbidity was considerably 
reduced as measured by the reduction of body weight loss, temperature drop and viral 
load in the lungs. The vaccine could be further improved through the expression of 
multiple M2e-sequences in tandem which induced a higher titer of M2e-specific 
antibodies which even exceeded the HBc-directed titer (De Filette et al. 2005). 
Intranasal administration of the M2e-VLP in combination with a mucosal adjuvant, 
CTA1-DD was also shown to induce high levels of M2e-specific antibodies and 
provide full protection against a lethal viral challenge (De Filette et al. 2006). Other 
potential carriers for M2e have been reported and include the tetrameric domain of 
GCN4 (General Control Nondepressible 4) (De Filette et al. 2008), N-terminus of the 
truncated HSP70 molecule of Mycobacterium tuberculosis (Ebrahimi et al. 2010, 
Ebrahimi and Tebianian 2010), toll-like receptor 5 (TLR5) ligand Salmonella 
typhimurium flagellin type 2 (STF2) (Huleatt et al. 2008), papaya mosaic virus (Denis 
et al. 2008), human papillomavirus (Ionescu et al. 2006) and phage Qβ-derived VLPs 
(Bessa et al. 2008). 
The potential of M2e as an influenza vaccine candidate in preclinical trials has been 
translated into clinical trials. Currently, several M2e-based vaccine constructs are 
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undergoing clinical trials for evaluation of their safety and immunogenicity profiles. 
Sanofi Pasteur Biologics Co., formerly Acambis (Massachusetts, USA) has carried out 
a Phase I clinical trial in which preliminary data have shown that ACAM-FLU-A (M2e-
HBc fusion protein) is safe and immunogenic with no serious side effects (Fiers et al. 
2009). VaxInnate Corp, (New Jersey, USA) has also announced in its Phase I clinical 
trial study that M2e-flagellin fusion influenza vaccine, at 0.3 and 1.0µg doses, is safe 
and well-tolerated in all healthy young volunteers, aged 18-49 and immunogenic in 75% 
vaccinees after the first dose and 96% after the second dose (VaxInnate).  
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Figure 2-4 Structural domains of M2 protein. 





Table 2.1 M2e amino acid sequences (position 10-20) in different host species 
The 5 amino acids, highlighted in bold, are determined by host specificity (Liu et al. 
2005).    
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2.1.7.2. Nucleocapsid Protein (NP) 
Cytotoxic T lymphocytes (CTLs) play an important role in host defense against 
intracellular pathogens such as viruses through recognition and elimination of virus-
infected cells (Yap, Ada and McKenzie 1978). In situations where humoral immunity is 
not or poorly protective against the circulating strain, CTLs may offer some degree of 
protection against infection and may have an impact on disease severity and mortality. 
However, it is important to note that a CTL response is unlikely to provide sterilizing 
immunity since infection or uptake of viral antigens by professional antigen-presenting 
cells is a pre-requisite for their activation (Rimmelzwaan, Fouchier and Osterhaus 
2007). Influenza virus-specific CTLs can recognize epitopes that are shared by different 
subtypes of influenza A virus as majority of virus-specific CD8+ CTLs induced upon 
infection are directed against relatively conserved viral proteins like the nucleoprotein 
(NP) and M1. This is represented by the cross-reactivity of human CTLs directed to 
human influenza A viruses of the H3N2 subtype with avian influenza A viruses of the 
H5N1 subtype.    
NP, the major viral protein, makes up about 30% of the total virion protein content 
(Lamb and Krug 2001). It is highly conserved and does not evolve much from one 
subtype to another (Shu, Bean and Webster 1993). Evidence in support of a protective 
role of NP-specific CTLs against influenza infection has been provided through 
vaccination with plasmid DNA expressing NP (Ulmer et al. 1993, Donnelly et al. 1997, 
Ulmer et al. 1996, Ulmer et al. 1998) or NP subunit preparations (Wraith, Vessey and 
Askonas 1987, Tite et al. 1990b, Tite et al. 1990a). Furthermore, since CTLs are 
specific to peptides rather than proteins, it might be more advantageous to use an 
immunodominant CTL epitope as a universal influenza candidate. Different factors, 
Chapter 2 Survey of Literature 
29 | P a g e  
such as immunodominance, HLA restriction of CTL responses, and composition of the 
TCR repertoire appear to play an important role in the selection of the determinants 
recognized by T-cell responses. NP366-374 /Db has been shown to be one of the 
immunodominant CTL epitopes that can induce protection against influenza infection 
in mice carrying Db (Belz et al. 2000b, Belz, Stevenson and Doherty 2000a, Cerundolo 
et al. 1991, Townsend et al. 1986, Zhong et al. 2003). CD8+ T cells specific for NP366-
374 are prominent during the primary response, but after secondary challenge, the NP336-
374-specific CD8+ T cells expand to dominate ~80-90% of all influenza-specific CD8+ T 
cells (Belz, Xie and Doherty 2001, Flynn et al. 1998, Flynn et al. 1999). The ability of 
NP366-374 /Db to induce NP366-374–specific CTLs in vivo was demonstrated by Nomura et 
al. through the immunization of mice with plasmid-transfected cells expressing NP366-
374 (Nomura et al. 1996). Furthermore, intranasal immunization with NP366-374 loaded 
lipsosomes has been shown to effectively induce mucosal immunity that reduced 
influenza A virus replication in the lung (Ninomiya et al. 2002). Adoptive transfer 
studies have suggested that protection against influenza infection conferred by NP366-374 
is primarily mediated by central memory (TCM) CD8+ T cells but not effector CD8+ T 
cells (TEM) (Castiglioni, Gerloni and Zanetti 2004). However, these studies have been 
limited to mouse models and evidence has yet to be provided to demonstrate the role of 
NP366-374 as an immunodominant CD8 epitope in influenza A-infected patients. 
Nevertheless, NP366-374 serves fundamental research as proof of concept studies to 
evaluate expression systems for induction of CTL responses.   
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2.2. Mucosal Vaccines 
2.2.1. Mucosal Immunity 
Mucosal surfaces, with a total surface area of about 400 square meters, represent the 
most common entry site for pathogens. Upon entry into the host, microorganisms can 
establish infection either through secretion of virulence factors or penetration into host 
tissues to cause systemic or organ-specific disease. The mucosal immune system is 
activated in response to infection and confers protection at two levels; (i) prevention of 
initial infection mediated by secretory IgA (S-IgA) antibodies, receptor-mediated 
endocytic activity and antigen presentation by phagocytic cells and, (ii) protection after 
establishment of infection through the production of systemic IgG responses and 
activation of cell-mediated responses, primarily the CD8+ and CD4+ T lymphocytes 
(Chadwick, Kriegel and Amiji 2009). With the increasing evidence of the crucial role of 
local mucosal immunity in protection against infectious diseases, mucosal surfaces 
present themselves as attractive targets for vaccine delivery. 
Through innate and acquired immunity, the mucosal immune system provides the first 
line of defence against pathogens at the site of infection. Although innate immunity 
contributes to the control of infections, it alone cannot eradicate the pathogen fully. 
Complementing the innate immunity is the adaptive immunity, which is specific but 
requires a longer time to reach maximal activity. Initiation of antigen-specific immune 
responses occurs mainly at inductive sites; the two most prominent ones are the Peyer’s 
patches located in the gut, and the nasopharynx-associated lymphoid tissue (NALT) 
(Figure 2-5). Microfold (M) cells which are located in the epithelium overlying follicles 
of the mucosa-associated lymphoid tissues deliver luminal antigens to the underlying 
Chapter 2 Survey of Literature 
31 | P a g e  
lymphoid tissues via the process of transepithelial vesicular transport (Nochi et al. 
2007).  Furthermore, antigen sampling may also occur via the direct uptake by lamina 
propria dendritic cells expressing transepithelial dendrites in intestinal villi, and via 
phagocytosis by enterocytes expressing toll-like receptor-4 (TLR-4) (Corthésy 2007). 
Following antigen entry, dendritic cells in the inductive tissues process and present 
newly acquired antigens to naïve T cells. TH2-differentiated CD4+ T cells preferentially 
mediate the activation and differentiation of naïve B cells to immunoglobulin-A (IgA) 
producing plasmocytes.  B cells undergo affinity maturation through the process of 
somatic hypermutation (Fagarasan and Honjo 2004). Following the sensitization of 
lymphocytes at the inductive tissues, antigen-specific T and B cells travel through 
lymph to the thoracic duct and enter the blood circulation, eventually reaching effector 
tissues such as surface epithelia, the lamina propria of various mucosae, and the stroma 
of exocrine glands (Brandtzaeg and Pabst 2004). Upon reaching the effector site, 
cytokines, such as transforming growth factor-β (TGF-β), interleukin-4 (IL-4), IL-5, IL-
6 and IL-10, promote the development into an IgA-secreting plasma cell. 
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Figure 2-5 The common mucosal immune system. 
Luminal antigens are sampled through microfold (M) cells at the nasopharynx-
associated lymphoid tissue (NALT) and Peyer’s patches and presented to dendritic cells 
for processing. Processed antigens are then presented to T cells, which in turn activate 
B cells to an IgA-committed phenotype. Upon immunoglobulin class switching and 
somatic hypermutation, B cells travel through lymph to the thoracic duct and enter 
systemic circulation. Eventually, they will migrate to specific effector tissues where 
cytokines produced by TH2 cells promote the differentiation into a IgA-secreting 
plasma cell. Adapted from Kiyono and Fukuyama, 2004. (Kiyono and Fukuyama 2004)  
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2.2.2. Vaccination by Mucosal Route 
There are several advantages to mucosal vaccination compared to injectable vaccines 
which include protection against diseases acquired through the mucosal and systemic 
route, painless and non-invasive administration procedure, avoidance of blood 
transmissible diseases due to needle re-use and bypass of highly trained personnel for 
administration. First, mucosal vaccination induces antigen-specific IgA antibodies at 
the site of infection. This local pathogen-specific response may be important not only to 
prevent infectious diseases in the vaccinee but also to avoid the subsequent 
transmission of infections to non-vaccinated individuals. S-IgA antibodies, the 
predominant immunoglobulin class in human external secretions are highly resistant to 
degradation in the protease-rich environment of mucosal surfaces due to their 
dimerization and high degree of glycosylation during synthesis in mucosal plasma cells, 
and by its association with a glycosylated fragment (Neutra and Kozlowski 2006). 
There are several functions of S-IgA in mucosal defence which include entrapment of 
antigens or microorganisms to prevent direct contact with the mucosal surface and 
steric hindrance with the microbial surface molecules that mediate epithelial attachment 
(Holmgren and Czerkinsky 2005, Neutra and Kozlowski 2006, Lamm 1997, Hutchings 
et al. 2004). Also, locally produced IgM and IgG, and serum-derived IgG can contribute 
to humoral immune defense at mucosal surfaces (Holmgren and Czerkinsky 2005).  
Mucosal CTL responses have also been shown to be essential in the immune clearance 
of pathogens in several animal models of infection with enteric or respiratory viruses 
and intracellular parasites (Franco and Greenberg 1995, Bender et al. 1992, Buzoni-
Gatel et al. 1997). Other than CTLs, IFN-γ-producing CD4+ T cells have also been 
documented to be important for mucosal immune defense against both bacterial and 
viral infections (Johansson et al. 1987, Johansson et al. 1997, Ermak et al. 1998, 
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Harandi et al. 2001). Mucosal delivery of vaccine candidates has thus been investigated 
and the oral route of administration has received most of the attention. However, rapid 
enzymatic degradation, poor absorption and exposure to low pH in the gastrointestinal 
tract are the obstacles encountered upon oral delivery of the vaccine candidates which 
often results in weak immunogenicity or necessitates high quantity of antigen co-
administered with a strong adjuvant (Garmory et al. 2003). Alternatively, the nasal 
delivery of vaccine candidates has been recently considered and has shown great 
promises. 
2.2.3. Intranasal Vaccination 
Nasal vaccination has been mainly studied and developed to target respiratory 
pathogens. In particular, for influenza infections, a live attenuated influenza virus 
vaccine (Flumist) has since been developed to be delivered intranasally so as to mimic 
natural infection. However, there remain challenges that have to be overcome in the 
development of nasal vaccines. Despite the reduced proteolytic and physical 
degradation compared to the gastric mucosa, high dose of antigens and repeated 
administrations are still required to trigger a strong immune response both locally and 
systemically. Therefore, nasal vaccines must be specifically formulated and optimised 
to induce a favorable immune response and at the same time prevent local irritation and 
other potential adverse effects. Studies have concluded that mucosal application of 
vaccines with an appropriate adjuvant can induce potent immune responses locally and 
systemically to prevent not only infectious diseases but also colonisation at mucosal 
surfaces. Unfortunately, there is a limited number of suitable adjuvants used for nasal 
delivery and some of them have raised safety concerns for use in humans.  As such, 
cholera toxin (CT) has been considered to be the “gold-standard” mucosal vaccine 
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adjuvant. However, mutant B subunit of CT has been documented to redirect the co-
delivered vaccine antigen to the olfactory nerve and bulb of the brain in mice, raising 
safety concerns when the brain is not the target organ (Armstrong et al. 2005). 
Escherichia coli heat-labile toxin (LT) has also been shown to display adverse side 
effects in humans, whereby both native and mutant LT (mLT) used as adjuvants were 
recently linked with the development of Bell’s palsy upon intranasal delivery (Couch 
2004, Lewis et al. 2009, Mutsch et al. 2004).  To overcome these limitations, the use of 
bacteria as live vectors to deliver heterologous vaccine antigens at the nasal mucosa has 
been more recently developed (Thole et al. 2000). Indeed, bacteria adapted to the 
respiratory tract can provide sustained production of the heterologous vaccine candidate 
thereby allowing efficient priming of the host immunity. Besides, live attenuated 
bacteria have intrinsic adjuvant activity as they replicate and have the ability to 
penetrate host tissues (Hantman et al. 1999). Therefore, recombinant live attenuated 
bacteria carrying heterologous antigens can act not only as vaccine delivery vehicle but 
also adjuvant at the same time. 
Animal model studies have demonstrated the potential of intranasal vaccination in 
eliciting both humoral and cell-mediated protection, which provide protection not only 
at the site of infection, but also throughout the body. Studies in mice, monkeys and also 
humans, have shown that intranasal administration of vaccines elicited specific mucosal 
IgA antibody responses in the salivary glands, upper and lower respiratory tracts, male 
and female genital tracts, as well as in the small and large intestines (Imaoka et al. 1998, 
Kozlowski et al. 2002, Rudin, Riise and Holmgren 1999, Staats, Montgomery and 
Palker 1997). Also, higher systemic antibody response has been detected in nasal 
immunization studies in humans and mice as compared to other mucosal immunization 
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routes, presumably due to antigens or APCs readily trafficking to draining lymph nodes 
from this site (Kozlowski et al. 2002, Staats et al. 1997). Immunization via the nasal 
route can also induce CTLs in distant mucosal tissues (Gallichan and Rosenthal 1998). 
Moreover, nasal immunization with certain live viral vectors has been shown to induce 
systemic antiviral CTLs and IgG comparable to those induced upon parenteral 
vaccination (Egan et al. 2004, Enose et al. 2002). 
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2.3. Bordetella pertussis Microbiology 
2.3.1. Re-emergence of Whooping Cough 
Whooping cough (“le Microbe de la coqueluche”) is one of the leading causes in infant 
mortality, accounting for 300,000 to 400,000 deaths per year. The first epidemic was 
reported by Guillaume de Bailou in 1943 (Lapin 1943). A classical hallmark of the 
disease is its longevity, usually lasting several weeks with gradually decreasing 
frequency and severity (Carbonetti 2007a).  
Whooping cough is most severe in young infants, yet vaccination against this disease 
begins no earlier than 6 weeks of age and frequently as late as 3 months of age, 
depending on the local vaccination schedule. The window of susceptibility to the 
disease may be prolonged further due to suboptimal compliance with recommended 
vaccination schedules (Grant et al. 2003). Generally asymptomatic in older children, 
adolescents and adults, the disease usually manifests as a persistent, chronic cough of 
varying severity after bacterial clearance.   
Despite wide vaccination coverage, whooping cough remains endemic and reports of 
increasing incidence in Australia (Andrews, Herceg and Roberts 1997), Canada (De 
Serres and Duval 2005) and Europe (Celentano et al. 2005) have been accumulating for 
the past twenty years. The resurgence of pertussis is believed to be due to the waning 
effects and sub-optimal efficacy of the vaccine in adults, resulting in household 
transmission to vulnerable infants, and calling for a reinforcement of the pertussis 
vaccination strategies. In addition, antigenic shift and adaptation of the B. pertussis 
circulating strains to the acellular vaccines may also account for the resurgence of 
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whooping cough (Mooi, van Loo and King 2001). Several measures to counteract the 
pertussis resurgence include the introduction of vaccine booster for adolescents in 1998, 
the “cocoon strategy” vaccination program in 2004 and a vaccine booster, still keeping 
the “cocoon strategy”, for 26- and 27-year old individuals on 2008 in France (Guiso 
2009).  
2.3.2. Clinical Manifestations and Complications of Bordetella pertussis 
Infection 
The classical disease symptom is a convulsive cough with whooping and vomiting, 
which is most commonly observed in unvaccinated infants. There are three stages to the 
pertussis disease development, namely (1) catarrhal, (2) paroxysmal and (3) 
convalescent (Wood and McIntyre 2008). The disease is characterized by the onset of a 
non-specific cold which lasts for 1 – 2 weeks. The next stage proceeds with a 
spasmodic cough, post-tussive vomiting and inspiratory whoop which persist for 4 – 6 
weeks followed by the convalescent stage when symptoms start to improve over 1 – 2 
weeks.  Temporary cessation of breathing is another frequent clinical manifestation 
observed in infants. 
Besides the display of classical symptoms of pertussis, complications may also occur in 
non-immune infants. These include pneumonia, cerebral hypoxia, seizures, 
encephalopathy, pulmonary hypertension, subconjunctival haemorrhage, rectal prolapse 
and secondary respiratory infections (Crowcroft and Pebody 2006). 
Although little is known on the airway pathology in non-fatal cases, mucus 
hypersecretion is often reported in non-fatal cases. Histopathological analysis from 
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postmortem observations, experimental animal infections and organ culture 
experiments include epithelial and ciliary damage, bronchopneumonia, pulmonary 
edema and focal hemorrhage (Carbonetti 2007a). 
2.3.3. The Bacterium - Bordetella pertussis 
Bordetella pertussis, the causative agent of whooping cough, belongs to the Bordetella 
genus. There are 3 species within the genus that have been extensively studied on, 
including B. pertussis, B. parapertussis and B. bronchoseptica. Phylogenetic studies of 
these 3 strains suggest that B. pertussis and B. parapertussis may have originated 
independently from a B. bronchoseptica ancestor through genome reduction with large-
scale rearrangements (Preston et al. 2007).  
B. pertussis, a gram-negative, aerobic ovoid bacterium, was first isolated by Jules 
Bordet and Octave Gengou in 1906 from the expectorate of Bordet’s son, Paul, using a 
particular medium, “Bordet-Gengou (BG) medium” (Bordet and Gengou 1906). Being 
a strict human pathogen, it is highly labile and cannot survive outside its host.  B. 
pertussis produces a variety of virulence factors, including adhesins and toxins to 
facilitate establishment and transmission of disease (Figure 2-6).  
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Figure 2-6 Virulence determinants of B. pertussis 
(Adapted from AlisonWeiss, ASM News, 1997) 
 
2.3.4. Pertussis Pathogenesis 
Establishment of the disease occurs in 2 phases, (1) initial colonization stage and (2) 
toxemic stage.  Disease transmission is through the inhalation of respiratory droplets 
from cough of infected individual. Upon inhalation, the bacteria attach to the ciliated 
epithelial cells of the trachea and nasopharynx and begin replication. Once established 
in the respiratory airways of the host, the toxemic stage sets in whereby toxins released 
damage the epithelial lining, resulting in the loss of ciliated cells which induces the 
characteristic coughing. These toxins also allow the bacterium to evade the host 
immune response by interfering with clearance mechanisms, halting ciliary function, 
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short-circuiting host G protein signalling apparatus and inhibiting immune cell function 
by upregulating cAMP levels (Smith, Guzmán and Walker 2001). 
Expression of the virulence factors in B. pertussis is regulated by a two-component 
signal transduction system known as the Bordetella virulence gene (bvg) locus. The bvg 
locus  encodes two proteins, histidine kinase sensor protein (BvgS) and DNA-binding 
response-regulator protein (BvgA) which allow the bacterium to ‘sense’ and ‘respond’ 
respectively, to specific yet unidentified environmental parameters by controlling the 
expression of more than a hundred genetic loci (Parkinson and Kofoid 1992). At high 
temperatures (above 25oC) and in the absence of MgSO4 and nicotinic acid, BvgA/S 
system activates the Bvg+ phase to promote transcription of virulence genes during the 
infection process by a series of phosphotransfer reactions (Figure 2-7). The reaction is 
initiated by the autophosphorylation of BvgS at the first conserved histidine residue 
with ATP as a donor. The phosphate is transferred to an aspartate within the 
cytoplasmic domain of BvgS, followed by transfer to the second conserved histidine in 
the C-terminal subdomain of BvgS. Termination of reaction occurs at the transfer of the 
phosphate group to the N-terminal receiver domain of BvgA which increases the 
affinity of BvgA for target DNA sequences located within promoter regions of the 
virulence genes, which then activates the transcription of these genes (Locht 1999). 
Also, the BvgA/S system represses the expression of another set of genes known as 
vrgs (Virulence Repressed Genes) by expression of an intermediate regulatory gene, 
bvgR which is under the transcriptional control of BvgA. In this section, three virulence 
factors will be developed further, namely filamentous hemagglutinin (FHA), Bordetella 
resistance killing antigen (BrkA) and adenylate cyclase toxin (CyaA); detailed 
discussion of other virulence determinants are beyond the scope of this thesis.  
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Figure 2-7 Bvg two-component system. 
(A) Detection of a periplasmic stimulus activates BvgS and leads to the transfer of a 
phosphate group from a donor (probably ATP) to BvgS. The phosphate group is relayed 
along BvgS and ultimately to BvgA. Phosphorylated BvgA has transcriptional regulator 
activity and activates the transcription of several genes. This Bvg-active state is referred 
to as the Bvg+ phase. (B) When the system is silent, the bacteria adopt the Bvg phase 
that is characterized by the expression of a subset of Bvg phase-specific genes. The 
identification of an intermediate phase (Bvgi) that includes the expression of Bvgi-
specific genes indicates that Bvg regulates a spectrum of responses. The figure lists 
factors that are expressed at each Bvg phase. Vrg, vir-repressed genes. Adapted from 
Preston A, Parkhill J andMaskell DJ, 2004) (Preston, Parkhill and Maskell 2004) 
  
(B) 
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2.3.4.1. Filamentous hemagglutinin 
Filamentous hemagglutinin (FHA) is a major adhesin molecule produced by B. 
pertussis that mediates adherence to the ciliated epithelial cells in the host respiratory 
tract. As one of the early genes expressed in the virulent (Bvg+) phase, it responds 
rapidly to activation and requires a lower concentration of phosphorylated BvgA for 
induction. It is produced as a 367-kDa precursor protein named FhaB. Approximately 
one third of the C-terminus of FhaB is proteolytically cleaved by SphB1, a specific 
protease of the subtilisin superfamily to obtain the biologically active FHA (Coutte et al. 
2001, Siezen and Leunissen 1997). 
Majority of the mature FHA remains non-covalently associated to the cell surface with 
a small proportion being secreted into the extracellular milieu. Association of mature 
FHA to the bacterial cell surface is mediated via interactions between its N-terminal 
domain and a translocation-mediating protein called FhaC (Mazar and Cotter 2006). 
FhaC transporter is a member of the outer membrane protein 85-two-partner secretion 
B (Omp85-TpsB) superfamily, commonly used in Gram-negative bacteria for secretion 
of large virulence proteins (Clantin et al. 2007). FhaC facilitates secretion through the 
formation of a transmembrane β-barrel that serves as an FHA-specific pore in the outer 
membrane (Guédin et al. 2000, Jacob-Dubuisson et al. 1999). Through binding to the 
POTRA 1 domain of FhaC, FHA is translocated in an extended hairpin conformation, 
with folding occurring at the cell surface (Clantin et al. 2007). Recent data have also 
indicated the role of periplasmic chaperone/protease DegP in FHA transport across the 
cytoplasmic membrane (Baud et al. 2009).   
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Secretion of FHA is critical for disease establishment as a SphB1-deleted mutant was 
shown to be highly attenuated in its ability to colonize murine lungs despite an 
enhanced ability to bind to pulmonary epithelial cells.  Transport of mature FHA across 
the cytoplasmic membrane is mediated by a Sec-signal dependent pathway whereby the 
signal peptide (SP) at the N terminus of FhaB is cleaved prior to transport (Jacob-
Dubuisson et al. 1996). As previously mentioned, a portion of the C-terminal precursor 
is removed to yield the mature FHA. Although the C-terminal is not part of the mature 
protein, it is important in the secretion of full-length FHA (but not truncated analogs), 
probably as an intramolecular chaperone to stabilize the protein and prevent incorrect 
folding (Renauld-Mongénie et al. 1996). 
Interaction of FHA with host cell is mediated by the action of multiple binding domains 
including an Arg-Gly-Asp (RGD) domain, a carbohydrate recognition domain (CRD), a 
glycosaminoglycan-binding site (GBD) present on host cell surfaces, a potential 
integrin-binding domain, and its mature C-terminal domain (MCD), located distally 
from the cell surface (Mazar and Cotter 2006). The Arg-Gly-Asp (RGD) triplet 
stimulates adherence to monocytes/macrophages and possibly other leukocytes via the 
leukocyte response integrin/integrin-associated protein (LRI/IAP) complex and 
complement receptor type 3 (CR3) (Ishibashi, Claus and Relman 1994, Relman et al. 
1990, Saukkonen et al. 1991). Specifically, the RGD motif of FHA has been implicated 
in binding to very late antigen 5 (VLA-5; an α5β1 integrin) of bronchial epithelial cells 
(Relman et al. 1990). The CRD domain of FHA mediates attachment to ciliated 
respiratory epithelial cells as well as to macrophages in vitro (Prasad et al. 1993).  The 
glycosaminoglycan-binding domain (GBD) allows B. pertussis to bind to heparin and 
dextran sulphate and this property has been exploited in the one-step purification of 
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FHA using heparin sepharose (Hannah et al. 1994, Menozzi et al. 1994). Figure 2-8 
shows the schematic drawing of FHA and its functional domains. 
FHA is a highly immunogenic molecule with the ability to trigger high levels of 
mucosal and systemic antibodies upon B. pertussis infection in mice (Cahill et al. 1995) 
and humans (Isacson et al. 1995). This attractive attribute has led to the inclusion of 
FHA in most acellular pertussis vaccines. In addition, FHA is also known to possess 
adjuvant properties for co-delivered antigens (Poulain-Godefroy et al. 1998, Poulain-
Godefroy et al. 2003), thus making it an attractive candidate as a carrier in the 
development of systems for heterologous antigen delivery by B. pertussis. The potential 
of FHA as a vaccine carrier is discussed in further detail in Section 2.3.6.1. 
 
 
Figure 2-8 Post-translational processing of precursor FhaB to biologically active 
FHA. 
The N-terminal signal peptide (SP) and C-terminal one-third of the precursor is cleaved 
in the maturation and translocation process of FHA to release the 220-kDa mature 
protein into the extracellular milieu. The various domains and binding sites of mature 
FHA are labeled. RGD, Arginine-Glycine-Aspartate tripeptide motif; CRD, 
carbohydrate recognition domain. 
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2.3.4.2. Bordetella resistance killing antigen (BrkA) 
Bordetella resistance killing antigen (BrkA), one of the virulence factors of B. pertussis, 
contributes to pertussis pathogenesis by conferring serum resistance to killing by 
classical pathway of complement and is involved in adherence and invasion (Fernandez 
and Weiss 1994). Similar to FHA, expression of BrkA is controlled by the bvgAS two 
component system and is produced during the virulent (Bvg+) phase (Weiss et al. 1989).  
BrkA belongs to the autotransporter family which comprises functionally diverse Gram 
negative proteins that mediate their transport across the bacterial outer membrane 
(Desvaux, Parham and Henderson 2004).  The BrkA autotranporter protein is composed 
of three distinct domains; an N-terminal signal sequence, the surface-localized 
passenger domain (α-domain) and a conserved C-terminal translocation domain (β-
domain) (Jose, Jähnig and Meyer 1995) (Figure 2-9). Consistent with the model of 
autotransporter secretion, BrkA is first produced as a 103-kDa precursor that is 
processed during secretion to yield a 73-kDa N-terminal passenger α-domain and a 30-
kDa C-terminal translocation β-domain (Shannon and Fernandez 1999). There are two 
functions to the C-terminal translocation β-domain of BrkA; (a) formation of a β-barrel 
pore in lipid bilayer membranes to allow the transport of the folded passenger domain 
to the bacterial cell surface (Shannon and Fernandez 1999) and (b) facilitation of proper 
folding of the BrkA passenger domain (Oliver et al. 2003b). Following translocation, 
the cleaved passenger domain remains tightly associated with the bacterial surface 
(Oliver, Huang and Fernandez 2003a).  Figure 2-10 shows the detailed steps in the 
processing of autotransporter proteins during secretion.  
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BrkA shares sequence homology with pertactin, another virulence factor produced by B. 
pertussis. Studies have shown the potential of BrkA as a vaccine candidate in which a 
three pertussis-component DTaP vaccine containing PT, FHA and a recombinant BrkA 
protein (rBrkA) was found to be as efficacious in protecting mice against a sublethal 
intranasal challenge with B. pertussis as the commercial Infanrix™ vaccine that 
consists of PT and FHA but pertactin (PRN) instead of rBrkA (Marr et al. 2008). In an 
earlier study, the passenger domain of BrkA was also shown to exhibit adjuvant 




Figure 2-9 Primary structure of an autotransporter protein. 
Domains involved in the secretion pathway are indicated in the above diagram. The aa 
residue numbers are specific for B. pertussis BrkA. (Adapted from Oliver et. al., 2003) 
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Figure 2-10 The autotransporter secretion pathway.  
Step I: the formation of the β-barrel pore at the outer membrane (OM). Step II: the 
linker region is first secreted through the pore. Step III: the autochaperone domain 
triggers the folding of passenger domain. Step IV: the folded passenger domain is 
exposed on the cell surface and released into the extracellular milieu (EM) after 
proteolytic cleavage. For BrkA, the passenger domain remains non-covalently 
associated with the membrane surface. (Adapted from Desvaux et al., 2004) 
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2.3.4.3. Adenylate Cyclase Toxin  
Adenlyate cyclase toxin (CyaA), one of the key virulence factors of B. pertussis, is 
involved in the bacterial colonization of the airways and development of whooping 
cough (Carbonetti 2007b, Locht, Antoine and Jacob-Dubuisson 2001). It is encoded by 
the cyaA gene which is part of an operon that also contains the genes, cyaB, D and E 
required for CyaA transport and secretion (Ladant and Ullmann 1999). Like the major 
toxins and adhesins of B. pertussis, CyaA expression is regulated by the two-
component BvgAS system and produced under the Bvg+ virulent phase.   
The 177 kDa Bordetella adenylate cyclase toxin is a member of the RTX (RTX, Repeat 
in ToXin) family of bacterial pore-forming toxins (Welch 2001). CyaA differs from 
other members of this family by being a protein fusion made of the N-terminal cell-
invasive adenylate cyclase (AC) catalytic domain and the C-terminal RTX hemolysin 
moiety (Figure 2-11). There are two functional regions in the RTX hemolysin moiety; 
multiple calcium binding sites at the C-terminal that confer hemolytic activity and the 
N-terminal part of the hemolysin which is responsible for mediating interaction with 
target host cells and channel formation due to high hydrophobicity and double acylation 
(Fiser and Konopásek 2009).  
First produced as a protoxin, CyaA is post-translationally acylated by CyaC to facilitate 
interaction with mammalian host cells. In vivo studies have suggested that CyaA exerts 
immunosuppressive effects on the innate and adaptive immune system, specifically 
targeting CD11b/CD18 expressing-myeloid cells such as macrophages, neutrophils and 
dendritic cells (Harvill et al. 1999, Gueirard et al. 1998, Guermonprez et al. 2001). The 
glycine and aspartate-rich repeat region, calcium binding and post-translational 
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acylation of the RTX domain mediates the specific binding to CD11b/CD18 host 
receptors and internalization of the enzymatic moiety into the host cells (El-Azami-El-
Idrissi et al. 2003). Upon entry into the cell, the AC enzymatic moiety is activated by 
host calmodulin and subverts cellular signalling by unregulated conversion of ATP to 
cAMP. Intracellular cAMP accumulation yields to suppression of bactericidal activities 
of phagocytes, such as chemotaxis and FcR-mediated phagocytosis, or superoxide 
production (Confer and Eaton 1982, Friedman et al. 1987, Njamkepo et al. 2000, 
Weingart et al. 2000) and eventually leads to apoptosis (Khelef, Zychlinsky and Guiso 
1993). Recent work also suggests the role of AC-induced cAMP signaling in shaping 
the adaptive immune system towards B. pertussis tolerance by driving monocyte-
derived dendritic cells differentiation to a semi-mature state and suppressing production 
of pro-inflammatory cytokines such as interleukin-12 and tumor necrosis factor-α 
(Bagley et al. 2002). In addition, CyaA also plays a role in the modification of a 
heparin-inhibiting carbohydrate binding domain of FHA to enhance in its ability to 
mediate adherence to cultured lung epithelial cells (Perez Vidakovics et al. 2006), 
presumably through a direct interaction between the two factors (Zaretsky, Gray and 
Hewlett 2002). 
 
Figure 2-11 Primary structure of adenylate cyclase toxin (CyaA). 
(Adapted from Fiser et. al., 2009) 
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2.3.5. Developments in Pertussis Vaccines 
2.3.5.1. Whole Cell Vaccines (Pw) 
Shortly after the successful isolation of the bacterium, whole cell (Pw) vaccines were 
developed using heat-killed bacteria. The B pertussis species, being strict human 
pathogens, exhibit a very low level of genetic diversity. Over the years, analyses have 
identified a few predominant circulating strains with no significant geographical pattern 
in their distribution. With that knowledge, 1, 2 or 3 different strains from the 
predominant types were selected for inclusion in the heat-killed Pw vaccines. 
Immunization with Pw vaccines offers the advantage of inducing a broad immune 
response against hundreds of bacterial proteins expressed in B. pertussis for effective 
control of the disease. However, earlier studies had investigated the feasibility of a birth 
dose of Pw vaccine to provide early protection against pertussis and reported some 
“immune tolerance” whereby the anti-B. pertussis antibody responses were reduced 
compared to infants who started their vaccination schedule at a later age (Provenzano, 
Wetterlow and Sullivan 1965, Barrett et al. 1959). Moreover, Pw-associated 
reactogenicity remains a major concern. Several local adverse effects such as erythema, 
swelling, and pain at the injection site, fever, and other mild systemic events (e.g., 
drowsiness, fretfulness, and anorexia) have been reported in vaccinated individuals 
(Long et al. 1990, Cody et al. 1981). More severe systemic events like acute 
encephalopathy and permanent neurological sequelae have also been associated to the 
use of Pw vaccine (Kerr and Matthews 2000). 
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2.3.5.2. Acellular Vaccines (Pa) 
Pw-associated adverse events have thus prompted the development and licensing of 
safer acellular pertussis (Pa) vaccines that consist of up to five purified B. pertussis 
components including the inactivated pertussis toxin (PT), filamentous hemagglutinin 
(FHA), pertactin (PRN) and fimbriae (FIM) types 2 and 3. Although Pa vaccines induce 
immunity against only a few bacterial proteins involved in the virulence of the 
bacterium, they were shown to be as protective against pertussis as the Pw vaccines 
(Roduit et al. 2002). Early neonatal immunization with Pa vaccines was recently shown 
to be safe, well tolerated and resulted in early anti-pertussis antibody responses (Knuf 
et al. 2008). In addition, Pa vaccines were suited for administration to adolescents and 
adults without the observed Pw-associated reactogenicity. However, the current 
pertussis immunization schedules with acellular vaccines do not offer life-long 
protection. Moreover, antigenic shift and adaptation of the B. pertussis circulating 
strains to the current acellular vaccines are believed to be responsible for pertussis 
resurgence among vaccinated individuals, resulting in household transmission to 
vulnerable infants (Mooi et al. 2001).  
Altogether, these observations indicate that alternative pertussis vaccination strategies 
have to be explored in order to afford life-long protection against pertussis and possibly 
starting at birth. 
2.3.5.3. Attenuated Live Pertussis Vaccines 
Natural infection with B. pertussis has long been known to induce strong and long-
lasting immunity that wanes later than vaccine-induced immunity (von König et al. 
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2002). Furthermore, natural infection with B. pertussis induces measurable antigen-
specific Th1-type immune responses even in very young children (as young as 1 month 
of age) (Mascart et al. 2003). Instead, numerous studies in humans and in animal 
models have suggested that the neonatal immune system is too immature to effectively 
mount a sustained protective immunity upon administration of acellular vaccines 
(Siegrist 2001). These observations suggest that live vaccines applicable by the nasal 
route, in order to mimic as closely as possible natural infection, may be attractive 
alternatives over the currently available subunit or whole cell inactivated vaccines. 
Such strategy would allow early immunization, possibly at birth, thereby reducing the 
incidence of pertussis in the very young and most vulnerable age groups. With current 
knowledge on the molecular mechanisms of microbial virulence and availability of 
suitable genetic tools, it is now possible to introduce precise and stable mutations into 
virulent microorganisms creating attenuated strains that are safer for vaccine use.   
Live attenuated B. pertussis strains have been developed since the late 1990s. To date, 
three generations of live attenuated B. pertussis strains have been reported. The first 
generation of live attenuated B. pertussis involves gene mutations in key metabolic 
pathways required for in vivo survival and growth (aro mutant) (Roberts et al. 1990). 
The aro mutant strain was shown to be highly attenuated in its colonization of the 
murine lung and infection was cleared within 8 days. A three dose regime of the aro 
mutant has demonstrated the potential in triggering production of high levels of anti-B. 
pertussis antibody response and protection upon challenge with wild-type B. pertussis. 
In 1997, Locht and coworkers developed the second generation of live attenuated B. 
pertussis, the BPRA strain in which the pertussis toxin-encoding gene has been deleted  
(Mielcarek et al. 1998). Single nasal immunization with BPRA was shown to enhance 
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the antibody response against the filamentous hemagglutinin (FHA), a major protective 
antigen, and protected against subsequent challenge with wildtype B. pertussis 
(Mielcarek et al. 1998). Finally, more recently, the third generation of live attenuated B. 
pertussis has been described (Mielcarek et al. 2006). The BPZE1 strain was genetically 
designed to reduce the destructive effects brought about by three toxins, namely 
pertussis toxin (PT), dermonecrotic toxin (DNT) and tracheal cytotoxin (TCT).  BPZE1 
strain is deleted for the DNT-encoding gene, produces an enzymatically inactive PT and 
overexpresses its ampG gene to reduce TCT production (Mielcarek et al. 2006). The 
authors described a markedly reduced lung inflammation in the mice nasally infected 
with BPZE1 bacteria, while maintaining the ability to colonize and induce a strong 
protective immunity. Furthermore, BPZE1 was found to induce protection in infant 
mice that is superior to the protection provided by the current acellular pertussis 
vaccines (Mielcarek et al. 2006). Recently the live attenuated BPZE1 strain has entered 
the early phases of clinical trial as a live pertussis vaccine (C. Locht, personal 
communication).  The potential of BPZE1 as a live vehicle for the delivery of 
heterologous vaccine candidates was also further explored in our laboratory and we 
have shown that nasal immunization with recombinant BPZE1 bacteria triggered in 
mice a sustained local and systemic response against the heterologous antigen (Ho et al. 
2008).  
2.3.6. Bordetella pertussis  as a Mucosal Vaccine Delivery System 
The potential of B. pertussis as a nasal vaccine delivery vector lies in its efficient 
colonization of the human respiratory tract and ability to induce both the local and 
systemic immune responses (Alonso et al. 2005). It can be easily genetically 
manipulated with a variety of genetic tools available. Moreover, the completion of 
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Bordetella genome sequencing project has allowed in depth investigations of Bordetella 
pertussis pathogenesis (http://old.genedb.org/genedb/pert/). Importantly, this 
microorganism expresses various protein secretion systems, which make it possible to 
secrete and/or expose foreign antigens at the bacterial surface. Last but not least, B. 
pertussis has been known and used for its adjuvant properties (Rijpkema et al. 2005, 
Tournier et al. 2002), thus further supporting the development of this bacterium as a 
live recombinant vaccine vector.  
2.3.6.1. FHA as an Antigen Carrier 
To date, FHA is the first carrier protein that has been explored in live B. pertussis to 
present heterologous antigens. Together with its highly immunogenic and adjuvant 
properties, FHA presents itself as an ideal vaccine carrier to secrete foreign antigens 
into the extracellular milieu or to present them at the bacterial surface of B. pertussis-
based live recombinant vaccines. Heterologous antigens that have been fused to FHA 
include the Schistosoma mansoni 28-kDa glutathione S-transferase (Sm28GST) 
(Mielcarek et al. 1998), Haemophilus influenzae HtrA (Alonso et al. 2005), SP70 from 
Enterovirus 71 (Ho et al. 2008) and M2e from influenza A virus (Li et al, 2011). Upon 
nasal administration of the live recombinant bacteria, significant levels of systemic 
and/or local (respiratory tract) antibody against the foreign antigens were detected. 
Fha44, a truncated form of FHA corresponding to the first 80 kDa N-terminal half of 
the mature protein has been described to be produced in higher quantities and secreted 
more efficiently than FHA (Renauld-Mongénie et al. 1996). It was further developed as 
an antigen carrier whereby it was fused to several heterologous antigens including the 
Neisseria meningitidis transferring-binding protein B (TbpB) (Coppens et al. 2001), 
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tetanus toxin fragment C (TTFC) (Reveneau et al. 2001) and HtrA from nontypeable 
Haemophilus influenza (Alonso et al. 2005). Despite an enhanced ability in its 
production and secretion, Fha44 was found to be less immunogenic than FHA, being 
able to induce anti-FHA IgG only in the presence of an adjuvant (Alonso et al. 2005). 
Furthermore, FHA-HtrA chimera was found to elicit higher anti-HtrA serum antibody 
levels than the Fha44-HtrA chimera, suggesting that the C-terminal moiety in mature 
FHA contains immunodominant/adjuvant activity. 
However, one of the major limitations in the use of FHA or its truncated version Fha44 
as antigen carrier is that a totally unfolded conformation of the protein is required for 
the efficient secretion of FHA across the outer membrane. Impairment in FHA secretion 
was observed upon folding of a passenger protein into a globular conformation prior to 
FhaC-mediated export (Guédin et al. 1998) and consequently, both the FHA moiety and 
the passenger protein are readily degraded in B. pertussis (Reveneau et. al., 2002). 
Therefore, cysteine-containing passenger proteins like the cholera toxin B subunit 
(Guédin et al. 1998), TTFC (Reveneau et al. 2001) and M2e from influenza virus  (Li et 
al. 2011) were poorly secreted when fused to FHA and/or Fha44, thus limiting the use 
of FHA as a carrier.  
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2.3.6.2. BrkA as an Antigen Carrier 
To overcome the challenges posed by cysteine-containing heterologous antigens, we 
explored the use of BrkA, an autotransporter protein expressed in B. pertussis as a 
carrier system. Autotransporters have been successfully used in other microorganisms 
to present heterologous antigens at bacterial surfaces (Ruiz-Olvera et al. 2003, Zhu et al. 
2006). Moreover, the efficient translocation across the outer membrane of folded 
protein domains containing Cys residues has been demonstrated (Veiga, de Lorenzo 
and Fernández 2004).  
A truncated version of BrkA, with a substantial deletion in the passenger domain has 
been shown to be efficiently transported and exposed at the bacterial surface (Oliver et 
al. 2003b), thus making it possible to use BrkA to present heterologous antigens of 
bigger size. Furthermore, the passenger domain of BrkA has been shown to be 
immunogenic and possesses adjuvant properties (Cainelli Gebara et al. 2007). 
Previously, our lab has successfully expressed tandem repeats of the neutralizing B cell 
epitope SP70 from Enterovirus 71 fused to the truncated BrkA on the bacterial surface 
of the BPZE1 strain and showed that significant amounts of neutralizing SP70-specific 
antibodies were induced in mice upon intranasal administration of the recombinant 
bacteria (Ho et al. 2008).  Recently, we have also demonstrated the versatility of BrkA 
as a carrier system to present large heterologous antigens of up to 98 amino acids 
without major detrimental effects on the outer membrane integrity, host cell viability 
and lung colonization efficacy of the recombinant strains (Khong, Chow and Alonso 
2009). Consequently, these studies present BrkA as a more adaptable vaccine carrier 
system than FHA in its ability to tolerate large and cysteine-containing heterologous 
antigens.  
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2.3.6.3. Other Potential Vaccine Carriers 
Besides FHA and BrkA, the adenylate cyclase toxin (CyaA) has also been developed as 
a carrier system for the delivery of heterologous antigens. CyaA, an important virulence 
factor involved in bacterial colonization of the airways and development of whooping 
cough, exerts immunosuppressive effects on both the innate and adaptive immune 
system by specifically targeting Cd11b/CD18 expressing-myeloid cells (macrophages, 
neutrophils and dendritic cells) and internalization of its enzymatic moiety into the host 
cells.(Harvill et al. 1999) This property has been exploited for the intracellular delivery 
of heterologous antigens from various pathogens fused to CyaA using both major 
histocompatibility (MHC) class I and II presentation pathways for activation of CD4 
and CD8 cytotoxic responses (Fayolle et al. 1996, Tartz et al. 2008, Loucká et al. 2002). 
Four different permissive sites within the CyaA catalytic domain have been identified 
for insertion of heterologous antigens (Ladant, Glaser and Ullmann 1992, Osicka et al. 
2000, Fayolle et al. 2001). Such flexibility renders possible the expression of multiple 
antigens in a single CyaA protein. In addition, disruption of the CyaA enzymatic 
activity upon insertion of the vaccine antigen candidate did not affect the stability of the 
protein and the ability of CyaA to deliver intracellularly the epitopes to APCs. (Saron et 
al. 1997, Karimova et al. 1998, Fayolle et al. 2001). Moreover, similar to BrkA, ACT 
displayed a high tolerance for the insertion of large polypeptide fragments of up to 206 
amino acids in its catalytic domain (Simsova, Sebo and Leclerc 2004). However, there 
remains a limitation in the expression of heterologous antigens in CyaA as electrostatic 
charges of peptides play a critical role in the translocation of the catalytic domain into 
eukaryotic cells. Karimova and collaborators have indeed reported that the insertion of 
negatively charged heterologous antigens may decrease the ability of CyaA catalytic 
domain to be efficiently internalized into host cells (Karimova et al. 1998).  
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All the recombinant CyaA proteins reported so far have been expressed and purified 
from E. coli.  Construction and expression of CyaA chimera in B. pertussis have yet to 
be reported. However, CyaA being a major virulence factor in B. pertussis, it is 
anticipated that the disruption of the CyaA enzymatic activity in BPZE1 may further 
attenuate the bacterial vector and impair its ability to colonize the respiratory tract, 
thereby possibly affecting its capacity at priming effectively the host immune system. 
Such possibility has yet to be investigated. 
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3. MATERIALS AND METHODS 
(I) ESCHERICHIA COLI WORK 
3.1. Bacterial Strains, Plasmids and Growth Conditions 
3.1.1. E. coli Strains and Plasmids 
The E. coli strains and plasmids used in this study are listed in the table below. 











Ampr, Kanr; high copy number TA cloning vector; 
LacZα gene for blue/white screening 
Invitrogen 
pBR322 Ampr, Tetr; Low copy number cloning vector (Bolivar et al. 
1992) 
pUC19 Ampr; High copy number cloning vector; LacZα (Yanisch-Perron, 




Gmr, Sms; Low copy number in E. coli and suicide 
vector in B. pertussis 
(Quandt and Hynes 
1993) 
Plasmids for BrkA-(M2e)3 Cloning 
pUCSY0 Ampr; pUC19 derivative with HindIII-HindIII 
brkA1-brkA2 fragment containing BamHI site 
(Ho et al. 2008) 
pUCAL1 Ampr; pUCSY0 derivative with BamHI-(M2e) 
fragment 
This study 
pUCAL2 Ampr; pUCAL1 derivative with BamHI-(M2e) 
fragment 
This study 
pUCAL3 Ampr; pUCAL2 derivative with BamHI-(M2e) 
fragment 
This study 
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pJQAL1 Gmr, Sms; pJQ200mp18-rpsL derivative with 
HindIII-HindIII brkA1-(M2e)-brkA2 fragment 
This study 
pJQAL2 Gmr, Sms; pJQ200mp18-rpsL derivative with 
HindIII-HindIII brkA1-(M2e)2-brkA2 fragment 
This study 
pJQAL3 Gmr, Sms; pJQ200mp18-rpsL derivative with 
HindIII-HindIII brkA1-(M2e)3-brkA2 fragment 
This study 
Plasmids for BrkA-(NP366-374)4 Cloning 
pUCAL6 Ampr; pUCSY0 derivative with BamHI-(NP366-374)2 
fragment 
This study 
pUCAL7 Ampr; pUCAL6 derivative with BamHI-(NP366-374)4 
fragment 
This study 
pJQAL6 Gmr, Sms; pJQ200mp18-rpsL derivative with 
HindIII-HindIII brkA1-(NP366-374)2-brkA2 fragment 
This study 
pJQAL7 Gmr, Sms; pJQ200mp18-rpsL derivative with 
HindIII-HindIII brkA1-(NP366-374)4-brkA2 fragment 
This study 
Plasmids for FHA-(M2eCysSer)3 Cloning 
pBRLR0 Ampr, Tetr; pBR322 derivative with HindIII-
HindIII FHAB fragment containing BglII RE 
site, from TOPO1  
 
(Li et al. 2011) 
pBRAL1 Ampr, Tetr; pBRLR0 derivative with BglII-
(M2eS)1 fragment  
 
This study 
pBRAL2 Ampr, Tetr; pBRAL1 derivative with BglII-
(M2eS)2 fragment  
 
This study 
pBRAL3 Ampr, Tetr; pBRAL2 derivative with BglII-(M2eS) 3 
fragment 
This study 
pJQAL12 Gmr, Sms; pJQ200mp18-rpsl derivative with 
HindIII-HindIII fhaB-(M2eS)3 fragment  
 
This study 
Plasmids for ∆cyaA BPZE1 Cloning 
TOPO2 Ampr, Kanr; TOPO® derivative with XbaI-SacI 
cyaC fragment 
This study 
TOPO3 Ampr, Kanr; TOPO® derivative with SacI-HindIII 
cyaB fragment 
This study 
pUCAL9 Ampr; pUC19 derivative with XbaI-SacI cyaC 
fragment 
This study 
pUCAL10 Ampr; pUCAL9 derivative with SacI-HindIII cyaB This study 
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fragment 
pJQAL10 Gmr, Sms; pJQ200mp18-rpsL derivative with XbaI-
HindIII cyaC-(∆cyaA)-cyaB fragment 
This study 
Ampr, Kanr, Tetr, Gmr refer to resistance to ampicillin, kanamycin, tetracycline and 
gentamicin respectively. Sms refers to sensitivity to streptomycin. 
Table 3.1 E.coli strains and plasmids. 
 
3.1.2. Growth Condition 
Culture of all E. coli strains was performed at 37oC overnight in 3 ml fresh Luria 
Bertani (LB) broth (Difco, Detroit, Mich.) or on LB agar (Difco). Selection of 
antibiotic-resistant strains was carried out by adding 50 or 100 g/ml ampicillin, 50 
g/ml kanamycin or 10 g/ml gentamicin when appropriate. 
3.2. Molecular Biology 
3.2.1. Oligonucleotides and Primers 
3.2.1.1. List of Oligonucleotides and Primers 
The sequences of the oligonucleotides and primers (Sigma) are shown in Table 3.2. 
When necessary, restriction sites (in bold) were engineered into the 5’ ends of the 
primers to facilitate cloning. The annealing temperature (TA) of the primers is 
calculated as follows: 
4 × N(G/C) + 2 × N(A/T) – 5 
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where N(G/C) and N(A/T) represent the number of G & C bases, and A & T bases 
respectively. 
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3.2.1.2. Hybridization of Oligonucleotides 
10μl of 50 mM of the sense and anti-sense oligonucleotides were mixed and incubated 
in a boiling water bath and left to cool down to room temperature, thereby allowing 
hybridization of the complementary DNA strands. 
Name Sequence (5’ to 3’) 


































Primers used for BrkA-(M2e)3 and BrkA-(NP366-374)4 
Cloning/Screening/Sequencing 
BrkA-M2e FP AGC-CTG-CTG-ACC-GAG-GTG-GAG 
BrkA-NP FP C-GCC-TCG-AAC-GAG-AAC-ATG-GAG 
BrkA-M2e/NP RP ATA-GAC-GCC-CGT-CGC-CTG-CG 
BrkA SeqP ATA-GAT-TCC-GTC-AAT-GTC-CG 
Primers used for FHA-(M2eS) Cloning/Screening/Sequencing 
FHA-M2eS FP/SeqP CGT-GGC-CAT-ACG-CTG-GAG-TCG 
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FHA-M2eS RP CTT-CGC-CTT-CTC-GTA-CTC-GCC-TTG 





∆cyaA FP CCA-TCG-TCA-TAC-GAC-ATG-CTG-G 
∆cyaA RP CCG-TGA-TAG-CGA-GCC-AGC-ATG 
Table 3.2 Oligonucleotides and primers used for E. coli work.  
Restriction sites are indicated in bold. 
 
3.2.2. Plasmid Extraction 
Plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit (Qiagen) 
following the manufacturer’s instructions. High and low copy number plasmids were 
eluted with 50 l and 30 l of deionised water respectively. 
3.2.3. Polymerase chain reaction (PCR) 
3.2.3.1. DNA Amplification 
The GoTaq® Hot Start Colorless Master Mix Product (Promega) was used to carry out 
all PCR reactions according to the manufacturer’s instructions, and using the 
GeneAmp® PCR System 2400 thermal cycler (PE Applied Biosystems, Foster City, 
CA). The PCR reaction was started at 95ºC for 2 min to inactivate the antibody and 
initiate hot-start PCR, followed by 25 cycles of DNA denaturation at 95ºC for 45s, 
primer annealing at TA for 50s and extension at 72ºC for 1 to 2 min (~1 min per 1 kb 
DNA). Finally, an elongation time of 10 min at 72ºC was included to allow complete 
extension of the PCR products.   
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3.2.3.2. Colony PCR Screening 
A bacteria colony was picked from the LB agar plate and dissolved in 30μl of deionised 
water, heated at 95ºC for 10 min and centrifuged at 13,000 rpm for 5 min. PCR was 
performed as described in Section 3.2.3.1 for 25 cycles, using  1μl of the supernatant as 
template. 
3.2.4. Restriction Enzyme Digestion 
Plasmid DNA was digested with the appropriate restriction enzymes (RE) in their 
corresponding buffers (New England Biolabs, Ipswich, MA) in accordance to 
manufacturer’s protocol. Digestion with a single RE or two REs of shared buffer 
compatibility was performed in a single-step incubation of 2 h at 37oC. Analysis of the 
restriction profile was performed by DNA gel electrophoresis (Section 3.2.5). 
3.2.5. DNA Gel Electrophoresis 
3.2.5.1. Gel Migration 
DNA/RNA electrophoresis was performed using 1.0% to 1.5% agarose in 1xTris-
acetate (TAE) running buffer (0.04 M Tris-acetate and 0.001 M 
ethylenedinitrilotetraacetic acid (EDTA), pH 7.8). Each DNA/RNA sample to be 
analyzed was mixed with 1/5 volume of 6x loading dye (0.25% bromophenol blue, 0.25% 
xylene cyanoland 25% Ficoll in water) before being loaded into the gel wells. 5 ml of 1 
kb or 100 bp DNA ladder (Promega) were used as markers for estimation of band size. 
Electrophoresis was carried out at 100 V for 1 h, after which the gel was stained in 0.5 
Chapter 3 Materials and Methods 
67 | P a g e  
g/ml of ethidium bromide solution (Invitrogen) for 15 min before viewing under an 
ultra-violet (UV) transilluminator (ChemiGenius, Syngene, UK). 
3.2.5.2. Gel Extraction 
After agarose gel electrophoresis, the DNA fragments of interest were cut under low 
UV light (366 nm) to prevent DNA damage and/or mutations and gel extracted using 
the QIAquick Gel Extraction (Qiagen, Mississauga, Ont.) according to the 
manufacturer’s protocol. 
3.2.6. DNA Cloning 
Digestion (Section 3.2.4) with the appropriate RE(s) was performed on plasmid DNA to 
open up the vectors and generate the inserts. Both digested vectors and inserts were 
electrophoresed on agarose gel and the DNA bands of interest were excised and 
purified from the gel as shown in Section 3.2.5. Cloning of inserts into the TOPO® 
vector was performed using the TOPO® TA Cloning Kit (Invitrogen, Carlsbad, CA) 
while DNA inserts were ligated into the pBR322, pUC19 and pJQ vectors using the 
Fast-LinkTM DNA Ligation Kit (Epicentre Technologies, Madison, WI). 
Recircularization of vectors digested with a single RE was prevented by 
dephosphorylation with alkaline phosphatase (Research Biolabs, Singapore) according 
to the manufacturer’s instructions. 
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3.2.7. Transformation of Chemically Competent E.coli  
Chemically competent One Shot® TOP10 E. coli (Invitrogen) were transformed with 
slight modifications to manufacturer’s protocol. Half volume of ligation mix was added 
to one vial of TOP10 cells and mixed gently. The tube was incubated on ice for 30 min, 
followed by a heat shock at 42ºC for 45 s. The tube was then immediately transferred to 
ice and 500 μl of LB medium without antibiotics were added. After incubation at 37ºC 
for 1 h, 100 μl of transformation mixture were plated on LB agar supplemented with the 
appropriate antibiotic or on imMediaTM Amp Blue ready-mix agar (Invitrogen) for 
blue/white screening. The plates were incubated at 37ºC overnight. 
3.2.8. DNA Sequencing 
Plasmids from the recombinant clones were sent for DNA sequencing (AIT Biotech, 
Singapore) with suitable primers (Table 3.2). Alignment of the obtained sequences with 
the relevant known sequences was performed using the online ClustalW programme 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
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(B)         BORDETELLA PERTUSSIS WORK 
3.3. Bacterial Strains and Growth Conditions 
3.3.1. B. pertussis Strains 
The B. pertussis strains used in this study are summarized in the following table. 
Strain Descriptiona Source/Reference 
BPZE1 Attenuated TohamaI derivative, mutant rpsL, ptx 
gene mutated (inactive pertussis toxin), 
dermonecrotic toxin gene deleted, ampG gene 
overexpressed (reduced tracheal cytotoxin 
production); Smr 
Pasteur Institute of 
Lille 
BPSY1 BrkA-knockout BPZE1 (Ho et al. 2008) 
BPAL1 BPZE1 derivative expresssing BrkA-
(M2e)1chimera 
This study 
BPAL2 BPZE1 derivative expresssing BrkA-(M2e)2 
chimera 
This study 
BPAL3 BPZE1 derivative expresssing BrkA-(M2e)3 
chimera 
This study 
BPAL6 BPZE1 derivative expresssing BrkA-(NP366-374)2 
chimera 
This study 
BPAL7 BPZE1 derivative expresssing BrkA-(NP366-374)4 
chimera 
This study 
BPAL12 BPZE1 derivative expresssing FHA-(M2eS)3 
chimera 
This study 
BPAL13 BPZE1 derivative expresssing BrkA-(M2e)3 and 
FHA-(M2eS)3 chimera 
This study 
BPSM TohamaI derivative, mutant rpsL; Smr Pasteur Institute 
of Lille 
BPAL10 Adenylate cyclase –knockout BPZE1 This study 
a. Smr refers to resistance to streptomycin.  
Table 3.3 B. pertussis strains. 
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3.3.2. Growth Conditions 
All B. pertussis strains were grown at 37ºC on pre-warmed sterile Bordet-Gengou (BG) 
agar (Difco) supplemented with 1% glycerol and 10% defibrinated sheep blood or in 
pre-warmed sterile modified Stainer-Scholte (SS) medium containing 1 g/L 2,6-O-
dimethyl-ß-cyclodextrin (Sigma) as described previously (Menozzi et. al., 1991). When 
appropriate, 10 μg/ml gentamicin or 100 μg/ml streptomycin (Sigma) were added to 
select for antibiotic-resistant strains. 
3.4. Molecular Biology 
3.4.1. List of Primers 
The primers (Sigma) used for B. pertussis work are listed in the table below.  
Name Sequence (5’ to3’) 





∆cyaA FP CCA-TCG-TCA-TAC-GAC-ATG-CTG-G 
∆cyaA RP CCG-TGA-TAG-CGA-GCC-AGC-ATG 
Primers for Southern blot analysis 
∆cyaA FSP GCA-TCG-ACA-CCG-TCA-AGT-CG 
∆cyaA RSP GCG-CTG-TAT-CAG-CCG-AGT-CA 
Table 3.4 Primers used for B. pertussis work. 
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3.4.2. Transformation of B. pertussis 
3.4.2.1. Preparation of Electrocompetent B. pertussis Cells 
10 ml of bacteria exponentially grown (OD600 3-4) in SS medium were centrifuged at 
7,000 rpm for 10 min at room temperature, and the pellet was washed three times in 10 
ml of sterile 10% glycerol. After the final wash, the pellet was resuspended in 1 ml of 
10% glycerol and the cells were immediately used for electroporation. 
3.4.2.2. Electroporation of Plasmid DNA into B. pertussis 
Between 100 ng to 1 g of plasmid DNA were mixed with 200 l of electrocompetent 
B. pertussis cells in an electroporation cuvette (0.2 cm) (Biorad Laboratories, Hercules, 
CA), and an electrical pulse of 2.5 kV, 800 W resistance and 25 mF capacitance was 
administered. One ml of pre-warmed SS medium without antibiotics was then added to 
the cells and the bacteria was incubated for 5 h at 37oC with shaking, before plating 200 
l of cells onto pre-warmed BG agar plates containing the appropriate antibiotic and 
incubating for 5-7 days at 37oC. 
3.4.3. Selection of Transformants 
Gentamicin-resistant (Gmr) colonies obtained upon electroporation were patched onto 
streptomycin and gentamicin plates, in this order. Clones were observed within 7 days 
and streptomycin-sensitive (Sms) Gmr clones were identified as transformants that had 
successfully undergone the first event of recombination. These intermediate strains 
were streaked onto a streptomycin plate to allow the second event of recombination to 
occur. After incubation at 37ºC for 5-7 days, 10 isolated Smr colonies were patched 
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onto gentamicin and streptomycin plates, in this order. Gms, Smr clones were identified 
as having undergone the second event of recombination. 
3.4.4. Selection of True Recombinants 
Colony PCR screening was performed on the Smr, Gms clones to genotypically 
distinguish true recombinants from revertant clones. Preparation of the template DNA 
was performed as described in Section 3.2.3.2 except that the dissolved bacteria were 
heated for 30 min instead of 10 min. PCR was carried out as shown in Section 3.2.3.1 
for 25 cycles using appropriate primers (Table 3.4) followed by agarose gel 
electrophoresis to analyze the PCR products (Section 3.2.5.1). When necessary, colony 
PCR screening was also performed on the Gmr, Sms intermediate clones to confirm 
integration of the pJQ construct. 
3.4.5. Bacterial Chromosomal DNA Extraction 
A 4 ml B. pertussis liquid culture exponentially grown in SS medium was centrifuged at 
8,000 rpm for 10 min and DNA extraction was carried out using the Genomic-tip 100/G 
Anion Exchange Resin and Genomic DNA Buffer Set (Qiagen) according to the 
manufacturer’s instructions. The final DNA precipitate was dissolved in 500 μl of 
ultrapure water at 55oC for 1-2 h. The extracted chromosomal DNA was visualized by 
DNA gel electrophoresis (Section 3.2.5.1) using 1% agarose and quantified by 
Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, U.S.A). 
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3.4.6. Southern Blot Analysis 
3.4.6.1. Synthesis of DIG-Labeled Probes 
Probes for Southern blot analysis were synthesized and labeled with digoxigenin (DIG) 
using the PCR DIG Probe Synthesis Kit (Roche) according to the manufacturer’s 
instructions. An unlabeled control reaction without the addition of the PCR DIG 
labeling mix was included to evaluate probe-labeling efficiency. Amplification was 
conducted in the GeneAmp® PCR System 2400 thermal cycler (PE Applied 
Biosystems, Foster City, CA) with the following conditions: initial denaturation at 95oC 
for 2 min, followed by 25 cycles of DNA denaturation at 95oC for 30 s, primer 
annealing at 59oC for 30 s, and DNA elongation at 72oC for 1 min. Finally, an 
additional 7 min of DNA extension at 72oC was included, after which the reaction was 
maintained at 4oC. The synthesized probe was analyzed and quantified by gel 
electrophoresis (Section 3.2.5.1) on a 1% agarose gel. 
3.4.6.2. Southern Blot 
Prior to Southern blot, 1 μg of B. pertussis chromosomal DNA was digested with the 
appropriate RE(s) (Section 3.2.4) for 4 h. The digested DNA was subjected to gel 
electrophoresis (Section 3.2.5.1) on a 1.5% agarose gel, which was then soaked twice in 
depurination solution (0.25 M hydrochloric acid) for 10 min with gentle agitation, 
rinsed in deionised water, soaked twice in denaturation solution (5% 10 N sodium 
hydroxide solution, 8.75% sodium chloride) for 15 min, and finally soaked twice in 
neutralization solution (7.7% ammonium acetate, 0.2% 10 N sodium hydroxide solution) 
for 30 min. The DNA fragments were then transferred onto a nitrocellulose membrane 
(Millipore) as described in Figure 3-1. Before assembly, the nitrocellulose membrane 
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was pre-wet in neutralization solution. After 2 h of transfer, the membrane was UV-
fixed for 1 min, then equilibrated in 10 ml of pre-heated DIG Easy Hyb solution (Roche) 
at 65oC for 20 min, with gentle agitation. Denaturation of the DIG-labeled probe was 
performed by boiling at 95oC for 5 min and immediately transferring to ice. About 5-25 
ng/ ml of denatured DIG-labeled DNA probe was added to the membrane in the DIG 
Easy Hyb solution and incubated in a hybridization oven at 65oC overnight. After 
hybridization, the membrane was washed twice in 2x SSC (0.15 M sodium chloride and 
0.015 M sodium citrate) containing 0.1% SDS for 5 min at room temperature, followed 
by 2 wash steps in 0.1x SSC containing 0.1% SDS for 15 min at 68oC. Blocking, 
washing and immunological detection was done using the DIG Wash and Block Buffer 
Set (Roche) according to manufacturer’s instructions. Detection was performed with an 
alkaline phosphatase (AP)-conjugated anti-DIG antibody (Roche) at a dilution of 




Figure 3-1 Semi-dry transfer of nucleic acids onto nitrocellulose membrane. 
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3.5. Protein Expression Studies 
3.5.1. Preparation of B. pertussis Samples 
3.5.1.1. Cell Extract 
Two ml of exponentially-grown B. pertussis liquid culture was centrifuged at 7,000 rpm 
for 10 min at room temperature. The supernatant was processed for protein analysis as 
described in Section 3.5.1.2. The pellet was resuspended in 500 μl of RNAse-free water, 
after which an equal volume of protein loading buffer (1 M Tris-HCl at pH 6.8, 100% 
glycerol, -mercaptoethanol, bromophenol blue, 20% SDS) was added and the mixture 
heated at 95ºC for 10 min. The chromosomal DNA was sheared by passing the 
suspension 10 times through a 27G needle followed by heating at 95ºC for 10 min and 
stored at -20ºC until further analysis.   
3.5.1.2. Supernatant      
The supernatant obtained was subjected to an additional round of centrifugation for 10 
min at maximum speed, to remove any remaining cell debris and concentrated up to 10 
times using the Ultra-4 Centrifugal Filter Device (Amicon) following manufacturer’s 
protocol. An equal volume of 2x protein loading buffer was then added to 200 l of the 
clarified supernatant and the mixture was heated at 95oC for 10 min, and stored at –
20oC until further use. 
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3.5.2. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Protein separation was conducted under denaturing conditions via SDS-PAGE using a 
Mini-PROTEAN® system (Bio-Rad) according to the manufacturer’s instructions. 
The slab gel was made up of a 3% polyacrylamide stacking gel and an 8% or 12% 
polyacrylamide separating gel, both containing 10% SDS. Cell extract and supernatant 
samples were heated at 95ºC for 5 min immediately before loading into the wells. Ten 
μl of BenchMarkTM Pre-Stained Protein Ladder (Bio-Rad) were used as the molecular 
weight standard. Electrophoresis was conducted in 1x Tris-Gly SDS Running Buffer 
(1st Base, Singapore) at 100 V for 2 h. 
3.5.3. Coomassie Blue Staining 
To visualize the protein bands after electrophoresis, the SDS-gel was stained with the 
Bio-Safe Coomassie Stain (Bio-Rad) according to manufacturer’s instructions. 
3.5.4. Western Blot 
After SDS-PAGE, the separated proteins were electro-transferred onto a nitrocellulose 
membrane (Bio-Rad) at 100 V for 2-4 h using a wet transfer system (Bio-Rad). After 
transfer, the membrane was blocked overnight in blocking buffer (5% blotting grade 
blocker non fat dry milk (Bio-Rad) in 1x TBS, 0.1% Tween 20) at 4ºC. The membrane 
was then incubated with the appropriate primary antibody (Table 3.5) diluted in 
blocking buffer for 1 h, with gentle shaking at room temperature, followed by 3 
washings in an excess of washing buffer (1x TBS, 0.1% Tween20) for 10 min. The 
appropriate AP-conjugated secondary antibody diluted in blocking buffer (Table 3.5) 
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was then added to the membrane and incubated for 1 h, with gentle shaking at room 
temperature, followed by washing as described above. Finally, the antibody-reactive 
bands were revealed by chromogenic detection upon adding NBT/BCIP substrate 
(Chemicon, Temecula, CA). 




Mouse anti-M2e antiserum   
(Li et al. 2011) 




antibody (Oliver et al. 
2003b) 
1:30,000 Goat anti-rabbit IgG (H+L) 
(Sigma) 
1:3,000 
Anti-Cya A (9D4) 
monoclonal antibody 
(Santa Cruz, C.A) 
1:250 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Table 3.5 Antibodies used in Western Blot. 
 
3.5.5. Fluorescence-Activated Cell Sorting (FACS) 
3.5.5.1. Preparation for FACS 
B. pertussis bacteria grown on BG agar were resuspended in 5 ml of sterile PBSG (1x 
PBS, 5% glycerol), centrifuged at 7,000 rpm for 10 min at room temperature, and 
washed again in the same buffer. Bacterial concentration was adjusted to 106 colony 
forming units (cfu) in 500 l of PBSG. The bacterial suspension was then incubated 
with rabbit anti-BrkA antiserum (Oliver et al. 2003b) diluted 1:200, for 2 h at 4ºC with 
constant agitation. This was followed by centrifugation at 7,000 rpm for 10 min and 3 
wash steps in 5 ml of PBSG. The pellet was then resuspended in 500 μl of PBSG and 
incubated with CyTM2-conjugated goat anti-rabbit IgG (Jackson Laboratories, West 
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Grove, PA) diluted 1:100, for 2 h at 4ºC with constant agitation. The suspension was 
then centrifuged at 7,000 rpm for 10 min, followed by 3 wash steps in 5 ml of PBSG. 
Finally, the pellet was resuspended in 100 μl of sterile 1x PBS, to which an equal 
volume of 4% paraformaldehyde was added to fix the cells. 
3.5.5.2. Flow Cytometry 
100 l of each sample was diluted with 700 μl of BD FACSFlowTM sheath fluid 
(Becton-Dickinson, Heidelberg, Germany) prior to FACS profiling. A Coulter Epics 
machine (Beckman Coulter, Palo Alto, CA) was used for the flow cytometric study. 
Samples were analyzed with laser excitation at 488 nm, and data acquisition was 
performed using EXPO Version 2.0 software (Applied Cytometry Systems, Sheffield, 
U.K.) and analyzed with WinMDI-2.8 software. 
3.5.6. Immunofluorescence 
The samples for immunofluorescence were prepared as described in Section 3.5.5.1 
before loading the cells onto poly-L-lysine-treated microscope slides. To treat the slides, 
100 μl of 0.1% poly-L-lysine (Sigma) was spread evenly onto each clean glass slide, 
which was then incubated at 37ºC for 20 min. Excess poly-L-lysine was discarded and 
the slides were washed with distilled water and air-dried. 100 μl of fixed bacteria were 
spread on a slide and one drop of the anti-fading agent VectorShieldTM (Oxford 
Instruments Analytical, U.K.) was added before placing a cover slip over each mount. 
The specimens were viewed under blue light excitation (488 nm) using an 
epifluorescence microscope with 1000x magnification (BX40, Olympus, Japan). Phase-
contrast and fluorescent images were captured digitally. 
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3.5.7. Mammalian Cell Infection 
Bacteria grown on BG plates for 3 days at 37oC were scraped, washed once in sterile 
PBS and resuspended in RPMI or DMEM medium; 2 × 105 mammalian cells per well 
were cultured for 2 days in 24-well plate. The bacteria were added to the cells at a 
multiplicity of infection (MOI) of 20. For adherence assays, the cells were incubated for 
1 h at 4oC, washed with PBS, lysed with H2O and appropriate dilutions were plated for 
colony counting. For invasion assay, the plates were incubated for 1 h at 37oC and 5% 
CO2, washed and further incubated at 37oC, 5% CO2 with 100 µg /µl gentamycin for 2 
h. Cells were washed, lysed and appropriate dilutions were plated for colony counting. 
Each sample was performed in quadruplicate. Each experiment was repeated twice 
independently. 
3.6. Animal Work 
3.6.1. Mouse Strains 
Three- or six-weeks-old female BALB/c mice were obtained from Centre for Animal 
Resources (CARE), Singapore and AG129 breeders (129/Sv mice deficient in both 
alpha/beta interferon (IFN-α/β) and IFN-γ receptors) were obtained from B & K 
Universal. The mice were kept under specific pathogen-free (SPF) conditions in 
individual ventilated cages (IVCs). All the animal experiments were carried out upon 
approval and under the guidelines of the National University of Singapore animal study 
board. 
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3.6.2. Intransal B. pertussis Infection 
B. pertussis bacteria grown on BG agar were resuspended in sterile PBST (1×PBS, 0.05% 
Tween80) and adjusted to a concentration of 2.5 × 108 colony cfu / ml. Infection of 
mice was performed by the intranasal route with 20 μl of bacterial suspension deposited 
in the nostrils of each animal, sedated with an anaesthetic cocktail (6% valium, 10% 
atropine, 20% ketamine, 64% 1x sterile PBS) administered intraperitoneally (150 μl per 
20 g of body weight). 
3.6.3. Lung Colonization Study 
Four mice per group were sacrificed at the indicated time points after intranasal 
infection with the various B. pertussis strains. The lungs from each mouse were 
aseptically removed and homogenized in 3 ml or 5 ml of sterile PBST using the High 
Shear homogenizer (Omni International). Appropriate dilutions of the lung 
homogenates (in PBST) from individual mice were then plated onto BG agar and the 
total cfu per lung was determined after 4-5 days incubation at 37ºC. Each colonization 
experiment was repeated twice independently. 
3.6.4. Histopathology of Mouse Lungs 
Two mice per group were sacrificed and their lungs were harvested 7 days post-
bacterial infection. The lungs were removed and immediately fixed in 10% formalin in 
PBS. After fixation, the lungs were embedded in paraffin, sectioned, and stained with 
H&E. 
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3.7. Immune Response Study 
3.7.1. Immunization Schedules 
Two immunization schedules were performed; (1) for the recombinant B. pertussis 
expressing influenza virus antigens, 6 BALB/c mice per group were given a three-dose 
regime whereby they were intranasally administered with 106 cfu of BPZE1 or 
recombinant B. pertussis strains, and then boosted for the first time four weeks later and 
boosted for the second time three weeks later with equal amount of bacteria and (2) for 
the ∆cyaA BPZE1 study, 6 BALB/c mice per group were given a single nasal 
administration with 105 cfu of BPZE1 or recombinant B. pertussis strain, BPAL10. 
3.7.2. Broncho-alveolar Lavage Fluids (BALFs) and Serum Collection 
Two weeks after the boost, bronchoalveolar lavage fluids (BALFs) were recovered 
from each euthanized mouse by flushing 1 ml of sterile 1x PBS twice into the lungs 
using a 1 ml syringe introduced into the trachea. BALFs were centrifuged at 4,000 rpm 
for 10 min at 4 ºC and then kept at -80ºC until further analysis. Two weeks after each 
boost, blood was collected from the sedated mice by retro-orbital plexus puncture and 
allowed to clot at room temperature for 1 h. The sera were obtained after centrifugation 
at 4,000 rpm for 10 min, transferred into a fresh Eppendorf tube and stored at -80ºC 
until further use. 
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3.8. Virus Work 
3.8.1. Virus Strains 
Influenza A virus strain H1N1 (A/PR/8/34) influenza virus (ATCC# VR-95) was a 
provided by our collaborator Prof. Vincent Chow. 
3.8.2. Virus TCID50 Quantification 
The virus titer was expressed as 50% tissue culture infective dose (TCID50) in Madin-
Darby Canine Kidney (MDCK) cells based on a typical cytopathic effect (CPE) 
produced by influenza virus infection. The infected mouse lungs were harvested and 
homogenized using mechanical disruption (Omni homogenizer), and tested for the 
presence of viable virus by TCID50 assay using a modified method reported by the 
WHO (WHO, 2002). Briefly, 90% confluent MDCK cells in 96-well plates were 
inoculated with 100 μl of 10-fold serially diluted in RPMI medium lung homogenates. 
Plates were incubated at 35°C in a humidified incubator and 5% CO2 for 3 days. 
TCID50 was determined by a reduction in CPE of 50%, and the log TCID50/lung was 
derived. Five mice per group per time point were individually assessed. 
3.9. Immunology Work 
3.9.1. Enzyme-Linked Immunosorbent Assay (ELISA)  
3.9.1.1. Coating Antigens 
The anti-B. pertussis and anti-M2e antibody titers were measured by ELISA using 
BPZE1 total cell lysate and unconjugated M2e (Mimotopes Pte Ltd, Clayton Victoria, 
Australia) as coating antigens, respectively. To prepare the BPZE1 total cell lysate, 10 
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ml of exponentially grown BPZE1 liquid culture were centrifuged at 7,000 rpm for 15 
min at room temperature. The pellet was washed three times with 5 ml of sterile 1x PBS 
and resuspended in 1 ml of 1x PBS. The suspension was sonicated on ice 15 times for 
15 s each, with intervals of 15 s (Model 150V/T Ultrasonic Homogenizer, BioLogics 
Inc., Manassas, VA). Total protein concentration of the lysate was measured using the 
NanoDrop® ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). 
3.9.1.2. Antibody Titer Determination 
Flat 96-well microtiter plates (Corning NUNC) were coated overnight at 4ºC with 50 μl 
of coating buffer (0.1 M Na2CO3-NaHCO3, pH 9.6) containing 5 μg/ ml of BPZE1 total 
cell lysate or 3 μg/ ml of unconjugated M2e. The wells were washed 3 times with wash 
buffer (1x PBS, 0.1% Tween20), before blocking with blocking buffer (1x PBS, 0.1% 
Tween20, 2% BSA) for 1 h at 37°C. The wells were then washed once and 50 μl of 
diluted mouse serum in blocking buffer or neat BALFs were added to each well. For 
detection of anti-B. pertussis antibodies, the mouse serum was diluted at 1:1,000. For 
detection of anti- M2e antibodies, the mouse serum was diluted at 1:40. After 
incubation at 37ºC for 1 hrs, the plate was washed thrice before adding 50 μl of 1:3,000 
diluted horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H+L) 
secondary antibody (Bio-rad), anti-mouse IgG1, IgG2a, IgG2b, IgG3 (Jackson 
Laboratories) or  anti-mouse IgA secondary antibody (Chemicon). The plates were 
again incubated at 37ºC for 1 h followed by 3 washes. The ELISA was developed by 
adding 100 μl of o-phenylenediamine dihydrochloride (OPD) substrate (Sigma) to each 
well and incubating at room temperature for 20 min in the dark. To stop the reaction, 50 
μl of 1 M sulphuric acid was added to each well and absorbance at 490 nm was 
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measured using the Biorad model 680 Microplate Reader and recorded with the 
Microplate Manager 5.2 software (Biorad). 
3.9.2. Flow Cytometry Analysis  
Mice were sacrificed, their lungs were harvested and single cell suspensions were 
prepared by digesting the lungs at 37°C for 15 min in 2 ml digestion buffer containing 
0.5 ?g/ml Liberase (Roche) in RPMI with 1 % FCS and 2 U/ml DNaseI (Qiagen), 
followed by centrifugation on Ficoll-PaqueTMPLUS (GE) for 20 min at 600g and room 
temperature. Cells were collected and washed twice with sterile FACS buffer (2% FCS, 
5 mM EDTA in PBS). A total of 106 cells were stained with PE labeled H-2Db NP366-374 
tetramer (ProImmune, UK) and analyzed on CyAnTM ADP cytometer (Dako). Five 
mice per group per time point were individually assessed. 
3.9.3. T-Cell Proliferation 
Lymphocyte proliferation was measured by incorporation of tritiated (3H) thymidine as 
described elsewhere (Kimman et al. 1995). Briefly, spleens from naïve and BPZE1-
treated mice (6 mice per group) were collected under aseptic condition. Single-cell 
suspensions were prepared and centrifuged on Ficoll-PaqueTMPLUS (GE) for 20 min 
at 600g and room temperature. The splenocytes were seeded in 96-well round-bottom 
plates (NUNC) at a density of 2 × 105 cells/well in 100 μl medium (RPMI640 
supplemented with 10% FCS, 5 × 10-5 M β-mercaptoethanol, 2 mM L-glutamine, 10 
mM HEPES, 200 U/ml penicillin, 200 μg/ml streptomycin). 100 μl medium containing 
20 μg/ml of BPZE1 whole cell lysate (test antigen) were added to the splenocytes. 
100ul of RPMI medium and 100 ul of RPMI medium containing 5 μg/ml concanavalin 
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A (conA) were used as mock and vitality controls, respectively. Cell culture supernatant 
was removed and kept at -80oC after 24 h incubation for cytokine measurement 
(Section 5.15). After 3 days incubation at 37oC with 5% CO2, the cultures were pulsed 
with 0.4 μCi [3H]thymidine in 20 μl RPMI complete medium for 18 hrs incubation. 
The cells were then harvested, washed and the incorporated radioactivity was measured 
in TopCount NXT™ Microplate Scintillation and Luminescence Counter (PerkinElmer). 
Results are expressed as stimulation index (SI) corresponding to the ratio between the 
mean of [3H]thymidine uptake in the presence of test antigen and the mean of 
[3H]thymidine uptake in the absence of test antigen. A SI>2 was considered positive. 
Each sample was assayed in quadruplicate. 
3.9.4. Interferon-gamma (IFN-γ) Measurement 
IFN-γ expression levels were measured in cell culture supernatants using mouse IFN-γ 
Ready-SET-Go! ELISA Kit (eBioscience, CA) according to the manufacturer’s 
instructions. After incubation with detection antibodies and streptavidin-PE complexes, 
samples were read at 450nm. 
3.10. Statistical Analysis 
Bars represent the means ± standard deviations (SD), and averages were compared 
using a bidirectional unpaired Student’s t test (when data follows a normal distribution 
or data is log transformed) or Mann-Whitney (when 2 sets of data are presented and 
compared) with a 5% significance level with * P≤0.05, and **P≤0.01. 
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4. DEVELOPMENT OF A UNIVERSAL INFLUENZA VACCINE USING 
ATTENUATED B. PERTUSSIS AS A LIVE NASAL VACCINE DELIVERY 
VEHICLE 
4.1. RESULTS 
4.1.1. Recombinant B. pertussis expressing the ectodomain of Matrix protein 2 
(M2e) using BrkA as a Carrier 
4.1.1.1. Construction of Recombinant B. pertussis Producing BrkA-(M2e) Chimeras 
Tandem repeats of the 24 amino-acid M2e protein have been fused in frame into the 23 
kDa deleted region (ranging from amino acid positions A52-H263) of the passenger domain 
of BrkA and expressed in B. pertussis BPZE1 strain, giving rise to the recombinant BPAL1, 
BPAL2 and BPAL3 strains which produce BrkA-(M2e)1, BrkA-(M2e)2, BrkA-(M2e)3 
chimeras respectively (Figure 4-1).  
The expression of the chimeras was analyzed by immunoblotting with polyclonal rabbit 
anti-BrkA and mouse anti-M2e immune sera, using a ∆brkA B. pertussis mutant strain, 
BPSY1 as a negative control. A single band was observed in the whole bacterial cell 
lysates prepared from each recombinant strain with a size corresponding to the full length 
BrkA-M2e chimeras. As expected, the signal intensity of the bands observed with the 
mouse anti-M2e immune serum increased with the number of M2e epitopes fused to BrkA 
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(Figure 4-2A). But interestingly, a higher signal was also detected for the BrkA-(M2e)3 
chimera when using an anti-BrkA immune serum as well (Figure 4-2B). Coomassie 
staining confirmed that equal loading of the different lysates was performed (Figure 4-2C).  
Thus, these observations suggested that increasing M2e epitope density fused to BrkA did 
not impair but rather improved the expression level of the chimera.  
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Figure 4-2 Western blot detection of M2e-expressing recombinant B.pertussis. 
30ul of whole cell lysates were analyzed by immunoblotting using (A) polyclonal rabbit 
anti-BrkA antiserum or (B) polyclonal mouse anti-M2e antiserum. (C) Coomassie staining 
was included to ensure equal loading of individual samples. Legend: 1, BPSY1; 2, BPZE1; 
3, BPAL1; 4, BPAL2; 5, BPAL3. 
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4.1.1.2. In vitro Growth Kinetic of the M2e-expressing Recombinant B. pertussis 
Strains  
To investigate the effects of the introduction of the M2e antigen into the BrkA 
autotransporter on the bacterial fitness, in vitro growth kinetic profiles of BPAL1, 2 and 3 
strains were determined in liquid medium and compared to that of the parental BPZE1 and 
∆brkA BPSY1 strains.  
The absence of BrkA was found to impair substantially the in vitro growth ability of B. 
pertussis (Figure 4-3, BPSY1 strain). This observation has never been reported before and 
indicates that the B. pertussis autotransporter BrkA plays a role in the overall bacterial 
fitness. The insertion of one and two copies of M2e into the BrkA passenger domain led to 
growth profiles comparable to that obtained with BPSY1 strain (Figure 4-3, BPAL1 and 2 
strains), suggesting that the insertion of one or two M2e copies impairs BrkA functional 
activity and in turn, translates into bacterial growth deficiency. Alternatively, the absence 
of the region spanning A52-H263  in the passenger domain of BrkA in the chimeric proteins, 
more than the presence of the M2e copies, may be responsible for the observed attenuated 
growth of the recombinant strains. The insertion of three M2e copies impaired even further 
the ability of the bacteria to grow and multiply efficiently (Figure 4-3, BPAL3 strain), 
indicating here a direct effect of the insertion of the M2e epitopes on the bacterial fitness. 
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Figure 4-3 In vitro growth kinetic profiles of BPAL1 (open squares), BPAL2 (open 
triangles) and BPAL3 (open circles) strains. 
Stained-Scholte medium was inoculated with an overnight pre-culture at an initial OD600nm 
of 0.5. Cultures were shaken vigorously at 37oC and OD600nm was monitored over a 48 
hours time course. Parental BPZE1 (closed circles) and BPSY1 (closed squares) strains 
were used as reference strains. 
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4.1.1.3. Cell Surface Exposure Studies of the Recombinant B. pertussis BPAL3 Strain 
Previous studies have shown that the magnitude of M2e-specific humoral response is 
directly proportional to the degree of epitope density (Liu et al. 2004). Based on our 
western blot analysis and despite an impaired in vitro growth ability (section 4.1.1.1 and 
4.1.1.2 above), we thus selected BPAL3 strain which expresses 3 copies of M2e, for further 
studies. To assess whether the BrkA-(M2e)3 chimera is successfully exposed at the 
bacterial cell surface, flow cytometry and immunofluorescence approaches were conducted 
on intact, non-permeabilized bacterial cells using the polyclonal rabbit anti-BrkA immune 
serum, with the parental BPZE1 and ∆brkA BPSY1 strains as  positive and negative 
controls respectively.  
Flow cytometry analysis indicated a proportion of 96.99 % BPAL3 cells expressing the 
BrkA-(M2e)3 chimeras at the bacterial surface which is comparable to the proportion of the 
parental BPZE1 cells which express the wild type BrkA protein (Figure 4-4A). However, 
the mean fluorescence intensity values suggested that each BPAL3 bacterial cell express 
fewer molecules of BrkA-(M2e)3 at the cell surface as opposed to the parental BPZE1 cells 
(Figure 4-4B). This observation was consistent with the immunofluorescence (IF) analysis 
which indicated that the signal intensity obtained with BPAL3 bacteria was significantly 
weaker than that obtained with parental BPZE1 bacteria (Figure 4-5). Alternatively, the 
absence of the region A62-H263 in the passenger domain of BrkA chimera may account for 
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the lower signal intensities observed for BPAL3 bacteria by flow cytometry and 
immunofluorescence for which a polyclonal anti-BrkA immune serum was employed. 
Together, the results from flow cytometry and immunofluorescence studies indicated that 
the BrkA-(M2e)3  chimera is successfully transported across the bacterial cell wall and 
exposed at the bacterial surface of the BPAL3 strain, confirming the potential of BrkA 
autotransporter as a carrier for heterologous vaccine candidates. 
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Figure 4-4 Flow cytometry analysis of intact B. pertussis bacteria. 
Intact BPSY1, BPZE1 or BPAL3 cellswere co-incubated with anti-BrkA polyclonal 
antibodies. BPZE1 bacteria stained with CY ™ 2-conjugated secondary antibody were 
used as an isotype control. (A) Panel A graphs are representative of individual experiments. 
(B) Average mean fluorescence intensity (MFI) obtained for 2 independent experiments. 
Results are expressed as means ± standard deviations. 
  
(B) 
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Figure 4-5 Epifluorescence microscope images showing surface exposure of BrkA or BrkA-(M2e)3 proteins in intact B. 
pertussis bacteria. 
Anti-BrkA antiserum was used to detect BrkA or BrkA-(M2e)3 on the surface of intact BPSY1 (B and F), BPZE1 (C and G), and 
BPAL3 (D and H) cells. Panels A and E depict images from isotype control. Panels A – D represent phase contrast images; 
panels E – H show images as seen under blue light excitation (488 nm).  
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4.1.1.4. Lung Colonization by Recombinant B. pertussis BPAL3 Strain 
To investigate the ability of the recombinant BPAL3 strain in colonizing the mouse 
respiratory tract, adult BALB/c mice were nasally administered with either BPAL3 or the 
parental BPZE1 bacteria and sacrificed at the indicated time-points for bacteria plating. As 
previously reported (Li et al. 2010), BPZE1 exhibited a slight peak of multiplication on day 
7 post-infection followed by a gradual clearance from the lungs (Figure 4-6). In contrast, 
there was no peak of multiplication for BPAL3 with a significant difference of the bacterial 
load between BPAL3 and BPZE1 on day 7 (p=0.02) post-infection. However, similar 
bacterial loads were detected at the other time points post-infection with even a 
significantly higher number of BPAL3 bacteria at 17 days post-infection (Figure 4-6). In 
conclusion, the overall trend of the colonization profiles of these 2 strains was similar.  
Therefore, the data here suggested that BPAL3 is able to colonize the murine lungs almost 
as efficiently as the parental BPZE1 strain and this is an attractive attribute to the BPAL3 
strain as colonization and multiplication of the bacteria is required for the sustained and 
efficient priming of the host immune system.                                                    
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Figure 4-6 Lung colonization profile of parental (BPZE1) (solid bars) and BPAL3 
strains (open bars). 
Adult BALB/c mice were administered intranasally with 5 × 106 CFU of B. pertussis. The 
lungs were harvested at the indicated time points and viable bacteria in the lungs were 
counted after plating appropriate dilutions of the lung homogenates onto blood agar plates. 
Four mice per group per time point were assessed individually. The results are expressed as 
means (± standard error) CFUs from 4 mice per group per time point, and are 
representative of two independent experiments. * p<0.05, compared with the values of 
BPZE1. 
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4.1.1.5. Antibody Responses Elicited by the Recombinant B. pertussis BPAL3 strain 
To analyze the antibody responses induced by the recombinant BPAL3 strain, adult 
BALB/c mice were nasally administered three times at 4 and 3 week-intervals with 
recombinant BPAL3 or parental BPZE1 strains. Two weeks after the last boost, broncho-
alveolar lavage fluid (BALF) and sera were collected for analysis of the local and systemic 
anti-B. pertussis and anti-M2e antibody levels respectively. 
As expected, nasal administration of BPAL3 triggered strong systemic and local anti-B. 
pertussis IgG and IgA antibody responses that were comparable to the antibody responses 
obtained with mice infected with the parental counterpart, BPZE1 (Figure 4-7A-C). These 
data correlated to the ability of BPAL3 to colonize the murine lungs as efficiently as 
BPZE1, thus allowing for effective priming of the host immune system. Significant but 
rather low levels of secretory IgA (sIgA) (Figure 4-7D) and IgG (Figure 4-7E) antibodies 
against the M2e peptide were also measured in the BALFs from BPAL3-infected animals. 
In contrast, no significant anti-M2e IgG antibody response was detected in the sera of the 
BPAL3- infected mice (Figure 4-7F). As reported before (Li, Lim et al, 2011), significant 
absorbance readings against the M2e peptide were observed in the BALFs and sera from 
the BPZE1-infected mice.  This may be attributed to cross-reactive epitopes shared 
between the M2e sequence of influenza A viruses and B. pertussis. 
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Therefore, although the recombinant B. pertussis BPAL3 does not trigger M2e-specific 
systemic antibody response, it is capable of triggering modest M2e-specific antibody 
responses locally in the respiratory tract which may provide some protection against 
influenza at the site of infection.  In addition, the insertion of M2e epitopes into the BrkA 
autotransporter does not affect BPAL3’s ability to trigger strong anti-B. pertussis antibody 
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Figure 4-7 Antibody responses elicited by nasal administration. 
5 x 106 CFU of BPAL3 of parental BPZE1 were nasally administered three times to adult 
BALB/c mice at 4 and 3 weeks intervals. Two weeks after 2nd boost, the mice were bled 
then sacrificed, and BALFs were recovered. The anti-B. pertussis (Panels A-C) and anti-
M2e (Panels D-F) antibodies were measured by ELISA using whole B. pertussis cell lysate 
and M2e peptide as coating antigen respectively. *, p<0.05 compared with the values of 
BPZE1 mice. 
(A) Local anti- B. pertussis sIgA responses. Neat BALFs were used for detection. 
(B) Local anti- B. pertussis IgG responses. Neat BALFs were used for detection. 
(C) Systemic anti- B. pertussis IgG responses. Immune sera were diluted to 1/50 prior to 
analysis. 
(D) Local anti- M2e sIgA responses. Neat BALFs were used for detection. 
(E) Local anti- M2e IgG responses. Neat BALFs were used for detection. 
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4.1.1.6. Protective Efficacy of BPAL3 against Heterologous Viral Challenge 
To assess the translation of the induced M2e-specific local antibody response into 
protective efficacy against viral challenge, adult BALB/c mice were nasally administered 
with either BPAL3 or parental BPZE1 bacteria with the same immunization schedule as 
described in the previous section and challenged with H1N1 (A//PR8) 2 weeks after the 
last immunization. The survival rate was determined after challenge upon monitoring the 
animals’ weight on a daily basis. Mice were sacrificed when body weight loss reached 20%. 
The M2e sequences expressed in the BPAL3 strain and heterologous viral strains for 
challenge experiments are listed in Table 4.1.  
(A) Non-mouse adapted H1N1 (A/PR8) 
 
In the naïve group, all of the mice succumbed to the viral infection within 8 days.  Our 
previous work has reported the cross-protective ability of BPZE1 against influenza viruses 
due to nonspecific anti-inflammatory properties of the attenuated bacteria (Li et al. 2010), 
thereby accounting for a protective efficacy of 20% for the BPZE1-immunized mice 
(Figure 4-8A) However despite the ability to induce local M2e-specific antibodies, there 
was no further improvement in the mortality rate (Figure 4-8A) and morbidity (Figure 4-8B) 
of the BPAL3-immunized mice upon a heterologous challenge with H1N1/A/PR8) virus. 
Eight out of 10 BPAL3-immunized mice succumbed to infection within 8 days of infection 
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and the remaining 2 mice which survived, did not display decreased body weight loss as 
compared to the parental BPZE1 strain. Therefore, the results presented in this section 
suggested that BPAL3 was unable to provide further protection against challenge with 
H1N1 (A/PR8) nor improve morbidity of the infected mice. Possible reasons that may 
contribute to the lack of improvement in protection of the BPAL3-immunized mice are 
induction of insufficient amounts of M2e-specific antibodies in the respiratory tract to 
confer protection at the site of infection and/or 4 amino acid variations in the M2e 
sequence expressed in BPAL3 and H1N1 (A/PR8) respectively (Refer to Table 4.1).  
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Bacteria/ Viral strain M2e sequences 
BPAL3 (A/Thailand/LFPN-2004/2004(H5N1)   MSLLTEVETPTRNEWECRCSDSSD 
H1N1 (A/PR8) MSLLTEVETPIRNEWGCRCNGSSD 
Table 4.1 Amino acid sequences of M2e expressed in BPAL3 and heterologous viral 
strain used. 
The highlighted portions represent the differing amino acids between BPAL3 and the 
heterologous viral strain used for challenge.  
  
Chapter 4 Development of a Universal Influenza Vaccine Using 
Attenuated B. pertussis as a Live Nasal Vaccine Delivery Vehicle 









































Figure 4-8 Effect of BPAL3 immunization on survival rate (A) and body weight 
changes (B) in mice challenged with heterologous virus, H1N1 (A/PR8). 
5 x 106 CFU of BPAL3 (open circles) or parental BPZE1 (closed circles) were nasally 
administered three times to adult BALB/c mice at 4 and 3 weeks intervals. Body weight 
was monitored daily and mice were sacrificed when their body weight loss exceeds 20% of 
the original weight. A group of naïve mice (closed squares) was used as a negative control 
for the challenge experiment. The dashed line represents the 80% body weight limit for 
survival.  
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4.1.1.7. Effect of BPAL3 Immunization on Viral Load of Infected Mice 
M2e antibodies have been reported to protect against influenza infections via the reduction 
of viral replication (Zebedee, Richardson and Lamb 1985) and mediation of the killing of 
infected lung epithelial cells (Mozdzanowska et al. 1999). Therefore, to further analyse the 
effect if any, of BPAL3 immunization on influenza infections, the viral load was 
determined in the lungs of the infected mice. Adult BALB/c mice were nasally 
administered with BPAL3 or parental BPZE1 as described in the above section, followed 
by challenge with a heterologous virus. Infected lungs were then harvested and quantified 
for viral load on day 3 and day 5 post-viral challenge. 
(A) Non mouse-adapted H1N1 (A/PR8) 
On day 3 post-infection, no apparent viral load reduction was observed in the BPAL3-
immunized mice ( 
Figure 4-9A). However, on day 5 post-infection, BPAL3-immunized mice displayed lower 
viral loads in the lungs as compared to the naïve mice ( 
Figure 4-9B). This slight reduction of the viral loads at day 5 post-infection may be 
attributed to the M2e-specific antibodies produced in the respiratory tract of the BPAL3-
immunized mice. However, this did not translate in improved survival rate of the 
immunized animals (Figure 4-8). 
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Figure 4-9 Viral load quantification in infected lungs of BPAL3-immunized mice. 
5×106 cfu of BPZE1 or BPAL3 were nasally administrated three times to the mice. Two 
weeks after the last boost, mice were challenged with 500pfu of H1N1 (A/PR8) virus. At 3 
(A) and 5 (B) days post-viral challenge, the viral loads were measured in the infected lungs 
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4.1.2. Recombinant B. pertussis expressing the ectodomain of Matrix protein 2 
(M2e) using FHA as a Carrier 
4.1.2.1. Construction of Recombinant B. pertussis Producing FHA--(M2eCysSer)  
Chimeras 
We recently reported that expression of the 24 amino-acid M2e protein into the FHA 
carrier resulted in impairment of secretion of the recombinant FHA into the extracellular 
milieu (Li et al. 2011). To be efficiently secreted, FHA and FHA chimera should remain in 
an extended, secretion-compatible conformation prior to FhaC-mediated export (Hodak 
and Jacob-Dubuisson 2007). Thus, FHA chimera containing heterologous antigens with 
one or several disulfide bond-forming cysteine (Cys) residues like M2e are likely to adopt 
globular conformations incompatible with FhaC-dependent secretion, as they will become 
the substrates of periplasmic disulfide oxidases/isomerases. Therefore, in this study, we 
aimed to improve the secretion efficiency of FHA-(M2e)3 chimera by replacing the 
cysteine residues with serine residues in M2e, giving rise to the recombinant BPAL12 
strain which produce FHA-(M2eCysSer)3 chimera  (Table 4.2). Prior study have indeed 
shown that replacing Cys with Ser does not affect the antigenicity of M2e (Mozdzanowska 
et al. 2003, De Filette et al. 2005). 
The expression of the chimera was analyzed by immunoblotting with polyclonal mouse 
anti-FHA and mouse anti-M2e immune sera, using BPLR3 expressing the FHA-(M2eCys)3 
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chimera as a positive control. A single band was observed in the 10x concentrated 
supernatant prepared from each recombinant strain with a size corresponding to the 
secreted FHA-M2e chimeras. As predicted, a higher signal was detected for the FHA-
(M2eCysSer)3 chimera in the BPAL12 strain than the FHA-(M2eCys)3 chimera in 
BPLR3 strain when using an anti-FHA antibody and anti-M2e immune serum (Fig 4.10). 
Thus, these observations suggested that substitution of the cysteine residues with serine 
residues from M2e fused to FHA improve the secretion efficiency of the chimera.
Chapter 4 Development of a Universal Influenza Vaccine Using 
Attenuated B. pertussis as a Live Nasal Vaccine Delivery Vehicle 
108 | P a g e  
 
 
Bacteria strain M2e sequences 
BPLR3 MSLLTEVETPTRNEWECRCSDSSD 
BPAL12 MSLLTEVETPTRNEWESRSSDSSD 





Figure 4-10  Western blot detection of M2e-expressing recombinant B.pertussis. 
20ul of 10x concentrated supernatant were analyzed by immunoblotting using polyclonal 
mouse anti-FHA antiserum or polyclonal mouse anti-M2e antiserum. Legend: 1, BPZE1; 2, 
BPLR3; 4, BPAL12. 
 
1 
Anti-FHA 220 kDA  
220 kDA  Anti-M2e antibody 
Anti-FHA antibody 
2 3 
Chapter 4 Development of a Universal Influenza Vaccine Using 
Attenuated B. pertussis as a Live Nasal Vaccine Delivery Vehicle 
109 | P a g e  
 
4.1.2.2. Lung Colonization by Recombinant B. pertussis BPAL12 Strain 
To investigate the ability of the recombinant BPAL12 strain to colonize the mouse 
respiratory tract, adult BALB/c mice were nasally administered with either BPAL12 or the 
parental BPZE1 bacteria and sacrificed at the indicated time-points for bacteria plating. 
BPZE1 exhibited a slight peak of multiplication on day 7 post-infection followed by a 
gradual clearance from the lungs (Figure 4-11). In contrast, there was no peak of 
multiplication for BPAL12 with a significant difference of the bacterial load between 
BPAL12 and BPZE1 from day 7 post-infection onwards. Rapid clearance of the BPAL12 
bacteria from the murine lungs was observed with no bacteria counts detectable by day 17 
post-infection.  
Therefore, the data here suggested that BPAL12 is impaired in its ability to colonize in the 
murine lungs and consequently, this may affect the subsequent sustained and efficient 
priming of the host immune system.   
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Figure 4-11 Lung colonization profile of parental BPZE1 (solid bars) and BPAL12 
strains (open bars). 
Adult BALB/c mice were infected intranasally with 5 × 106 cfu of B. pertussis. The lungs 
were harvested at the indicated time points and viable bacteria in the lungs were counted 
after plating appropriate dilutions of the lung homogenates onto blood agar plates. 4 mice 
per group per time point were assessed individually. The results are expressed as means (± 
standard error) CFUs from 4 mice per group per time point, and are representative of two 
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4.1.2.3. Antibody Responses Elicited by the Recombinant B. pertussis BPAL12 strain 
To analyze the antibody responses induced by the recombinant BPAL12 strain, adult 
BALB/c mice were nasally administered three times at 4 and 3 week-intervals with 
recombinant BPAL12 or parental BPZE1 strains. Two weeks after the last boost, broncho-
alveolar lavage fluid (BALF) and sera were collected for analysis of the local and systemic 
anti-B. pertussis and anti-M2e antibody levels respectively. 
As predicted, nasal administration of BPAL12 triggered weaker local and systemic anti-B. 
pertussis IgG and IgA antibody responses as compared to the antibody responses obtained 
with mice infected with the parental counterpart, BPZE1 (Figure 4-12A-C). Also, the 
attenuation in lung colonization of BPAL12 translated into the inability of BPAL12 to 
induce M2e-specific secretory IgA (sIgA) and IgG antibodies in the BALFs and serum 
from infected animals (Figure 4-12D-F). As reported before (Li et al. 2011), significant 
absorbance readings against the M2e peptide were observed in the BALFs and sera from 
the BPZE1-infected mice.  This may be attributed to cross-reactive epitopes shared 
between the M2e sequence of influenza A viruses and B. pertussis. 
In all, although replacement of cysteine residues within the M2e sequence improved the 
secretion efficiency of the FHA chimera in BPAL12, its attenuation in colonization of the 
murine lungs led to the inability to induce local M2e-specific antibody response in the 
Chapter 4 Development of a Universal Influenza Vaccine Using 
Attenuated B. pertussis as a Live Nasal Vaccine Delivery Vehicle 
112 | P a g e  
 
BALFs as previously seen with the BPLR3 bacteria expressing the FHA-(M2eCys)3 
chimera (Li et al. 2011).           
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Figure 4-12 Antibody responses elicited by nasal administration. 
5 x 106 CFU of BPAL12 or parental BPZE1 were nasally administered three times to adult 
BALB/c mice at 4 and 3 weeks intervals. Two weeks after 2nd boost, the mice were bled 
then sacrificed, and BALFs were recovered. The anti-B. pertussis (Panels A-C) and anti-
M2e (Panels D-F) antibodies were measured by ELISA using whole B. pertussis cell lysate 
and M2e peptide as coating antigen respectively. *, p<0.05; **, p<0.01 compared with the 
values of BPZE1 mice. 
(A) Local anti- B. pertussis sIgA responses. Neat BALFs were used for detection. 
(B) Local anti- B. pertussis IgG responses. Neat BALFs were used for detection. 
(C) Systemic anti- B. pertussis IgG responses. Immune sera were diluted to 1/100 prior 
to analysis. 
(D) Local anti- M2e sIgA responses. Neat BALFs were used for detection. 
(E) Local anti- M2e IgG responses. Neat BALFs were used for detection. 
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4.1.3. Recombinant B. pertussis expressing the ectodomain of Matrix protein 2 
(M2e) using dual carriers  
4.1.3.1. Construction of Recombinant B. pertussis Producing BrkA-(M2e) and FHA-
(M2eCysSer) Chimeras 
Previously, we have observed weak local and systemic M2e-specific antibody responses 
induced by the recombinant strains expressing either BrkA-(M2e)3 (Section 4.1.1) or FHA-
(M2e)3 (Li et al. 2011). Therefore, in this study, we aim to further improve M2e-specific 
antibody response by expressing M2e concurrently in both carriers, BrkA and FHA, giving 
rise to the recombinant BPAL13 strain which produce BrkA-(M2eCys)3 and FHA-
(M2eCysSer)3 chimeras.  
The expression of the chimeras was analyzed by immunoblotting with polyclonal rabbit 
anti-BrkA, polyclonal mouse anti-FHA and mouse anti-M2e immune sera, using BPZE1 as 
a negative control. A single band was observed in the 10x concentrated supernatant 
prepared from each recombinant strain with a size corresponding to the secreted wildtype 
FHA or FHA-M2e chimeras. As expected, a weaker signal was detected for the FHA--
(M2eCysSer)3 chimera in the BPAL13 strain than the wildtype FHA in BPZE1 strain 
when using an anti-FHA antibody and anti-M2e immune serum (Figure 4-13). A single 
band was observed in the whole bacterial cell lysates prepared from each recombinant 
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strain with a size corresponding to the full length wildtype BrkA or recombinant BrkA-
M2e chimeras (Figure 4-13). 
Thus, these observations suggested that BrkA-(M2eCys)3 and FHA-(M2eCysSer)3 
chimeras are successfully expressed in the BPAL13 bacteria.  
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Figure 4-13 Western blot detection of M2e-expressing recombinant B.pertussis. 
20ul of 10x concentrated supernatant and 30ul of whole cell lysate were analyzed by 
immunoblotting using polyclonal mouse anti-FHA antiserum, polyclonal rabbit anti-BrkA 
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4.1.3.2. Lung Colonization by Recombinant B. pertussis BPAL13 Strain 
To investigate the ability of the recombinant BPAL13 strain to colonize the mouse 
respiratory tract, adult BALB/c mice were nasally administered with either BPAL13 or the 
parental BPZE1 bacteria and sacrificed at the indicated time-points for bacteria plating.  
BPZE1 exhibited a slight peak of multiplication on day 7 post-infection followed by a 
gradual clearance from the lungs (Figure 4-14). Similar to the lung colonization profile of 
BPAL12, there was no peak of multiplication for BPAL13 with significant differences of 
the bacterial load between BPAL13 and BPZE1 from day 7 post-infection onwards. Rapid 
clearance of the BPAL13 bacteria from the murine lungs was observed with no bacteria 
counts detectable by day 17 post-infection.  
Therefore, the data here suggested that BPAL13 is impaired in its ability to colonize the 
murine lungs and this is most likely attributed to the expression of (M2eCysSer) in the 
FHA carrier as observed in Section 4.1.2.2. As a result, this may affect the subsequent 
sustained and efficient priming of the host immune system.   
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Figure 4-14 Lung colonization profile of parental BPZE1 (solid bars) and BPAL13 
strains (open bars). 
Adult BALB/c mice were infected intranasally with 5 × 106 cfu of B. pertussis. The lungs 
were harvested at the indicated time points and viable bacteria in the lungs were counted 
after plating appropriate dilutions of the lung homogenates onto blood agar plates. 4 mice 
per group per time point were assessed individually. The results are expressed as means (± 
standard error) CFUs from 4 mice per group per time point, and are representative of two 
independent experiments.  ** p<0.01 compared with the values of BPZE1. 
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4.1.3.3. Antibody Responses Elicited by the Recombinant B. pertussis BPAL13 strain 
To analyze the antibody responses induced by the recombinant BPAL13 strain, adult 
BALB/c mice were nasally administered three times at 4 and 3 week-intervals with 
recombinant BPAL13 or parental BPZE1 strains. Two weeks after the last boost, broncho-
alveolar lavage fluid (BALF) and sera were collected for analysis of the local and systemic 
anti-B. pertussis and anti-M2e antibody levels respectively. 
Nasal administration of BPAL13 triggered weaker local and systemic anti-B. pertussis IgG 
and IgA antibody responses as compared to the antibody responses obtained with mice 
administered with BPZE1 (Figure 4-15A-C). Also, similar to that of BPAL12, the 
attenuation in lung colonization of BPAL13 translated to the inability to induce M2e-
specific secretory IgA (sIgA) and IgG antibodies in the BALFs and serum from infected 
animals (Figure 4-15D-F).  
In all, due to the attenuation observed in the colonization profile, BPAL13 was unable to 
induce local and systemic M2e-specific antibody response in the BALFs as previously seen 
in the BPAL3 (Section 4.1.1.5) and BPLR3 (Li et al. 2011) bacteria expressing the BrkA-
(M2eCys)3 and FHA-(M2eCys)3 chimera respectively. 
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Figure 4-15 Antibody responses elicited by nasal administration. 
5 x 106 CFU of BPAL13 or parental BPZE1 were nasally administered three times to adult 
BALB/c mice at 4 and 3 weeks intervals. Two weeks after 2nd boost, the mice were bled 
then sacrificed, and BALFs were recovered. The anti-B. pertussis (Panels A-C) and anti-
M2e (Panels D-F) antibodies were measured by ELISA using whole B. pertussis cell lysate 
and M2e peptide as coating antigen respectively. *, p<0.05; **, p<0.01 compared with the 
values of BPZE1 mice. 
(A) Local anti- B. pertussis sIgA responses. Neat BALFs were used for detection. 
(B) Local anti- B. pertussis IgG responses. Neat BALFs were used for detection. 
(C) Systemic anti- B. pertussis IgG responses. Immune sera were diluted to 1/100 prior 
to analysis. 
(D) Local anti- M2e sIgA responses. Neat BALFs were used for detection. 
(E) Local anti- M2e IgG responses. Neat BALFs were used for detection. 
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4.1.4. Recombinant B. pertussis expressing the CD8 epitope from nucleocapsid 
protein (NP366-374) 
4.1.4.1. Construction of Recombinant B. pertussis Producing BrkA-(NP366-374) 
Chimeras 
Using the same cloning strategy as the M2e-expressing recombinant B. pertussis, 2 and 4 
copies of the 9-amino acid NP366-374 CD8 immunodominant epitope from nucleocapsid 
protein were fused in frame into the passenger domain of the BrkA autotransporter and 
expressed in the BPZE1 strain, yielding the recombinant BPAL6 and BPAL7 which 
produces BrkA-(NP366-374)2 and BrkA-(NP366-374)4 respectively (Figure 4-16).  
Western blot analysis of the whole cell lysate prepared from the recombinant B. pertussis 
bacteria was carried out using the anti-BrkA polyclonal immune serum. Similar to the 
M2e-expressing recombinant B. pertussis strains, a single band was detected in the whole 
cell lysate of BPAL6 and BPAL7 at 84 kDa and 82 kDa  respectively, corresponding to the 
unprocessed forms of the BrkA-NP366-374 chimeras (Figure 4-17). However, the intensity of 
the bands detected in the whole cell lysate of BPAL6 and BPAL7 appeared substantially 
weaker than that of the wild-type BrkA expressed by the parental BPZE1 strain. Therefore, 
the blot analysis suggested that although the BrkA-NP366-374 chimeras are successfully 
produced by the recombinant bacteria, they are expressed at lower levels than their wild-
type counterpart. In addition, increasing NP epitope density fused to BrkA did not affect 
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the expression levels of the chimeras as observed with the recombinant B. pertussis strains 
expressing the BrkA-M2e chimeras.   
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Figure 4-16 Schematic diagram of integration of CD8 immunodominant NP366-377 





Figure 4-17 Western blot detection of NP366-374-expressing recombinant B.pertussis. 
30ul of whole cell lysate from 1, BPZE1; 2, BPSY1; 3, BPAL6; 4, BPAL7 were analyzed 
by immunoblotting using (A) polyclonal rabbit anti-BrkA antiserum (B) Coomassie 
staining was included to ensure equal loading of individual samples. 
82 kDA 
103 kDA  
(A) 
(B) 
84 kDA  
1   2   3   4   
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4.1.4.2. In vitro Growth Viability of the NP366-374-expressing Recombinant B. pertussis 
Strains 
To investigate if insertion of NP366-374 into the passenger domain of BrkA affects the in 
vitro bacterial fitness of recombinant BPAL6 and BPAL7 strains, the in vitro growth 
profiles were determined in liquid culture upon absorbance readings at the indicated time-
points.  
The data indicated that the parental BPZE1 strain replicates and multiplies more efficiently 
than BPAL6, BPAL7 and ∆brkA BPSY1 (Figure 4-18). The growth kinetic profiles 
obtained with BPAL6 and BPAL7 correlated to that of the M2e-expressing recombinant B. 
pertussis strains whereby increasing epitope density impairs the overall bacterial fitness in 
liquid culture (Refer to Figure 4-3). 
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Figure 4-18 In vitro growth kinetic profiles of BPAL6 (open squares) and BPAL7 
(open circles) strains. 
Stained-Scholte medium was inoculated with an overnight pre-culture at an initial OD600nm 
of 0.5. Cultures were shaken vigorously at 37oC and OD600nm was monitored over a 48 
hours time course. Parental BPZE1 (closed circles) and BPSY1 (closed squares) strains 
were used as reference strains.  
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4.1.4.3. Cell Surface Exposure Studies of the Recombinant B. pertussis BPAL7 Strain 
Handel and colleagues have reported that the antigen presentation is a limiting factor in 
activation of NP366-374-specific cytotoxic T lymphocytes during secondary infection 
(Handel and Antia 2008). Therefore, we selected BPAL7 which expresses more copies of 
the CD8 immunodominant NP366-374 epitope for further studies. Before proceeding to the in 
vivo studies, the ability of BPAL7 bacteria to express the BrkA-NP366-374 chimeras on the 
surface was analyzed by flow cytometry and immunofluorescence (IF). 
The percentage of positive cells detected by flow cytometry analysis indicated that 
insertion of NP366-374 epitope into BrkA does not compromise the ability of BrkA chimera 
to be presented on the bacterial surface and that BPAL7 was capable of expressing the 
BrkA-NP377-374 chimera on the cell surface as efficiently as wild type BrkA produced by 
BPZE1 (Figure 4-19A). However, based on the mean fluorescence intensity data (Figure 
4-19B) and IF images (Figure 4-20), lower intensities were observed for the individual 
BPAL7 cells as compared to parental BPZE1 strain. Again, while the decrease in the 
signals intensity may be due to the loss of a number of epitopes from the BrkA passenger 
domain in the chimera, we cannot exclude the possibility that fewer chimeric molecules are 
expressed  at the surface  of BPAL7 bacteria compared to wild type BrkA expressed by 
BPZE1 bacteria.   
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Figure 4-19 Flow cytometric profiles of intact B. pertussis strains. 
Intact BPSY1, BPZE1 or BPAL7 cells were co-incubated with anti-BrkA polyclonal 
antibodies. BPZE1 bacteria stained with Cy™ 2-conjugated secondary antibody were used 
as an isotype control. (A)Panel A graphs are representative of individual experiments. (B) 
Panel B shows the average mean fluorescence intensity (MFI) for the 2 independent 
experiments. Results are expressed as means ± standard deviations. 
(A) 
(B) 
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Figure 4-20 Epifluorescence microscope images showing surface localization of BrkA or BrkA-(NP366-374)4 chimeras in 
intact B. pertussis strains. 
Anti-BrkA antiserum was used to detect BrkA or BrkA-(NP366-374)4 on the surfaces of intact BPSY1 (B and F), BPZE (C and G), 
and BPAL7 (D and H) cells. Panels A and E depict images from isotype control. Panels A – D represent phase contrast images; 
panels E – H show images as seen under blue light excitation (488 nm).  
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4.1.4.4. Lung Colonization by Recombinant B. pertussis BPAL7 Strain 
As colonization efficacy is instrumental in triggering a successful immune response in 
the host, we assessed the ability of BPAL7 bacteria to colonize the murine lungs. Adult 
BALB/c mice were nasally administered with BPAL3 as described in Section 4.1.1.4 
and the infected lungs were collected at the indicated time-points for determination of 
the colony counts. 
At day 7 (p=0.02) and 10 (p= 8.1 X 10-4) post- administration, the number of BPAL7 
bacteria recovered was significantly lower than the number of BPZE1 bacteria, 
indicating some impairment in the ability of BPAL7 to multiply and reside in the 
murine lungs. However, BPAL7 bacteria were cleared at a gradual rate and comparable 
CFU numbers were counted in the lungs at 17 days post-administration for both 
BPAL7- and BPZE1-infected mouse groups (Figure 4-21). Therefore, even though 
BPAL7 did not colonize the respiratory tract as efficiently as parental BPZE1, the 
gradual clearance from the lungs and persistence is likely to be sufficient to prime 
efficiently the host immune system. 
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Figure 4-21 Lung colonization profile of parental BPZE1 (solid bars) and BPAL7 
strains (open bars). 
Adult BALB/c mice were infected intranasally with 5 × 106 cfu of B. pertussis. The 
lungs were harvested at the indicated time points and viable bacteria in the lungs were 
counted after plating appropriate dilutions of the lung homogenates onto blood agar 
plates. 4 mice per group per time point were assessed individually. The results are 
expressed as means (± standard error) CFUs from 4 mice per group per time point, and 
are representative of two independent experiments.  * p<0.05, ** p<0.01 compared with 
the values of BPZE1.  
  
Chapter 4 Development of a Universal Influenza Vaccine Using 
Attenuated B. pertussis as a Live Nasal Vaccine Delivery Vehicle 
131 | P a g e  
 
4.1.4.5. CD8 T Cell Responses Elicited by the Recombinant B. pertussis BPAL7 
strain 
To analyze the NP366-374-specific cytotoxic T lymphocyte (CTL) responses induced by 
the recombinant BPAL7 strain, adult BALB/c mice were nasally administered three 
times at 4 and 3 week-intervals with recombinant BPAL7 or parental BPZE1 strains. 
Three days after the last boost, mice were sacrificed and their lungs and spleens were 
collected aseptically for FACS analysis after staining with Db/ASNENMETM tetramers. 
An additional group of mice infected with live H1N1(A/PR8) virus (sublethal dose) 
was used as a positive control. 
A significant increase in the population of NP366-374 –specific CTLs in the lungs 
(34.19%) and spleens (7.64%) of H1N1-infected mice from the naïve mice was 
observed, thus confirming the expansion of the NP366-374–specific CTLs upon influenza 
infection. However, there was no significant difference in the NP366-374–specific CTLs 
population of the lungs (Table 4.3A) and spleens (Table 4.3B) between the BPAL7-
immunized and naïve groups.  
To understand further the reason for the inability of BPAL7 to induce the expansion of 
NP366-374–specific CTLs upon immunization, the total CD8 population in the B. 
pertussis-infected mice was also analyzed. Surprisingly, upon nasal administration of B. 
pertussis parental or recombinant strains no significant expansion of the total CD8 T 
cell population could be detected in both the lungs and spleens. 
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This observation thus suggested that the absence of expansion in NP366-374-specific CTL 
population may be due to the inability of B. pertussis to induce a CD8 response.  
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Immunogen Lung CD8 T cell population (%) 
NP366-374-specific CD8 T 
cells population (%) 
Naïve pooled 6.86 0.04 
BPZE1 pooled 7.86 0.22 
H1N1 pooled 34.19 22.41 
BPAL7 M1 8.23 0.61 
M2 7.04 0.14 
M3 5.64 0.18 
M4 8.23 0.36 
M5 8.10 0.49 
M6 7.50 0.13 
 
Immunogen Spleen CD8 T cell population (%) 
NP366-374-specific CD8 T 
cells population (%) 
Naïve pooled 4.55 0.62 
BPZE1 pooled 3.67 0.39 
H1N1 pooled 10.04 7.64 
BPAL7 M1 6.89 0.29 
M2 4.72 0.21 
M3 4.45 0.22 
M4 6.12 0.16 
M5 4.50 0.22 
M6 3.83 0.52 
Table 4.3 Expansion of NP366-374-specific CD8 T cell population elicited by nasal 
administration. 
5 x 106 CFU of BPAL7 or parental BPZE1 were nasally administered three times to 
adult BALB/c mice at 4 and 3 weeks intervals. 3 days after the 2nd boost, the mice 
were sacrificed, and lungs (A) and spleens (B) were recovered for tetramer staining of 
NP366-374-specific CTLs.  
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4.2. DISCUSSION 
4.2.1. Development of a universal influenza vaccine using attenuated B. pertussis 
as a live nasal vaccine delivery vehicle 
4.2.1.1. Recombinant B. pertussis expressing the ectodomain of Matrix protein 2 
(M2e) 
Influenza A infections have been a persistent problem worldwide due to frequent 
antigenic drifts and shifts. Although vaccination remains the best preventive tool 
against influenza infections, there remains the challenge to successfully match the 
vaccine strains with the circulating strain of the next flu season. Therefore, to address 
these current challenges, it is highly desirable to develop a universal influenza vaccine 
candidate that can provide protection against different influenza virus subtypes. M2e is 
a relatively conserved epitope of the influenza A viruses and is expressed abundantly on 
virus-infected cells. M2e-mediated protection has been shown to aid in viral clearance 
by killing virus-infected cells by antibody-mediated cell cytotoxicity (Refer to Section 
2.1.7.1).    
Furthermore, live attenuated bacterial vaccines have been studied as potential vaccine 
delivery systems for presentation of heterologous vaccine candidates in order to mimic 
natural infection and allow efficient priming of the host immune system due to their 
ability to survive and multiply within host to facilitate sustained exposure to antigen. 
Therefore, development of live attenuated bacterial vaccines by the nasal route may 
present themselves more relevant in triggering immunity not only at the systemic level 
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but also at the site of infection. In particular, live attenuated B. pertussis is an 
interesting vaccine delivery candidate as the natural route of infection resembles that of 
influenza viruses. Studies have been conducted to evaluate the use of live B. pertussis 
for expression of heterologous antigens and it has been shown to induce potent local 
and systemic antibody responses against the heterologous antigen upon immunization 
(Reveneau et al. 2001, Coppens et al. 2001, Ho et al. 2008). Furthermore, our lab has 
successfully developed the use of a highly attenuated strain of B. pertussis, BPZE1 as a 
vaccine delivery system for expression of heterologous antigens (Ho et al. 2008, Li et al. 
2011). The promising attribute to the use of BPZE1 as a vaccine delivery system is (1) 
despite its reduced lung inflammation, it is still able to colonize murine lungs efficiently 
and trigger strong immune responses and (2) BPZE1 is in the early phases of clinical 
trials for evaluation as a live nasal pertussis vaccine. 
In my study, I have explored the use of two vaccine carriers, BrkA and FHA for 
expression in BPZE1 of the influenza antigen vaccine candidates M2e and NP366-374. In 
the next few sections, we will discuss the findings for each of the vaccine carriers 
utilized and the limitations we faced for each construct. 
(A) BrkA as a carrier 
Oliver et. al. has demonstrated that deletion of the region from aa A52 to P600 of the 
passenger domain does not affect surface-exposure of BrkA (Oliver et al. 2003b). 
Therefore, this finding allows the region to be replaced by heterologous protein 
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antigens so that the size of the BrkA chimeric protein does not exceed the size of wild-
type BrkA. However, the passenger domain is found to possess adjuvant and 
immunogenic properties (Cainelli Gebara et al. 2007). Thus, we deleted a smaller 
region within the passenger domain from A52 to H263 for insertion of heterologous 
protein antigens. In an earlier study, our laboratory demonstrated the potential of the 
truncated BrkA as a vaccine delivery carrier for expression of SP70, a 15-amino acid 
peptide derived from Enterovirus 71 capsid protein and its ability to induce a specific 
neutralizing antibody response (Ho et al. 2008). 
In my study, due to the small size of M2e antigen (23aa), tandem repeats of M2e have 
been cloned into the truncated passenger domain of BrkA for expression of the BrkA-
M2e chimeras at the bacterial surface of B. pertussis. As evidenced by western blot 
analysis, we observed that increasing the number of M2e copies does not affect the 
expression levels of the BrkA-M2e chimeras at the protein level; instead it improves the 
expression of the BrkA-M2e chimeras with increasing epitope density. Furthermore, we 
found that insertion of the Cys-containing M2e epitopes into the BrkA carrier does not 
affect the ability of the BrkA-M2e chimeras to be presented at the bacterial surface and 
colonization ability of murine lungs by the recombinant BPAL3. This is consistent with 
previous findings that reported the efficient translocation of folded BrkA fusion 
proteins containing Cys residues across the outer membrane (Veiga et al. 2004, Khong 
et al. 2009). Once again, BrkA is shown to be highly versatile as a carrier system to 
present at the bacterial surface Cys-containing proteins without major detrimental 
effects on the outer membrane integrity and lung colonization efficacy of the 
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recombinant strains. This is a major improvement as compared to the FHA vaccine 
carrier in B. pertussis which is less tolerant to Cys-containing proteins as FHA requires 
an unfolded conformation for efficient secretion.  
Previous studies have reported that high M2e epitope density in fusion proteins 
impacted on B cell recognition that resulted in M2e–specific antibodies with higher 
average affinity, which is likely attributed to stronger helper function of M2e-specific 
CD4+ T-cells. Therefore, we selected BPAL3 which expresses 3 copies of M2e in the 
truncated passenger domain of BrkA for further analysis. However, BPAL3 was shown 
to trigger only modest M2e-specific antibody responses locally in the respiratory tract 
but not M2e-specific systemic antibody response in the blood circulation. Nevertheless, 
the modest M2e-specific antibody responses elicited at the respiratory tract may provide 
some level of protection against influenza at the site of infection. Since M2e-specific 
antibodies are documented to have a high affinity for virus infected cells and act via 
ADCC to mediate the killing of infected cells by the complement or cells of the innate 
immune system, natural killer (NK) cells, viral load in lungs was quantified and we 
observed a slight reduction of the viral loads at day 5 post-infection in the BPAL3-
immunized mice. However, this did not translate in improved mortality or morbidity of 
the immunized animals upon an influenza challenge as compared to the parental 
BPZE1-immunized mice. This may be attributed to several reasons; (1) suboptimal 
levels of M2e-specific antibodies induced or (2) the mismatch between the M2e 
sequence expressed in BPAL3 and the viral strain used for challenge experiments, 
H1N1 (A//PR8) (Table 4.1).  
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Highly conserved as it is, mutations can still occur within the M2e sequences. 
Furthermore, 5 amino acid positions within the region of amino acids 10-20 of M2e 
were shown to be host restricted. (Liu et al. 2005) Consequently, it is imperative to 
study whether an M2e-based vaccine can provide protection against influenza A virus 
strains with different M2e sequences. Here, we have used the M2e sequence from 
H5N1 virus (A/Thailand/LFPN-2004/2004(H5N1) for expression in B. pertussis with 
the objective of developing a universal influenza vaccine against HPAI influenza strains 
whereas the influenza virus that we have used in the challenge experiments is from the 
H1N1 (A/PR8) subtype.  
Since there are four amino acid variations in the M2e sequence between these two virus 
strains (Table 4.1), this could contribute to the lack of improvement in protection seen 
in the BPAL3-immunized mice upon influenza challenge.  
(B) FHA as a carrier 
FHA has been studied extensively as a vaccine delivery vehicle for heterologous 
protein antigens in live B. pertussis (Ho et al. 2008, Coppens et al. 2001, Reveneau et al. 
2001, Alonso et al. 2005, Li et al. 2011). However, there is a major limitation in the use 
of FHA as a vaccine carrier as an extended form of FHA chimera is required for 
efficient secretion. Therefore, proteins with cysteine residues susceptible to form intra- 
and/or intermolecular bonds which result in globular conformation of the chimera may 
not be suitable for expression in the FHA carrier.  In a previous study, we observed the 
inverse correlation between the number of cysteine-containing M2e copies fused to 
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FHA and the secretion efficacy of the chimera (Li et al. 2011). The impairment in 
secretion efficiency of the FHA-M2e chimeras was hypothesized to result in suboptimal 
levels of local and systemic anti-M2e antibody responses induced by BPLR3 expressing 
the cysteine-containing FHA-(M2e)3 that were not high enough to confer further 
protection against a viral challenge (Li et al. 2011).  
One of the objectives of my study was to improve the secretion efficacy of the FHA-
M2e chimeras in the recombinant bacteria that may lead to the production of higher 
anti-M2e immune responses and thus better protection. Studies have shown that 
substitution of cysteine for serine does not affect M2e antigenicity (recognition by 
protective monoclonal antibodies) (Mozdzanowska et al. 2003, De Filette et al. 2005). 
Therefore, we replaced the cysteine residues in M2e with serine residues to prevent 
disulfide bond formation that are incompatible with FHA secretion (Table 4.2). 
Upon substitution of the cysteine residues, we observed an improvement in the 
secretion efficiency of the FHA--(M2eCysSer)3 chimera in the recombinant BPAL12 
strain as compared to the recombinant BPLR3 expressing the FHA-(M2eCys)3 chimera. 
However, the secretion efficiency was not restored to wild type FHA in parental BPZE1 
strain. Unexpectedly, despite an improvement in the secretion efficiency of FHA-
(M2eCysSer)3 chimeras, there was severe attenuation in the ability of recombinant 
BPAL12 to colonize murine lungs and bacterial clearance was completed by day 17 
post-infection. The attenuation in lung colonization translates into inability to prime the 
host immune system effectively, as evidenced by the weak B. pertussis antibody 
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responses elicited. Therefore, improvement in secretion efficiency of the FHA-
(M2eCysSer)3 chimera did not lead to production of higher anti-M2e antibody 
responses but in contrast, was unable to trigger M2e-specific antibody responses both 
locally and systemically as previously observed in BPLR3-immunized mice due to 
rapid bacterial clearance. A possible reason for the severe attenuation of BPAL12 in 
colonization of murine lungs may be due to steric interference introduced through 
amino acid substitution that in turn mask the host binding sites on FHA. Therefore, 
FHA is unable to bind to host ciliated epithelial cells in the host respiratory tract to 
allow B. pertussis establishment in host. Alternatively, the low levels of secreted FHA-
(M2eCysSer)3 chimera is still insufficient to sustain good colonization. Previous 
work has shown the necessity of FHA secretion for optimal colonization (Coutte et al. 
2003). The inadequate secretion efficiency of FHA-(M2eCysSer)3 chimera may be 
attributed to (1) ineffective cleavage by SphB1 peotease or (2) overall transport to the 
bacterial surface may be less efficient than wildtype FHA. 
(C) Dual carrier 
As previously discussed, suboptimal levels of M2e-specific antibodies are likely a key 
contributing factor to poor ability of recombinant BPAL3 (Section 4.1.1) or BPLR3 to 
confer protection against influenza challenge (Li et al. 2011). Therefore, we sought to 
improve the levels of M2e-specific antibodies induced through the expression of the 
M2e epitope concurrently in both carriers, BrkA and FHA leading to BPAL13 
expressing both BrkA-(M2eCys)3 and FHA-(M2eCysSer)3 chimeras. Since previous 
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studies have shown that the magnitude of M2e-specific humoral response is directly 
proportional to the degree of epitope density (Liu et al. 2004, Liu and Chen 2005), we 
reasoned that expression of M2e epitope by two carriers may improve the 
immunogenicity conferred through the increase in M2e epitope density being presented 
to the host immune cells. 
As expected, severe attenuation was observed in the ability of recombinant BPAL13 to 
colonize murine lungs similar to the recombinant BPAL12 bacteria expressing FHA-
(M2eCysSer)3 chimera. Furthermore, since lung colonization ability is one of the 
critical parameters for the induction of an effective immune response upon nasal 
administration of live recombinant B. pertussis strains, the drastic attenuation in lung 
colonization resulted in the induction of a weaker B. pertussis antibody response and 
similarly, BPAL13 was cleared at a rapid rate that did not allow the bacteria to have 
adequate time to induce M2e-specific antibodies, and despite a greater M2e epitope 
density at the bacterial surface. 
To conclude this section, as M2e is a non-immunogenic molecule, it needs to be 
coupled to an appropriate carrier to render it immunogenic enough to induce M2e-
specific antibodies. In the two carriers explored in B. pertussis, both of them have 
displayed limitations as a vaccine delivery carrier for M2e. Although BrkA is relatively 
tolerant towards expression of cysteine-containing heterologous antigens, it is not 
immunogenic enough to prime the host immune system for production of adequate 
amounts of M2e-specific antibodies to improve mortality and morbidity. In contrast, 
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although FHA is a highly immunogenic molecule, there remain several limitations as 
insertion of heterologous antigens into FHA may affect the secretion efficiency of the 
FHA chimeras or impair the adherence properties of FHA that lead to an attenuation in 
the bacteria’s ability in colonizing the murine lungs which in turn translates into weak 
priming of the host immune system. 
4.2.1.2. Recombinant B. pertussis expressing the CD8 epitope from nucleocapsid 
protein (NP366-374) 
Previous studies have focused in using live BPZE1 as vaccine delivery vehicle for 
expression of epitopes to trigger humoral immunity (Ho et al. 2008, Li et al. 2011) but 
little have been researched on the possibility of using live B. pertussis as a vaccine 
delivery carrier for induction of T cell responses. Since cytotoxic T lymphocytes (CTLs) 
have been documented to play an important role in host defense against intracellular 
pathogens such as viruses through recognition and elimination of virus-infected cells 
(Yap et al. 1978), we investigated the potential of BrkA as a vaccine carrier for CD8 T 
cell epitopes. Influenza nucleoprotein (NP) has been widely explored as an influenza 
vaccine candidate in triggering CTL responses against influenza infections as of its 
relatively well conserved sequence (Saha et al. 2006, Ohba et al. 2007, Altstein et al. 
2006). To date, there are several live attenuated bacterial or viral expression systems 
that have been demonstrated to express recombinant NP and trigger NP-specific T cell 
responses successfully including Salmonella typhimurium, vaccinia virus and 
adenovirus (Zhou et al. 2010, Ashraf et al. 2011, Goodman et al. 2011). Previously, our 
lab has shown that cytoplasmic expression of full-length NP in B.pertussis does not 
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lead to significant specific T-cell priming in mice upon nasal administration of the live 
recombinant bacteria (Li 2010). This is in agreement with previous studies using other 
live bacteria as vector for the delivery of subunit vaccines whereby cytoplasmic 
expression of the vaccine candidates seems to be the least immunogenic compared to 
secretion in the extracellular milieu and exposure at the bacterial surface (Reveneau et 
al. 2002). Therefore, in this study, we utilized BrkA as the vaccine carrier for NP366-374, 
an immunodominant CD8 T cell epitope identified from murine models infected with 
influenza A virus to present the recombinant heterologous antigen on the bacterial 
surface.  
Similar to M2e, tandem repeats of NP366-374 were fused to BrkA due to its small size of 
9 amino acids. Our data suggested that although BrkA-(NP366-374)4 is successfully 
expressed on the bacterial surface and is able to maintain sustained colonization of 
murine lungs up to day 17 post-infection, no NP366-374-specific CTL immune responses 
were found in the BPAL7-immunized mice. To understand further the reason for the 
inability of BPAL7 to induce the expansion of NP366-374–specific CTLs upon 
immunization, we analyzed the total CD8 population in the parental BPZE1- and 
BPAL7-infected mice and no significant expansion of the total CD8 T cell population 
was detected in both the lungs and spleens. This observation suggests that the absence 
of expansion in NP366-374-specific CTL population may be due to the inability of the 
bacteria to induce a CD8 response.  
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There are several parameters that govern the ability of the live recombinant bacteria in 
induction of immune responses such as the identity/nature of the carrier, host cellular 
location of the vector upon infection. Immune response to B. pertussis is predominantly 
Th1 and Th17-mediated (Mills et al. 1998a). Direct evidence of the protective role for 
antibodies in humans was provided through the demonstration that passive 
immunization with B. pertussis specific anti-sera reduced the severity of disease in 
infected individuals (Granström et al. 1991). Antibodies may function either by 
neutralizing bacterial toxins, inhibiting extracellular bacteria from binding to cells in 
mucosal tracts or by enabling bacterial uptake and destruction by macrophages and 
neutrophils. The first evidence of the importance of the role of T cells in immunity to B. 
pertussis was reported in athymic or severe combined immunodeficient (SCID) mice 
who failed to clear B. pertussis infection whereas in normal BALB/c mice clearance 
occurs after 35 days (Mills et al. 1993). In addition, CD4 KO mice were shown to be 
unable to provide protection upon intranasal infection and depletion of CD4+ T cells in 
wild type mice prior to challenge of mice immunized with killed bacteria, which did not 
affect antibody production, abrogated protection (Leef et al. 2000). Conversely, CD8-
depleted mice were protected against B. pertussis by immunization with inactivated 
bacteria and adoptive transfer of immune CD8+ T cells did not confer protection to 
sublethally irradiated mice (Mills et al. 1993). Therefore, these data suggest that CD4+ 
T cells, but not CD8+ T cells, mediate protection against B. pertussis. In addition, 
studies have shown that extracellular versus intracellular location of bacteria generally 
drives the type of T-cell responses induced, whereby intracellular bacterial pathogen 
trigger strong CD8 T cell responses whereas extracellular pathogen such as B. pertussis 
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trigger predominantly CD4 T cell responses (Mollenkopf, Dietrich and Kaufmann 
2001). Furthermore, avirulent B. pertussis mutants have been demonstrated to be 
impaired in their uptake by macrophages compared to the virulent parental strain, and 
were unable to survive intracellularly (Friedman et al. 1992, Steed, Setareh and 
Friedman 1991, Guzman et al. 1994). The internalization process, as well as 
intracellular survival, is dependent on the presence of virulence factors such as AC, 
FHA and PT. Therefore, although the exact cellular location of BPZE1 is unknown, it is 
possible that there is impairment in the ability of BPZE1 to be taken up by host cells for 
processing and presentation of heterologous antigens for induction of CD8 T cell 
responses as the bacteria has genetic alterations in three of its virulence factors, PT, 
DNT and TCT.  Thus, it appears that B. pertussis, and BPZE1 in particular, does not 
represent a promising live vector for triggering CD8 T cell responses. 
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5. DEVELOPMENT OF ATTENUATED BORDETELLA PERTUSSIS AS A 
LIVE PERTUSSIS VACCINE 
5.1. Results 
5.1.1. Construction of BPAL10, a ∆cyaA BPZE1 mutant 
Adenylate cyclase (AC), one of the major virulence factors of B. pertussis, is produced 
mainly to evade host immune responses in order to facilitate establishment of infection. 
It is encoded by the cyaA gene which is part of an operon that also contains the open 
reading frames (ORF) cyaB, D and E, required for AC transport and secretion (Figure 
5-1). Therefore, to further attenuate the existing BPZE1 strain, the AC toxin was 
removed by an in-frame unmarked deletion of the cyaA ORF by allelic exchange as 
described before.  
Deletion of the AC toxin in the recombinant BPAL10 strain was analyzed at the 
genome and protein levels. At the genomic level, southern blot analysis was performed 
to confirm the deletion of the AC-encoding cyaA gene. Chromosomal DNA extracted 
from recombinant BPAL10 and parental BPZE1 strains was double digested with SacI 
and SphI, followed by hybridization with the 536-bp DIG-labeled probe which maps 
from nucleotide 1025 to 1561 of cyaB, (Figure 5-2A). As shown in Figure 5-2B, an 
expected 1.8-kb band and 3.4-kb band were detected for BPAL10 and BPZE1 
respectively (Figure 5-2B), thus verifying the deletion of cyaA gene in the recombinant 
BPAL10 strain. At the proteomic level, western blot was carried out to further affirm 
the inability of the recombinant BPAL10 strain to produce AC toxin. Whole cell lysates 
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of the recombinant BPAL10 and parental BPZE1 were prepared for immune-blotting 
using a mouse monoclonal anti-CyaA antibody. As expected, a 200kDa band was 
observed for the parental BPZE1 strain but not in the recombinant BPAL10 strain 
(Figure 5-3). Therefore, western blot confirms the absence of AC toxin production in 
BPAL10.  Furthermore, absence of hemolysis upon growing BPAL10 bacteria onto 
blood agar plate indicated the abolishment of the hemolytic activity attributed to the 
RTX domain of AC toxin (Figure 5-4). Taken together, these data confirm the absence 
of AC toxin production in the recombinant BPAL10 strain.  
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Figure 5-1 Construction of the recombinant BPAL10 strain. 
(A) Schematic diagram of the wild-type cya operon in parental BPZE1 strain. (B) 
Schematic diagram of the cya operon in recombinant BPAL10 with deletion of cyaA 
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Figure 5-2 Southern blot analysis of B. pertussis BPAL10. 
(A) Schematic diagram of the probe design for southern blot analysis of BPAL10. 
Restriction enzymes are indicated by arrows. (B) Southern blot analysis of the cyaA 
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Figure 5-3 Western blot detection of AC toxin-expressing recombinant B.pertussis. 
(A) 30ul of whole cell lysate from BPZE1 and BPAL10 were analyzed by 
immunoblotting using monoclonal mouse anti-CyaA antibody. 
 
 
Figure 5-4 Hemolytic activity of recombinant B. pertussis on blood agar. 
Single isolated colonies of recombinant BPAL10 and parental BPZE1 was streaked 
onto Bordet-Gengou blood agar plates that selects for B. pertussis and incubated for 3 
days. Hemolytic activity is characterized by the clearing of zones which indicate lysis 
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5.1.2. In vitro Growth Ability of the Recombinant BPAL10 Strain  
To investigate the impact of the deletion of AC toxin on the bacterial fitness, the in 
vitro growth kinetic profile of BPAL0 strain was determined in liquid medium and 
compared to that of the parental BPZE1.  
Comparable profiles were observed for both the recombinant BPAL10 and parental 
BPZE1 strains, indicating that AC toxin does not play a role in the bacteria’s ability to 
grow and multiply in liquid culture medium (Figure 5-5).  
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Figure 5-5 In vitro growth kinetic profiles of recombinant BPAL10 (open circles) 
strain. 
Stained-Scholte medium was inoculated with an overnight pre-culture at an initial 
OD600nm of 0.5. Cultures were shaken vigorously at 37oC and OD600nm was monitored 
over a 48 hours time course. Parental BPZE1 (closed circles) was used as the reference 
strain. 
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5.1.3. In vitro Adherence and Invasion Properties of the Recombinant BPAL10 
Strain 
Previous studies have indicated a role of AC during mammalian cell invasion by 
impairing some of the host bactericidal activities (Boyd et al. 2005, Khelef et al. 1993, 
Guermonprez et al. 2001). Cell adherence and invasion assays were thus performed 
using the human pulmonary epithelial cells A549 and/or the murine macrophages 
J774A.1, two cell lines commonly used to study the adherence/invasion properties of B. 
pertussis.  
No statistical difference was observed in the adherence capabilities between BPZE1 and 
BPAL10 strains to both the A549 and J774A.1 cell lines (Figure 5-6A), indicating that 
AC toxin does not directly contribute to the adherence of the bacteria during 
establishment of disease, thus enabling BPAL10 to adhere to the surface of the cells as 
efficiently as the parental BPZE1 strain. However, in the cell invasion assay, a 
significantly lower number of BPAL10 bacteria were recovered from the murine 
macrophages as compared to the BPZE1 parental strain as early as 6 hours post-
infection (Figure 5-6B). This result indicated that the absence of AC impaired BPAL10 
bacteria to invade macrophages. This observation is in agreement with a previous study 
which has reported that AC toxin binds specifically to αMβ2 integrin, CD11b/CD18 
(also known as CR3 or Mac-1) expressed on myeloid cells such as macrophages, 
neutrophils and dendritic cells, and on natural killer cells (Guermonprez et al. 2001).  
Together, these data show that the absence of AC toxin does not interfere with the 
adherence properties of B. pertussis but rather, accelerates the bacterial clearance by the 
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macrophages possibly by impairing the ability of recombinant BPAL10 strain to induce 
macrophage apoptosis.   
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Figure 5-6 In vitro adherence (A) and invasion (B) assays of recombinant BPAL10 
(open columns/circles) strain. 
Cell monolayers were incubated with recombinant BPAL10 bacteria at an MOI of 
1:100. (A) After incubation for 1h in 4oC, cell monolayers were washed, scrapped and 
plated for colony counting. (B) After incubation for 1h in 37oC, cell monolayers were 
washed and lysed with water to release intracellular bacteria. The cell monolayers were 
then scrapped and plated for colony counting. Parental BPZE1 (closed columns/circles) 
was used as a reference strain. * p<0.05, ** p<0.01 compared with the values of BPZE1.
(A) 
(B) 
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5.1.4. Lung Colonization by Recombinant B. pertussis BPAL10 Strain and 
Histological Examination in various Mouse Models 
5.1.4.1. Immunocompetent BALB/c mice 
The ability to colonize the respiratory tract for a live pertussis vaccine candidate is 
crucial to trigger strong immune priming and protective efficacy upon challenge with 
virulent B. pertussis. AC toxin has been previously reported to be an important 
colonization factor for B. pertussis to initiate infection (Goodwin and Weiss 1990). We 
thus assessed whether deletion of the AC encoding gene in BPAL10 would impair 
significantly the ability of the bacteria to colonize the lungs from adult (6 weeks old) 
BALB/c mice over a period of 17 days post-nasal administration. Furthermore, since 
ideally such live attenuated pertussis vaccine candidate would be administered early 
after birth, the colonization profile of BPAL10 was also monitored in infant (3 weeks 
old) mice.  
BPAL10 displayed a strong impairment in the ability to replicate and persist into the 
lungs from adult mice compared to its parental counterpart BPZE1, with bacterial loads 
close to the detection limit at day 17 post-infection (Figure 5-7A). In contrast, 
interestingly such drastic attenuation was not observed in infant mice where more than 
2 Logs of BPAL10 bacteria were still detected 17 days post-infection even though the 
bacterial loads recovered throughout the course of infection were significantly lower 
than those recovered from BPZE1-immunized animals (Figure 5-7B).  
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We also observed a dose-dependent effect on the lung colonization profile of the B. 
pertussis strains. At a high vaccine dose of 5x105 CFU, BPAL10 displayed a mild 
attenuation in the ability to replicate and persist into the lungs from adult mice 
compared to its parental counterpart BPZE1. However, at a low vaccine dose of 5x103 
CFU, attenuation in lung colonization became more pronounced with rapid bacterial 
clearance within 7 days post infection (Figure 5-8).  
Furthermore, previous histological examination showed that unlike the virulent strain 
BPSM, the BPZE1 derivative does not induce strong peri-bronchiovascular infiltrates 
and inflammatory cell recruitment 7 days after infection (Mielcarek et al. 2006). 
Similarly, BPAL10 did not induce severe inflammation in the lungs from infant mice 
(Figure 5-9). 
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Figure 5-7 Lung colonization profile of parental BPZE1 (solid circles) and 
BPAL10 strains (open circles) in an immunocompetent mouse model. 
Adult (A) and 3 week-old (B) BALB/c mice were infected intranasally with 5 × 105 cfu 
of B. pertussis. The lungs were harvested at the indicated time points and viable 
bacteria in the lungs were counted after plating appropriate dilutions of the lung 
homogenates onto blood agar plates. 4 mice per group per time point were assessed 
individually. * p<0.05, ** p<0.01 compared with the values of BPZE1. The dashed line 
represents the detection limit of the number of CFU present in the lungs. 
(A) 
(B) 
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Figure 5-8 Dose-dependent effect on lung colonization profile of parental BPZE1 
and BPAL10 strains at different doses administered. 
3 week-old BALB/c mice were infected intranasally with 5 × 105 or 5 × 103 cfu of B. 
pertussis. The lungs were harvested at the indicated time points and viable bacteria in 
the lungs were counted after plating appropriate dilutions of the lung homogenates onto 
blood agar plates. 4 mice per group per time point were assessed individually. ** 
p<0.01 compared with the values of BPZE1. The dashed line represents the detection 
limit of the number of CFU present in the lungs. 
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Figure 5-9 Histological examination of lungs infected with recombinant BPAL10 
strain. 
Three week-old BALB/c mice were infected intranasally with 5 X105 CFU of BPAL10, 
BPZE1, BPSM or PBS (sham control). Lungs were harvested aseptically one week after 
infection and fixed in formaldehyde. Parrafined sections were stained with hematoxylin 
and eosin, and examined under a light microscope. 
  
Chapter 5 Development of Attenuated Bordetella Pertussis as a Live 
Pertussis Vaccine 
161 | P a g e  
 
5.1.4.2. Immunocompromised AG129 mice 
IFNγ plays an essential role in controlling B. pertussis infection whereby disruption of 
the gene coding for the IFN-gamma receptor resulted in an atypical disseminated 
disease which was lethal and was characterized by pyogranulomatous inflammation and 
postnecrotic scarring in the livers, mesenteric lymph nodes and kidneys (Mahon et al. 
1997). In contrast, BPZE1 bacteria did not disseminate in IFNγ-R KO mice upon 
aerosol challenge and did not induce atypical pathology (Skerry and Mahon 2011). 
To further confirm the attenuated phenotype and safety profile of the BPAL10 strain, 
we assessed its colonization/dissemination ability upon nasal administration to AG129 
mice, deficient for IFNα/β- and γ-receptors.  BPAL10 and BPZE1 displayed a similar 
colonization profile characterized by the inability to multiply effectively but were able 
to persist up to at least 17 days post-infection. However, the number of BPAL10 
bacteria recovered was significantly lower than the number of BPZE1 bacteria from day 
7 post-infection onwards (Figure 5-10).  
Histological examination of the BPAL10 and BPZE1-infected lungs showed mild signs 
of bronchi-associated lymphoid tissue (BALT) hyperplasia, which differ greatly from 
that of the BPSM-infected lungs (Figure 5-11). 
Taken together, these data suggest that although BPAL10 displays a safety profile 
similar to BPZE1, there is a greater impairment in BPAL10’s colonization ability of 
immunocompromised mice.  
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Figure 5-10 Lung colonization by BPAL10 (open circles) and BPZE1 (filled circles) 
in an immunocompromised mouse model. 
6 to 8 wk old AG129 mice were infected intranasally with 5 X 105 CFU of BPAL10. 
Parental BPZE1 strain was used as control. The results are expressed as means (± 
standard error) CFUs from three to four mice per group. P values of 0.01 (**) compared 
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Figure 5-11 Histological examination of lungs infected with recombinant BPAL10 
strain in an immunocompromised mouse model. 
6-8 week old AG129 mice were infected intranasally with 5 X105 CFU of BPAL10, 
BPZE1, BPSM or PBS (sham control). Lungs were harvested aseptically a week after 
infection and fixed in formaldehyde. Sections were stained with hematoxylin and eosin, 
and examined by light microscopy. B- BALT hyperplasia 
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5.1.5. Local and Systemic Anti-B. pertussis Antibody Responses Induced by 
Recombinant BPAL10 Strain 
Host antibody responses against pertussis infection have been shown to play an 
important protective role whereby passive immunization with B. pertussis specific anti-
sera reduced disease severity in infected individuals (Granström et al. 1991).  It has also 
been suggested that IgA antibodies in the respiratory tract are capable of inhibiting 
adherence of B. pertussis to human ciliated cells (Tuomanen et al. 1984). Therefore, the 
anti-B. pertussis local and systemic antibody responses in the broncho-alveolar lavages 
fluids (BALFs) and sera from BPAL10-immunized infant mice were measured by 
ELISA two months after a single nasal administration and compared to the antibody 
responses measured in BPZE1-immunized age-matched animals.  
The results showed that BPAL10-immunized mice produced comparable levels of IgA 
(Figure 5-12A) and significantly higher levels of total IgG (Figure 5-12B) in their 
BALFs compared to the levels measured in the BALFs from BPZE1-immunized mice. 
The levels of systemic anti-pertussis total IgG antibodies were comparable between 
both animal groups (Figure 5-12C), whereas no significant serum IgA response was 
detected (Figure 5-12D).  
Furthermore, isotyping of the anti-B. pertussis subtypes was carried out in the immune 
sera of these mice and indicated that BPAL10-immunized mice produced high levels of 
IgG2a and IgG2b antibodies similar to those measured in BPZE1-immunized mice 
(Table 5.1), suggestive of a strong Th1 immune response in both animal groups, and 
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Figure 5-12 B. pertussis-specific antibody responses induced in infant mice by 
BPAL10 immunization. 
3 weeks old mice were nasally administered with 5 X 105 CFU of BPAL10 or BPZE1. 
Bronchoalveolar lavage fluid (A and B) and sera (C and D) were collected 2 month 
post-infection and total IgA  (A and C) and IgG (B and D) antibody responses to whole 
cell lysate of B. pertussis were determined by ELISA. P values of <0.01 (**) compared 
to BPZE1-immunized mice were considered significant. The data presented is 
representative of three independent experiments. 
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serum IgG1 IgG2a IgG2b IgG3 
Naïve pooled  0.15 0.08 0.09 0.14 
BPZE1 pooled 1.21 2.68 2.96 1.27 
BPAL10 M1 0.87 2.85 2.95 1.66 
M2 1.68 2.89 2.95 2.15 
M3 1.78 2.50 2.92 2.24 
M4 1.79 2.81 2.99 1.63 
M5 1.19 2.67 3.14 1.33 
M6 1.13 2.92 2.96 0.98 
 
Table 5.1. Anti- B. pertussis IgG isotyping in immune sera. Mice sera were collected 
2 month post-infection and analyzed by ELISA for anti-B.pertussis IgG1, IgG2a, IgG2b 
and IgG3 titers. Sera from individual mice of naïve group were pooled, while serum 
from each BPAL10-immunized mice was tested individually. Sera from all groups were 
diluted 1/50 prior to testing. 
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5.1.6. T Cell Proliferation and IFN-gamma Production Induced by 
Recombinant BPAL10 Strain 
Experimental studies in a murine model have demonstrated that protection is 
maintained after waning of circulating antibodies, through the generation of 
immunological memory with Pw or Pa (Mahon, Brady and Mills 2000). Therefore, to 
assess the memory recall responses in BPAL10-immunized infant mice, their 
splenocytes were harvested 2 months post-infection and re-stimulated in vitro with B. 
pertussis whole cell lysate. T cell proliferation was assayed and IFN- production was 
measured in the culture supernatants. The results were compared to the responses 
obtained with splenocytes from BPZE1-immunized mice. 
Splenocytes from BPAL10-immunized mice were more potent than splenocytes from 
BPZE1-immunized animals to trigger T cell proliferation upon re-stimulation with 
whole cell B. pertussis lysate (Figure 5-13A). However, the levels of IFN- produced in 
the culture supernatant by BPAL10-primed splenocytes were slightly but significantly 
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Figure 5-13 T cell proliferation and IFN-γ production in culture supernatants of 
splenocytes from BPAL10-immunized mice upon stimulation with whole B. 
pertussis extract. 
3-week-old BALB/c mice were intranasally immunized with 5 X105 CFU of BPAL10 
or BPZE1 and spleens were harvested 2 months post-infection for stimulation with 
whole cell lysate of B. pertussis. (A) T cell proliferation was assessed by [3H]thymidine 
incorporation. Results are expressed as the stimulation index (SI) corresponding to the 
ratio between the mean of [3H]thymidine uptake in the presence of test antigen and the 
mean of [3H] thymidine uptake in the absence of test antigen. An SI value of 2 was 
considered positive. Each sample was assayed in triplicate. (B) IFN-γ concentrations 
were measured in the culture supernatant of the re-stimulated splenocytes. P values of 
<0.05 (*) compared to BPZE1-immunized mice were considered significant. 
(A) 
(B) 
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5.1.7. Protective Efficacy of Recombinant BPAL10 Strain against Pertussis 
Challenge 
To assess the ability of BPAL10 to protect against subsequent pertussis infection, 
challenge experiments were conducted over a range of immunizing doses. Three week-
old mice were nasally administered once with 5x105 (high dose) or 5x103 (low dose) 
CFU of BPAL10 or BPZE1 bacteria and challenged with virulent B. pertussis BPSM 
strain 1 month post-immunization. 
5.1.7.1. High Immunizing Dose of 5x105 CFU/mouse 
In the naïve mice, the virulent BPSM was able to grow and multiply efficiently in the 
lungs up to day 5 post-infection. In contrast, nasal administration with BPZE1 prior to 
challenge with the virulent BPSM bacteria resulted in efficient clearance of the BPSM 
bacteria by day 5 post-infection (Figure 5-14A). Similarly, efficient bacterial clearance 
was observed upon challenge in the BPAL10-immunized mice (Figure 5-14A).  No 
statistical difference was observed in the bacterial counts between the BPAL10- and 
BPZE1-immunized animal groups at all the time points tested. 
5.1.7.2. Low Immunizing Dose of 5x103 CFU/mouse 
In the naïve mice, the virulent BPSM was able to grow and multiply efficiently in the 
lungs up to day 5 post-infection. In contrast, nasal administration with BPZE1 prior to 
challenge with the virulent BPSM bacteria resulted in efficient clearance of the BPSM 
bacteria by day 5 post-infection (Figure 5-14B). However, bacterial clearance was 
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visibly impaired upon challenge in the BPAL10-immunized mice as compared to the 
mice immunized with the parental BPZE1 bacteria and the differences in bacterial 
count between the two groups are significant on day 3 and 5 post-infection (Figure 
5-14B).  
Therefore, these data demonstrated that at a high vaccine dose, the deletion of AC toxin 
in BPZE1 does not compromise its protective efficacy against pertussis in an 
immunocompetent infant mouse model of pertussis. However, when given a low 
vaccine dose, deletion of AC toxin impairs the ability of the immunized mice to 
efficiently clear the bacteria from the lungs. 
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Figure 5-14 Challenge experiments with wildtype B. pertussis in mice immunized 
at (A) high vaccine dose (5x105 CFU/mouse) and (B) low vaccine dose (5x103 
CFU/mouse). 
3 week old mice were intranasally immunized with PBS (naïve) (black columns), 
BPAL10 (grey columns) or BPZE1 (open columns) and challenged with 5 X 106 CFU 
of B. pertussis BPSM 1 month post-infection. Lungs were harvested at indicated time 
points for colony plating. The results are expressed as the number of mean CFU (the 
number of standard errors of the mean CFU) from three to four mice per group. The 
dashed line represents the detection limit of the number of CFU present in the lungs. P 
value of <0.01 (**) compared to BPZE1 mice were considered significant. 
(A) 
(B) 
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5.2. DISCUSSION 
Pertussis is one of the major recurring childhood health problems despite high 
vaccination coverage. Chemical-inactivated whole cell (Pw) and acellular (Pa) vaccines 
are currently available and routinely used worldwide to protect against pertussis. Earlier 
studies had investigated the feasibility of a Pw vaccine dose at birth to provide early 
protection but reported some “immune tolerance” whereby the anti-B. pertussis 
antibody responses were reduced compared to infants who started their vaccination 
schedule at a later age (Provenzano et al. 1965, Barrett et al. 1959). Moreover, Pw-
associated reactogenicity remains a major concern. Local adverse effects, such as 
erythema, swelling, and pain at the injection site, fever, and other mild systemic events 
(e.g., drowsiness, fretfulness, and anorexia) have been reported in vaccinated 
individuals (Cody et al. 1981, Long et al. 1990). More severe systemic events like acute 
encephalopathy and permanent neurological sequelae have also been associated to the 
use of Pw vaccine (Kerr and Matthews 2000), but their causual link to pertussis 
vaccination remains difficult to establish. 
These observations have thus prompted the development and licensing of safer Pa 
vaccines that consist of up to five purified B. pertussis components, including 
inactivated PT, filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae (FIM). 
Pa formulations provide protection levels similar to those of Pw vaccines (Roduit et al. 
2002). In addition, early neonatal immunization with Pa vaccines was recently shown to 
be safe, well tolerated and resulted in early anti-B. pertussis antibody responses (Knuf 
et al. 2008). However, the current pertussis immunization schedules with Pa vaccines 
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do not offer life-long protection. Moreover, antigenic shift and adaptation of the 
circulating B. pertussis strains to the current Pa vaccines have been proposed to 
participate in the pertussis resurgence among vaccinated individuals, resulting in 
household transmission to vulnerable infants (Mooi et al. 2001). Altogether, these 
observations indicate that alternative pertussis vaccination strategies have to be 
explored in order to afford long-lasting protection starting ideally at birth.  
Natural infection with B. pertussis has long been known to induce strong and long-
lasting immunity that wanes later than vaccine-induced immunity (von König et al. 
2002). Furthermore, natural infection with B. pertussis induces measurable antigen-
specific Th1-type immune responses even in very young children (as young as 1 month 
of age) (Mascart et al. 2003). By contrast, numerous studies in humans and in animal 
models have suggested that the neonatal immune system is too immature to effectively 
mount sustained protective immunity upon administration of Pa vaccines, which 
stimulate a humoral, Th2-biased immune response (Siegrist 2001).  These observations 
suggest that live vaccines applicable by the i.n. route, in order to mimic as closely as 
possible natural infection, may represent attractive alternatives over the currently 
available Pa or Pw vaccines. This would allow early immunization, possibly at birth, to 
reducing the incidence of pertussis in the very young, most vulnerable age group. With 
the current knowledge on the molecular mechanisms of microbial virulence and the 
availability of suitable genetic tools, it is now possible to introduce precise and stable 
mutations into virulent microorganisms creating attenuated strains that are safe for 
vaccine use.  In that context, the attenuated B. pertussis strain BPZE1 has shown great 
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promise in pre-clinical models (Feunou et al. 2008, Mielcarek et al. 2006, Skerry et al. 
2009) and is currently undergoing a phase I clinical trial.  
However, BPZE1 still produces parental levels of AC, one of the major toxins produced 
by B. pertussis. AC exerts immunosuppressive effects on both the innate and adaptive 
immune systems through unregulated production and accumulation of intracellular 
cAMP which yields to the suppression of bactericidal activities of phagocytes, or 
superoxide production (Confer and Eaton 1982, Friedman et al. 1987, Njamkepo et al. 
2000, Weingart et al. 2000) and eventually leads to apoptosis (Khelef et al. 1993). Also, 
AC-induced cAMP signaling was proposed to shape the adaptive immune system 
towards B. pertussis tolerance by driving monocyte-derived dendritic cells 
differentiation to a semi-mature state and suppressing production of pro-inflammatory 
cytokines such as interleukin (IL)-12 and tumor necrosis factor (TNF)-α (Bagley et al. 
2002). The ability of AC to translocate inside the host cells and trigger MHC-I and II-
mediated immune responses (Loucká et al. 2002, Holubova et al. 2012) has been used 
to deliver heterologous vaccine candidates for induction of specific T cell responses 
(Fayolle et al. 2001, Tartz et al. 2008, Holubova et al. 2012) and has prompted us to 
investigate whether such feature would participate to the cell-mediated protection 
offered by BPZE1. We thus constructed an AC-deficient BPZE1 strain and 
characterized its protective efficacy compared to its parental counterpart.  
Our in vitro data show that AC does not play a critical role in the growth and 
multiplication of the bacteria in liquid media, nor does it affect adherence to 
mammalian cells. In contrast, AC deletion impaired the bacterial survival ability within 
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macrophages as well as the mouse lung colonization efficacy in a dose-dependent 
manner. Accelerated clearance of BPAL10 may represent a desirable feature for a live 
vaccine, as the shorter infectivity window frame is likely to reduce the recovering 
period time. However, rapid bacterial clearance may also result in a less efficient 
priming of immunity and trigger suboptimal protection against pertussis. Consistently, 
assessment of different immunizing doses revealed a decreased ability of BPAL10 to 
confer protection against pertussis in a dose-dependent manner. At a high vaccine dose 
(105 CFU) BPAL10 conferred a comparable protection level to the parental BPZE1 
strain. However, the protective efficacy of BPAL10 was greatly impaired with reduced 
bacterial clearance when the vaccine dose was lower (103 CFU). The vaccine dose-
dependent protective efficacy may be very important, especially since the actual 
vaccination dose has yet to be determined for human use. BPZE1 thus appears to be 
more robust than BPAL10, as it provides stronger protection than the latter at a low 
vaccine dose.  
Protection against B. pertussis depends on both humoral and cell-mediated immunity 
(Mills et al. 1998b). Therefore, investigating the ability of BPAL10 to induce both arms 
of immunity is important to evaluate the bacteria’s protective efficacy against pertussis. 
Removal of AC in BPZE1 did not lead to a reduced ability in triggering efficient anti-B. 
pertussis antibody responses, nor did it alter the predominant IgG2a/2b isotype profile. 
The clear bias to Th1-orientated immune responses has been previously reported in 
mice primed with Pw and is important for the complete clearance of the secondary 
infections within 5 to 7 days (Redhead et al. 1993). In contrast, we observed a 
significant impairment in the production of IFN-γ by T cells, despite enhanced cell 
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proliferation upon re-stimulation of the BPAL10-primed splenocytes. INF-γ-producing 
Th1 cells have been shown to play a key role in protection against pertussis (Mills et al. 
1998b, Peppoloni et al. 1991, Barbic et al. 1997). Therefore it is tempting to attribute 
the lesser protective efficacy of BPAL10 to the impaired IFN- γ production upon 
challenge.   
In conclusion, our study demonstrates that the production of active AC in BPZE1 
contributes to the protective efficacy of this live vaccine candidate. Whereas AC 
inactivation may intuitively be seen as a safer alternative, doing so impairs the fine 
balance between attenuation and immunogenicity. The determination of the optimal 
vaccine dose for human use will be instrumental to ensure that the administration of 
BPZE1 remains safe and provides maximal protection. 
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6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1. Conclusions  
Despite high vaccination coverage, B. pertussis infection remains endemic and reports 
of increasing incidence in Australia (Andrews et al. 1997), Canada (De Serres and 
Duval 2005) and Europe (de Melker et al. 1997) have been accumulating for the past 
twenty years. Recently, in 2010, an outbreak of pertussis occurred in California, with 
more than 8,300 reported cases of pertussis (including eight infant deaths) (Roehr 2010). 
The waning and/or sub-optimal efficacy of the current pertussis vaccines in adults have 
been proposed to account for resurgence. Antigenic shift and adaptation of the 
circulating strains to the vaccines may also be involved, thus calling for the 
development of a new generation of pertussis vaccines. Natural infection with B. 
pertussis is known to induce strong and long-lasting immunity that wanes later than 
vaccine-induced immunity (von König et al. 2002). A live attenuated B. pertussis 
vaccine might therefore represent an interesting alternative or complement to the 
current acellular pertussis vaccines. A highly attenuated B. pertussis strain, named 
BPZE1, has been described in which three toxins have been genetically inactivated 
(Mielcarek et al. 2006). Despite markedly reduced lung inflammation in the infected 
mice, BPZE1 maintained the ability to colonize and induce a strong protective 
immunity. In addition, it was able to confer superior protection against pertussis in 
infant mice as compared to acellular vaccines. Furthermore, BPZE1 has recently 
completed a phase I clinical trial in adult human volunteers.  
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As BPZE1 bacteria still produce parental levels of AC, one of the major toxins 
responsible for the cytotoxic activity of the pathogen, but also a potential antigen 
involved in the BPZE1 cell mediated protection. In order to test the role of AC in the 
BPZE1 protective potential, we thus generated an AC-deficient BPZE1 strain and our 
findings indicate that the protective efficacy of the AC-deleted BPZE1 strain was 
significantly impaired when given at low doses. Therefore, whereas AC inactivation 
may be seen as a safer alternative, doing so is likely to impair the fine balance between 
attenuation and immunogenicity. Therefore, this study once again highlights the 
delicate balance between attenuation and immunogenicity and presents BPZE1 as an 
attractive pertussis vaccine candidate as it maintains its immunogenicity despite being 
highly attenuated.  
Like pertussis, influenza virus infection occurs via the nasal route and has high 
mortality rates amongst the very young due to immature neonatal immune system. 
Therefore, development of a B. pertussis-vectored influenza vaccine is a highly 
attractive solution as it can mimic natural infection of influenza virus to induce immune 
responses against the influenza antigen and maintain sustained and efficient priming of 
the immune system due to the ability of B. pertussis to grow and multiply within host 
cells. In addition, in a mouse model of severe influenza-induced pneumonitis, Li et. al. 
observed that prior nasal administration of BPZE1 provided effective and sustained 
protection against lethal challenge with mouse-adapted H3N2 and H1N1 influenza A 
viruses through dampening the influenza-induced cytokine storm (Li et al. 2010).  In 
my study, we investigated the potential of BPZE1 as a nasal vaccine delivery vehicle 
for the presentation of subunit vaccine candidates against influenza virus whereby 
Chapter 6 Conclusions and Future Directions 
180 | P a g e  
 
expression of the universal influenza vaccine candidate M2e as BrkA-(M2e)3 chimera, 
induced the production of anti-M2e sIgA antibodies in the respiratory tract that led to 
reduced viral loads in the lungs. This approach thus combines the non-specific anti-
inflammatory properties of the vehicle BPZE1 with the specific adaptive immunity 
induced by the expression of the BrkA-(M2e)3 chimera to confer protection against 
influenza infection. Most importantly,  development of such live attenuated B. pertussis 
vectored influenza vaccines represents an interesting approach to provide concurrent 
protection against both pertussis (the vehicle) and influenza (M2e- heterologous antigen) 
in  highly susceptible newborn infants. 
In our study, we observed an inability of BPZE1 to trigger CD8 responses concurring 
with earlier studies that demonstrates that CD8+ T lymphocytes are almost dispensable 
in cellular immunity against B. pertussis (Mills et al. 1993). Therefore, BPZE1 may not 
be an appropriate vaccine delivery vehicle for CD8 T cell epitopes and should only be 
considered when triggering antibody responses or CD4+ T cell-mediated immunity. 
6.2. Future Directions 
First and foremost, it will be interesting to assess the ability of the live attenuated B. 
pertussis vectored M2e vaccines to protect against influenza strains of different M2e 
sequences. This will provide further insight into the possibility of M2e-based vaccines 
being a universal influenza vaccine without annual review and formulations to strain-
match the next circulating virus and allow us to further understand the lack of 
improvement of BPAL3 in protection against influenza in our study. Therefore, future 
studies include challenge experiments whereby immunized mice will be infected with 
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mouse-adapted H3N3 (A/swine/Ontario/42729A/01), an influenza strain with M2e 
sequences that matches closely to that expressed in BPAL3 (Table 4.1).  
In addition, live attenuated B. pertussis vectored influenza vaccines can be developed 
further using the FHA or BrkA carriers to express other conserved epitopes of influenza 
virus such as HA2, the stem region of HA. The potential in expressing the stem region 
of HA is that it is considerably more conserved than HA1 (Both et al. 1983) and 
monoclonal antibodies raised against this region have been shown to cross-react and 
neutralize several subtypes of viruses across clades, thus providing heterologous 
protection (Okuno et al. 1993, Okuno et al. 1994, Ekiert et al. 2009, Sui et al. 2009, 
Throsby et al. 2008, Sánchez-Fauquier, Villanueva and Melero 1987). These antibodies 
presumably target the HA2 region by preventing the conformational change of HA at 
low pH to block the fusion of viral and host membranes. Hence, the HA2 stem region 
might be a potential vaccine candidate for universal influenza vaccines. 
Also, since FHA and BrkA have shown some limitations in their ability to trigger a 
specific antibody response against the heterologous antigen M2e, we can explore other 
potential carriers that are cell wall anchored or secreted for expression in BPZE1. One 
of the potential vaccine carriers is pertactin (Prn), an outer membrane protein involved 
in bacterial adherence. Prn, a member of the autotranporter family (Henderson, 
Navarro-Garcia and Nataro 1998), is known to bind directly to eukaryotic cells to 
mediate adherence. Several studies have demonstrated that Prn is an immunoprotective 
antigen, being used in subunit and live oral vaccines to protect mice from respiratory 
challenge with virulent B. pertussis (Novotny et al. 1991, Roberts et al. 1993, Strugnell 
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et al. 1992, Romanos et al. 1991, Shahin et al. 1990). Therefore, Prn appear to be worth 
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8. Appendices  
APPENDIX 1: REAGENTS FOR GEL ELECTROPHORESIS 
 
1.1 DNA Electrophoresis 
 
1.1.1 50X Tris-Acetate-EDTA (TAE) Buffer 
 Per L 
Tris base 242 g 
Glacial acetic acid 57.1 ml 
0.5M EDTA (pH 8.0) 100 ml 
Final pH adjusted to 7.8 
 
1.1.2 Agarose Gel 
 1% 1.5% 
Agarose 0.5 g 0.75 g 
1X TAE 50 ml 50 ml 
1X TAE was prepared by adding 20 ml of 50X TAE buffer to 980 ml of ddH2O. 
 
1.1.3 6X DNA Loading Dye 
Bromophenol blue 0.25 % 
Xylene cyanol 0.25 % 
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1.2.1.1 5X SDS/Glycine Electrophoresis Buffer 
 Per L 
Tris base 15.1 g 
Glycine 72 g 
SDS 5 g 
 
1.2.1.2 10% or 12% Separating Gel 
 Per 30ml 
30% Acrylamide-bisacrylamide (29:1) 8.75 ml or 10.5 ml 
1M Tris-HCl (pH8.8) 7.5 ml 
10% SDS 300 µl 
20% APS 400 µl 
TEMED 40 µl 
ddH2O 13.01 ml or 11.26 ml 
 
1.2.1.3 4% Stacking Gel 
 Per 10ml 
30% Acrylamide-bisacrylamide (29:1) 2 ml 
1M Tris-HCl (pH6.8) 1.25 ml 
10% SDS 100 µl 
20% APS 400 µl 
TEMED 40 µl 
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1.2.1.4 2% Protein Loading Buffer 
 Per 50ml 
1M Tris-HCl (pH8.8) 6.25 ml 
100% glycerol 5 ml 
SDS powder 5 g 
Bromophenol blue 1 drop 
Β-mercaptoethanol 5 ml 
 
1.2.2 Coomassie Blue Staining Solution 
 
1.2.2.1 Coomassie Blue Staining Solution 
Coomassie brilliant blue 0.2% 
Ethanol 45% 
Acetic acid 10% 
ddH2O 45% 
 
1.2.2.1 Destaining Solution 
Ethanol 25% 
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APPENDIX 2: REAGENTS FOR GROWTH MEDIA 
 
2.1 E.coli Culture Media 
 
2.1.1 Luria-Bertani (LB) Agar 
 Per L 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Agar 15 g 
Autoclaved at 121oC for 15 min. 
 
2.1.1 Luria-Bertani (LB) Broth 
 Per L 
Tryptone 10 g 
Yeast extract 5 g
NaCl 10 g 
Autoclaved at 121oC for 15 min. 
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2.2 B. pertussis Culture Media 
 
2.2.1 Stainer-Scholte (SS) Medium 
Fraction A: 
 Per L 
Na-L-Glutamate 11.84 g 
L-Proline 0.24 g 
NaCl 2.5 g 
KH2PO4 0.5 g 
KCl 0.2 g 
MgCl2.6H2O 0.1 g 
CaCl2.2H2O 0.02 g 
Tris 1.5 g 
Casamino acids 10 g 
Di-methyl-β-cyclodextrine 1 g 
Final pH adjusted to pH 7.4. Autoclaved at 121oC for 15 mins. 
Fraction B: 
 Per 10 ml 
L-Cysteine 0.04 g 
FeSO4.7H2O 0.01 g 
Nicotinic acid 0.04 g 
Ascorbic acid 0.4 g 
Gluthathione 0.15 g 
Filter-sterilized with 0.2µM filter unit. 
Add 10ml of filter-sterilized Fraction B to 1L of autoclaved Fraction A. 
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2.2.2 Bordet-Gengou (BG) Agar 
 Per L 
Potato Infusion from 125g 4.5 g 
NaCl 5.5 g 
Agar 20 g 
Glycerol 10 g 
 
Autoclaved at 121ºC for 15 mins.  
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APPENDIX 3: REAGENTS FOR ANIMAL WORK 




1X PBS 64% 
Cocktail must be prepared under sterile conditions. 
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